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Abstract 
Bismuth compounds have been widely used in medicine for more than two 
centuries for the treatment of various diseases especially for the treatment of gastric and 
duodenal ulcers. However the biological chemistry and pharmacology of bismuth are 
poorly understood. The major biological target for Bi appears to be proteins and 
enzymes. 
Transferrin is a bilobal glycoprotein with the function of transporting iron and 
other metal ions including diagnostic radioisotopes, therapeutic and toxic metal ions. A 
similar protein (ferric-ion-binding-protein) has also been found in several Gram-negative 
bacteria. An unexpectedly strong binding of Bi 3 (ionic radius 1.03A) to the recombinant 
N-lobe of transferrin (hTF/2N) was found. The binding constant was calculated to be log 
K* 18.9± 0.2 at 310 K, 5 mM bicarbonate, 10 mM Hepes buffer at pH 7.4. This strong 
binding requires concomitant binding of a synergistic anion (carbonate) as proved by 13 C 
NMR spectroscopy. Such a strong binding has led to the rationalization of the strength of 
metal binding to transferrin, which correlates well with metal acidity. Significantly this 
allowed the discovery of a new metal ion (Ti 4+) binding to transfernn, which may be 
relevant to Ti 4+ anticancer activity. 
2D ['H, ' 3 C] NMR spectra of recombinant E- 13C-Met labeled transferrin at very 
low concentration were obtainable within a short time. The selectivity of lobe loading 
with Bi3 is compared with that of other metal ions (Fe 
3+'  A13 and Ga3 ) and preferential 
loading to the C-lobe was found. Bi 3 induced similar chemical shift changes of Met 
3+ 	3+ 	3+ 
	
residues as those induced by Fe , A1 3+ 	Ga suggesting similar structural changes of 
the protein, probably from lobe-open to lobe-closed form although the local structure 
(Trp 128 patch) may slightly different upon binding of different metal ions. 
A site-specific mutant 1132M with c-' 3 C-Met labeled hTF/2N was used as a 
model to investigate possible target sites for bismuth in blood plasma. Using the 
chemical shift changes of Met residues as a probe, it was found that bismuth 
preferentially binds to transferrin in the presence of large excess of albumin (biologically 
relevant conditions) and even in intact blood plasma, and binding also induces a 
conformational change, e.g. from lobe-open to lobe-closed, which is crucial for 
transferrin cell receptor recognition. Albumin has been previously thought to be a 
potential target site for bismuth due to its free cysteine (Cys34). However, bismuth only 
associates weakly with albumin. For the first time, a direct detection of metallodrug 
binding to a protein at biologically relevant concentrations without separation was 
achieved. 
Metallothionein (MT) is a metal- and thiolate- (Cys) rich small protein with the 
function of detoxifying of heavy metal ions and inserting metals into apoproteins. 
Bismuth is known to induce the synthesis of metallothionein in the kidney. Bi 3 binds 
strongly to metallothionein and forms a stable Bi 7MT complex. The kinetic displacement 
of Zn2 and Cd2 by Bi3 was studied via electronic absorption and NMR spectroscopy, 
and Zn2 and Cd2 in the 13-domain was displaced much faster than from the (X-domain. 
EXAFS studies showed that Bi 3 (in Bi7MT) is coordinated to three sulfur atoms with 
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Chapter 1 Introduction 
Chapter 1 
Introduction -Bismuth, Transferrin and 
Metallothionein 
1.1 Bismuth 
1.1.1 The Chemistry of Bismuth 
Bismuth, atomic number 83 and atomic weight of 208.9, is the heaviest stable 
element in the periodic table, in group 15 together with nitrogen, phosphorus, arsenic 
and antimony. Bismuth was first discovered as early as the 15th  century. It is most 
commonly found in nature as the oxide (Bi203), carbonate ((BiO)2CO3) and sulfide 
(Bi2S3), and also obtained as a byproduct of lead, zinc and copper mining. Bismuth 
has two major oxidation states (III and V), with the 3+ state being the most common 
and stable form. Bi(V) is a powerful oxidant in aqueous solution, with a Bi(V) 
/Bi(III) potential E ° = 2.03 V. The ionic radius of Bi(III) is 1.03 A (6 coordinate), and 
Bi(V) is 0.76 A. The electronic configurations of Bi(III) and Bi(V) are: 
Bi(III): (Xe)4f145& 06s2 and Bi(V): (Xe)4f 145d) ° 
Bismuth is a borderline metal ion in the hard-soft classification [1]. Bi(III) 
has a high affinity for both oxygen and nitrogen ligands in aqueous solution. It binds 
to nitrogen donor macrocycles even in a strongly acidic solution (pH Ca. 0) [2], but it 
coordinates to -SH when there are thiol-containing ligands such as glutathione and 
cysteine are available [3]. The coordination number of bismuth varies from 3 to 10 
* The abbreviations used in this chapter are: 
ADH, alcohol dehydrogenase; BSS, bismuth subsalicylate; CBS, colloidal bismuth 
subcitrate; CN, coordination number; EDTA, ethylenediamine tetraacetate; GSH, 
glutathione; hTF, human serum transferrin; LF, lactoferrin; MI, metallothionein; 
NTA, nitrilotriacetate; oTF, ovotransferrin; RBC, ranitidine bismuth citrate. 
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[4]. The structures of Bi(III) compounds are irregular, from pyramidal (CN: 3 e.g. 
[Bi(SAr)3 ] [5]), octahedral (CN: 6, e.g. [Bi60 4(OH)4] 6 [6]) to bicapped trigonal 
prism (CN: 8, e.g. [Bi(NTA)(H20)2] and [Bi(HEDTA)]-2H20 [7] Figure 1.1). Bi(III) 
thioate complexes also exhibit coordination numbers of three, four, five and six, and 
the overall structures are either monomers, or loose dimers [5], with Bi-S bond 
lengths ca. 2.5-2.6 A for intramolecular and ca. 3.1-3.3 A for intermolecular 
interactions. Some structures of bismuth thiolate complexes are shown in Figure 1.2. 
The structure of the aqua complex of [Bi(H 20)9] 3 , in which bismuth 
coordinates to nine water molecules with a tricapped trigonal prismatic structure 
(Figure 1.3A) was solved recently [8]. The first pK a for a Bi(III) aqua ligand is 1.51 
[9]. At high pH, [Bi(0)] forms and polymeric cations such as [Bi60 4(OH)4] 6 always 
form in solution before precipitation of the hydroxide complex. The X-ray crystal 
structure of [Bi604(OH)4] 6 (Figure 1.3B) shows that six Bi atoms are at the apices 
of an octahedron at non-bonding separations and the octahedron is face-capped by 0 
and OH, which forms Bi-O-Bi bridges [6]. The lone pair of electrons on Bi is 
directed away from the cage. 
1.1.2 Bismuth in Medicine 
Historic Overview: Bismuth compounds have been widely used in medicine 
for more than 200 years. The earliest use appears to be in the Middle Ages as 
bismuth subnitrate, a white pigment, also used in beauty care and painting. The first 
full account of internal administration of a bismuth compound was in 1786 by Louis 
Odier [10]. In 1805, Alexander Marcet used bismuth subnitrate to treat spasms of the 
stomach at Guy's Hospital, London [11]. In the later 19th  century, several new 
bismuth compounds, such as bismuth derivatives of phenol, bromophenol, 
pyrogallol, naphthol and salicylate, were introduced into medicine specifically for 
treatment of intestinal and gastric disorders. It was also found that bismuth might be 
useful as an antisyphilitic agent [12]. 









',. 	 (B) 
Figure 1.1 Structures of (A) IBi(NTA)(H 20)2 1 and (B) IBi(HEDTA)12H 20. 









o . . 
Figure 1.2 Structures of bismuth thiolate complexes. (A) [Bi(SAr) 3 1 Ar=2,4,6-t- Bu 3 
C6H2 , Bu is omitted (B) (Bi(SC 6F)3(SPPh 3)], and (C) IBi((SC 6F5)3 (S=C(NHMe) 2 )1 3. 
Color code: Bi- yellow, C- green. P- red, N-blue, F- pale blue and S- purple. 
(A) 	 (B) 
Figure 1.3 Structures of (A) IBi(H 20)9 1 ,and (B) IBi 604(OH)4 1 6 , H is omitted. 
Color code: Bi- yellow, 0- red, and H-gray. 
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During this century, various bismuth complexes, such as the subnitrate, 
subgallate, subcitrate, tartrate, subcarbonate and subsalicylate, have been used to treat 
syphilis, hypertension, infections, skin conditions and gastrointestinal disorders [14]. 
Bismuth subsalicylate (BSS, Pepto-Bismol; the Procter & Gamble Company, 
Cincinnati, Ohio, USA) was found to be effective in the prevention and treatment of 
diarrhoea and dyspepsia. Bismuth citrate drugs have also been successfully used in 
the treatment of both gastric and duodenal ulcer diseases. 
Recently, many efforts have been made towards developing new bismuth 
drugs. [Bi(NTA)], [Bi(EDTA)] - and (guanidinum)2[Bi(DTPA)] all exhibit 
antibacterial activities, with [Bi(NTA)] being the most active [7]. Both Bi(III) and 
Bi(V) troloponates complexes show promising activities against H. pylori in an agar 
dilution test and some even have higher activity in vitro [15]. Complexes of bismuth 
with sialic acid inhibitors have shown activity against two types of strains of H. 
pylori comparable to that of bismuth citrate, and these complexes are more effective 
than traditional bismuth compounds in terms of inhibiting the adherence of H pylon 
to gastric epithelium [16]. Some bismuth complexes such as {Na 2 [BiO(mp)3 1 .3H20} 
and {[BiO(tgn)31-3.5H20}  (where mp= 6-mercaptopurine; tgn= thioguanine) have 
even been found to exhibit anti-cancer activity [17]. {Na 2 [BiO(mp)31-3H20} was 
significantly effective in the treatment of Dunning ascitic leukemia in rats [1 8]. Also 
some organometallic bismuth(III) thiolate complexes exhibit an optimum cure rate of 
100% against fluid Ehrlich ascites tumour with a therapeutic index of 3.2-5.0 [19]. 
Furthermore some bismuth complexes have recently been shown to inhibit HIV-1 
virus production from chronically infected H9 cells with a selective index of Ca. 5 
[20]. 
Bismuth Citrate Drugs: Colloidal bismuth subcitrate (CBS, De-Nol; Gist 
Brocades, Delft, The Netherlands, launched in 1976) has been used since the 1970s 
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to treat ulcer diseases as effectively as histamine 1 ­12-antagonists. It is highly water-
soluble which is different from previous bismuth compounds. The empirical formula 
of colloidal bismuth subcitrate (CBS) is often given as K 3 (NH4)2[Bi603(OH)5(Hcit)4] 
[21]. By variation of the pH and the ratios of bismuth and citrate, nine different 
bismuth citrate adducts have been isolated and characterized by X-ray 
crystallography [22]. The coordination number of bismuth in these complexes is 
high, from 6 to 9 with short Bi-alkoxide bonds of Ca. 2.13A. Most of them contain 
the stable dinuclear unit [Bi(cit) 2Bi] 2 with additional 2,  0H and H20 ligands as 
shown in Figure 1.4A . This dinuclear unit can further aggregate by citrate or water 
bridging to form channels and sheets by H-bonding as shown in Figure 1.4B. Both 
the high coordination number (eight) for bismuth in this dimer and the aggregation of 
[Bi(cit)2Bi] 2 subunits to form channels could account for the high solubility of this 
compound in water. Notably all of the bound atoms lie on one side of the Bi 
coordination sphere, and the vacant side axial site is occupied by the lone pair of 
electrons. However all the complexes crystallised previously do not have exactly the 
same composition as CBS, and the solid-state and solution structures of CBS are still 
unknown. 
Recently, a new bismuth-containing drug ranitidine bismuth citrate (RBC, 
Pylorid, GlaxoWeilcome plc.) with a ratio of ranitidine to bismuth citrate of 1:1, has 
been approved for clinical use and is on sale in many countries around the world. It 
combines the antisecretory action of ranitidine with the mucosal protectant and 
bactericidal properties of bismuth [23,24]. Ranitidine bismuth citrate (RBC) is also 
highly soluble in water (ca. 1.0 g/ml), giving a pH of 4.6. Ranitidine is not 
coordinated to Bi and appears to be involved in specific second-coordination sphere 
interactions with bismuth citrate [25]. The solution structure of this drug has been 
studied using diffusion-ordered 2D ['H, ' 3C] HSQC NMR spectroscopy with the aid 
of isotope-labelling of the citrate, which shows that an equilibrium between free 
5 
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Figure 1.4 Structures of Bi(HI) citrate complexes. (A) The dinuclear bismuth 
citrate unit, (B) Polyanionic chain of F{Bi(cit) 2Bi}1 2 ° 1221. Color code: Bi-yellow; 
0-red; C-green. 
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citrate, [Bi(cit) 2Bi] 2 and multinuclear bismuth citrate cluster exists at physiological 
pH values [26]. The solid-state structure of RBC may be closely related to that of 
Na2[Bi2(cit) 2] 71­120 [22], which contains the highly stable dimeric unit [Bi(cit)2Bi] 2 
in which two Bi(III) ions are doubly bridged by citrate carboxylate oxygens as shown 
in Figure 1.4A. These dimeric units are assembled into infinite polymeric chains via 
double syn-anti carboxylate bridges (Figure 1.4B). 
The polymeric structures of bismuth citrate drugs may be very important 
since the drugs could be deposited on the ulcer crater to form a protective coating, or 
on the bacteria that can occur in ulcer. Indeed, various tiny crystalline species have 
been found in the ulcer craters of patients after treatment with colloidal bismuth 
subcitrate [27]. 
1.1.3 Bismuth Pharmacology and Toxicity 
After oral administration of bismuth drugs, a protective coating is thought to 
be formed in the stomach probably involving BiOC1, bismuth citrate and other salts 
which are taken up into the gastric mucus and bind to proteins within the base of 
ulcers after contact with gastric juice [28]. The absorption of bismuth is low, with 
less than 0.5% of the ingested dose absorbed for RBC and CBS [29,30] and most of 
the dosed bismuth drug is recovered in the urine. The site of bismuth absorption in 
the gastrointestinal tract is not known, but is probably in the small intestine. The 
mechanism by which bismuth crosses the small intestinal mucosa is possibly via 
some kind of endocytosis [31]. The more water soluble bismuth salts, e.g. CBS and 
RBC, are better absorbed from the gastrointestinal tract than the insoluble drugs such 
as BSS. The levels of Bi in gastric mucosal after oral administration of bismuth drugs 
(CBS, BSS and RBC) are above the minimum inhibitory concentration (32 ng/l) for 
eradication of H. pylon, and these levels fall rapidly over a 3 h period [32,33]. 
7 
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A significant rise of Bi concentration in the blood (17-38 pg/l) has been 
noted after oral administration of bismuth compounds to healthy volunteers [14]. 
Incubation of blood with radioactive bismuth citrate gave 17% of the radioactivity 
associated with erythrocytes, and the rest bound nonspecifically to some serum 
proteins [34]. The maximum concentration of bismuth in plasma after single-dose 
administration of RBC, BSS and CBS is less than 30 nglml, and with multiple dosing 
for 28 days is still less than 100 nglml [35]. The adsorbed bismuth binds to plasma 
proteins and is distributed throughout all tissues, predominantly the kidney. After 14 
months of administration of CBS to rats, bismuth levels found in the kidney ranged 
from 13.9 g/g (net weight), in muscle 0.13 [tg/g, and for other organs in the order of 
kidney >lung >spleen >liver >brain >muscle [36]. Concentrations of bismuth in the 
brain were higher for human and animals receiving bismuth than for untreated 
controls [36]. 
Bismuth compounds were once thought to have low or even no toxicity due to 
their extremely low absorption. However, extended or high doses of bismuth 
compounds can cause a number of toxic effects in humans and animals, such as 
nephropathy, encephalopathy, osteoarthropathy, gingivitis and stomatitis [14]. 
Different bismuth compounds may effect different organs. Many cases of bismuth-
related neurotoxicity (encephalopathy) were reported from France and Australia 
between 1973 and 1980 due to administration of large doses of bismuth subnitrate or 
bismuth subgallate (700 mg to 20 g/d) for long periods (from 4 weeks to 30 years) 
[37]. The diagnosis for encephalopathy is generally confirmed by elevated bismuth 
concentrations in blood, plasma, serum or CSF. Hillemand et al. studied the 
relationship between bismuth levels in blood and encephalopathy in humans, and 
suggested that bismuth levels in blood over 100 jtg/I are a warning sign of toxicity, 
and less than 50 ig/l is the safety level [38]. However, this is not justified by current 
knowledge since this range was based on early French studies in which the sample 
E3 
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handing and analytical methods used were uncertain. It is not clear how bismuth is 
transported into the brain although a recent study suggests that bismuth may share a 
similar mechanism with other xenobiotic metals (e.g. Hg, Ag and Au) for entry, 
distribution and storage in the brain [39]. Further studies are urgently needed. 
1.1.4 Mechanism of Action of Bismuth Drugs 
Although it is already known that after administration, some bismuth drugs 
can coat ulcer craters or be present on bacterial surface as polymers (e.g. BiOC1, Bi 
citrate), the mechanism of action of bismuth drugs is still poorly understood. So far 
there is no evidence for interactions between bismuth drugs and DNA. Recent reports 
have demonstrated that peptides, proteins and enzymes may be important in the 
mechanism of action and the metabolism of bismuth drugs. 
Bismuth Complexes with Glutathione: Glutathione is an abundant thiol-
containing tripeptide (y-L-Glu-L-Cys-Gly) that is present in most cells at 
concentrations in the range 1-10 mM [40]. It can bind to a variety of metal ions and, 
in particular, its thiolate sulfur atom has high affinity for "soft" metal ions (such as 
Cut, Au, and Hg24 ) [41-43], resulting in the formation of GS-Metal complexes. It 
has been thought that GSH plays a major role inredox reactions of many metal ions 
in vivo and in the mobilization and transport of some of them across membranes [44]. 
OOC\ OH 	OH II 	I II 
CH
- 
 r CHCH2C — NCHCNCH2COO 





It has been found that cysteine and glutathione can prevent precipitation of 
colloidal bismuth subcitrate even at pH 2.0 [45]. Simultaneous oral administration of 
bismuth salts and thiolates produces a significant rise in the bismuth concentration in 
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blood plasma [46]. Recently, Rao and Feldman found that most of the bismuth added 
to whole blood entered red blood cells, with less than 10% remaining in the plasma 
[47], while Garner et al. reported that when red blood cells were treated with 
colloidal bismuth subcitrate in vitro, most of the bismuth was adsorbed onto the 
outside of the cells [48]. It has also been shown that after administration of 
ammonium bismuth citrate, bismuth is transported from liver to bile as a GSI-I 
complex [49]. The first chemical study of the complexation of Bi(III) by GSH 
demonstrated that Bi(III) coordinates only to the -SH group and forms a very strong 
complex [Bi(GS)3]. Glutathione bound to Bi(III) is kinetically labile with respect to 
exchange with free GSH which would allow facile transport of Bi(III) amongst thiol 
ligands in a biological system and a wide distribution of Bi(III) in the body is 
expected [3]. 
Other thiol-containing ligands, such as cysteine, D-penicillamine and 2-
mercaptoethanol have also been found to bind to Bi(III) [50-52]. Recently, 
bismuth(III) thiolate complexes have been tested in vitro for antibacterial activity 
towards Helicobacter pylon. The results show that the activity of a thiol-containing 
ligand (2-mercaptoethanol) is significantly enhanced after bismuth binding [52]. 
Therefore, thiol-containing ligands may also play an important role in antibacterial 
activities of bismuth drugs. 
Bismuth(III) Complexation with Proteins and Enzymes: There appear to 
be only a few reports on interactions of bismuth(III) with proteins and enzymes, and 
most of them on clinical and biological aspects. For instance, bismuth has been 
shown to bind strongly to connective tissue proteins, mucus glycoproteins and 
enzymes [53], but little is known about the binding mode or kinetic behavior. Some 
metallothionein-like proteins, copper-binding proteins, and the copper-containing 
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blood plasma protein caeruloplasmin have also been found to interact with bismuth 
[54]. 
A gel filtration study of human blood after incubation with bismuth subgallate 
showed an association of bismuth with the high molecular fraction (over 200 KDa) 
possibly consisting of a2-macroglobulin, 1gM, 3-lipoprotein and haptoglobulin [55]. 
The ultrafiltration study of bismuth binding to human serum albumin suggests that 
Cys34 is the likely binding site on albumin, however, only one binding site per 53 
molecules was found [47]. Further studies are needed. Recently, the first chemical 
study of bismuth binding to the serum protein transferrin has been made [56]. This 
finding is significant and may have implications for transport and delivery of bismuth 
and even toxicity of bismuth especially neurotoxicity (encephalopathy). 
Enzymes have been thought to play a role in the mechanism of action of 
bismuth-containing drugs. The mode of action of colloidal bismuth subcitrate (CBS) 
in the treatment of gastroduodenal disorders appears to involve the prevention of 
adhesion of H pylori to epithelial cells and inhibition of enzymes secreted by H. 
pylon, such as proteases, lipases, glycosidases, and phospholipases [57]. CBS can 
also induce a dose-dependent inhibition of phospholipases A (PLA2) and C of both 
H pylori lysates and filtrates possibly involving competition for the calcium site on 
the PLA2 enzyme [58]. Bismuth subcitrate inhibits H pylon F-l-ATPase, an enzyme 
involved in bacterial energy metabolism and the inhibition is prevented and reversed 
by the mercaptan glutathione suggesting that bismuth interferes with sulfhydryl 
groups of the enzyme [59]. It has been reported that CBS can inhibit pepsin activity 
at pH 1.0 and 2.0, and the inhibition was thought due to negatively- charged bismuth 
salts derived from CBS at pH 1.0 and 2.0 via an ionic interaction with positively-
charged groups of pepsin which inactivates the enzyme [60]. 
Colloidal bismuth subcitrate, and bismuth subsalicylate can inhibit alcohol 
dehydrogenase (ADH) activity from H pylori and consequently suppress 
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acetaldehyde production from endogenous or exogenous ethanol [61,62]. ADFI 
contains two Zn(II) ions which occupy two separate domains. One Zn(II) ion resides 
in the catalytic domain and is coordinated to two cysteinate sulfur atoms, one 
histidine nitrogen atom, and a water molecule. The other Zn(II) binds to four cysteine 
thiolate ligands and is inaccessible to solvent [63]. The inhibition probably involves 
the displacement of Zn(II) by Bi(III). 
Bismuth (III) inhibition of urease produced by H. pylori may also account for 
the antibactericidal activity of bismuth-containing drugs [64]. However, the 
mechanism of inhibition is still unknown. The crystal structure of urease from 
Kiebsiella aerogenes has been solved recently [65]. There are two Ni(II) ions which 
are 3.5 A apart. One Ni(II) ion is coordinated pseudotetrahedrally to two nitrogen 
atoms from histidines, one oxygen from bridging carbamylated lysine, and one water 
oxygen. The other Ni(II) ion is coordinated approximately trigonal-bipyramidally to 
one oxygen of the bridging carbamylated Lys, two His nitrogen, one carboxylate 
oxygen of Asp, and one water oxygen. The inhibition of urease by -mercaptoethanol 
has been attributed to the binding of 3-mercaptoethanol, which bridges the two Ni(II) 
ions in the active site through the sulfur atom and chelates one Ni(II) through the OH 
functionality. Also another molecule of 3-mercaptoethanol forms a mixed disulfide 
with a Cys residue, thus sealing the entrance to the active site cavity by steric 
hindrance [66]. A Bi mercaptoethanol complex has been found to have Ca. 1000 
times higher activity than mercaptoethanol alone against urease [52]. Further studies 
on the mechanism of inhibition of urease by bismuth drugs are needed. 
Bismuth Drugs Inhibition of Bacteria: H. pylori is a micro-aerophilic, 
Gram-negative, slow-growing, spiral-shaped and flagellated organism [67], and was 
discovered by Australian physicians Robin Warren and Barry Marshall [68]. The 
presence of this bacterium in the gastric mucosa is associated with chronic active 
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gastritis and is implicated in more severe gastric disease, including chronic atrophic 
gastric, peptic ulceration and mucosa-associated lymphoid tissue lymphomas [69]. It 
has a smooth outer coat usually with seven tail-like flagella at one end, which enable 
it to penetrate the mucus layer of the mucosa. Recently the complete genome 
sequence of the gastric pathogen H. pylori has been reported by Tomb et al. [67]. It 
produces a nickel-containing enzyme, urease, which catalyzes the hydrolysis of urea 
to form ammonia and carbon dioxide. The ammonia buffers the acid concentration 
around the bacterium and enables it to survive under acidic conditions. Like all other 
bacteria, H pylori requires an iron-scavenging system for survival in the host [70]. 
Genome analysis suggests that H pylori has several systems for iron uptake. One is 
analogous to the siderophore-mediated iron uptake fec system of E. coil. A second 
system is that H pylori can assimilate ferrous iron in a fashion similar to the 
anaerobic feo system of E. coil. Other systems consist of the three frpB genes which 
encode proteins similar to either heme- or lactoferrin-binding proteins. Indeed, the 
antimicrobial effect of bismuth among Gram-negative bacteria is dependent on both 
iron concentration and iron transport mechanisms [71]. Competition with iron(III) 
may be the main means by which bismuth complexes inhibit bacteria, and binding of 
bismuth at iron sites in proteins and active-sites in enzymes is likely to be the 
primary mechanism. Other mechanisms may also be involved such as inhibition of 
cell wall synthesis, inhibition of cell membrane function, inhibition of protein 
synthesis, and inhibition of ATP synthesis. 
1.2 Transferrin 
1.2.1 Introduction 
Transferrins are typically monomeric glycoproteins with a single polypeptide 
chain containing about 670700 amino acids with molecular masses of 
approximately 80 kDa. Transferrin has been thought originally to be restricted to 
vertebrates. However transferrin-like proteins have now been identified in several 
invertebrate species where they occur in the hemolymph [72]. In vertebrates, 
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transferrins are found in a variety of body fluids including the serum transferrins (TF) 
in blood, ovotransferrins (oTF) found in avian egg white, lactoferrins (LF) found in 
milk, tears, saliva and other secretions, and melanotransferrins found anchored to the 
membrane surface of melanocytes and other cells via a glycosyl-phosphatidylinositol 
linkage. Serotransferrin has been found in the blood of all vertebrates including 
mammals, birds, reptiles, amphibians, and fish [73]. It has also been found in many 
other mammalian fluids, including bile, amniotic fluid, cerebrospinal fluid, lymph, 
colostrom, and milk [74]. In human serum the concentration of transferrin is about 
2.5 mg/ml (35 tiM). Several features of the transferrin family are summarized in 
Table 1.1. 
Table 1.1 Properties of the transferrins 
Transferrin Ovotransferrin Lactoferrin 	Melanotransferrin 
Mol wt (Da) 79,570 77,770 82,400 97,000 
Residues 679 686 703 719 
Lobes 2 2 2 2 
Glycans 2C 1C IN, 1C IN, 1C(?) 
Disulfides 8N, 11C 6N, 9C 6N, 10C 7N, 7C 
p1 (diferric) 5.6 5.8 8.7 - 
Source Serum Egg white Milk,tears,saliva Melanomas 
Ref. 75,76 77,78 79 80 
Here C and N refer to the C-lobe and the N-lobe of transferrin, respectively. 
The fundamental role [81] of transferrins, except melanotransferrin, is to 
control the levels of free iron in body fluids by binding, sequestering and transporting 
Fe 31 ions. This helps to maintain the availability of iron while preventing the 
deposition of insoluble ferric hydroxide aggregates. Ovotransferrin and lactoferrin 
also have antimicrobial activity. This is probably due to the fact that apo-transferrins 
are able to bind Fe(III) so tightly that it is unavailable for bacterial growth. While 
serum transferrin has the role of transporting iron from sites of absorption to sites of 
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storage and utilization. They may also play a regulatory role in iron metabolism, 
protect against toxic effects of free iron that might otherwise catalyze the formation 
of the free radicals that damage cells, and transport metal ions other than iron, such 
as aluminium, implicated in Alzheimer's disease. 
1.2.2 Structure 
The first crystallographic studies on transferrin date back more than 20 years 
[82], but it was not until 1987, with the publication of the structure of human 
lactoferrin [83], that full details of a transferrin structure emerged. The structure of 
rabbit serum transferrin soon followed [84,85], and many other structural studies of 
intact transferrins and a number of fragments have also appeared. These are 
summarised in Table 1.2. 
Crystal structures of transferrins show (Table 1.2) that transferrins consist of a 
single polypeptide chain of 670 - 700 amino acid residues. The polypeptide folding is 
very similar for all proteins of the transferrin family. This is attributed to their high 
(-'.40 %) sequence identity. The polypeptide chain is first of all folded into two 
globular lobes, representing the N-terminal (first 330 residues) and C-terminal (last 
- 330 residues) halves of the molecule, referred to as the N-lobe and C-lobe, 
respectively (Figure 1.5). There is one metal and anion binding site per lobe. The 
two lobes are connected by a short peptide, which is a random coil in human serum 
transferrin but a three-turn helix in lactoferrin [81]. The two lobes do not have 
equivalent orientations with respect to the molecule as a whole, being arranged front-
to-back as shown in Figure 1.6. Each lobe can be further divided into two domains 
(Figure 1.6) which may have a crucial functional significance since the cleft 
separating the two domains of each lobe houses the metal binding site. The folding 
pattern for a typical transferrin lobe or half-molecule is shown in Figure 1.7. It can 
be seen that each domain consists of a mixed n-sheet overlaid with cc-helices. This 
folding pattern is particularly important, since the N-termini of many helices are 
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directed toward the central binding cleft and the positive charge they carry would 
help attract anions into the binding cleft. Two extended n-strands run behind the iron 
site and link the two domains, and can be thought of as backbone strands crucial to 
the conformational change during binding of metal ions. 
Table 1.2 X-ray crystal structures of transferrins. 
Transferrin Residues Geometry 	Resolution PH Comments 	Refs 
FechTFt 	679 	Distorted 3.0 A 	 N-lobe open (apo) 	[86] 
octahedral 	 C-lobe closed (Fe 3 ) 
apo hLFt 	692 	 2.8 A 	8.2 N-lobe open 	[87] 
C-lobe closed 
Fe2-hLF 692 Octahedral 2.2 A 7.8 Carbohydrate 	- [83, 
partially defined 88] 
Fe2rTFt 676 Distorted 3.3 A 6.0 Two lobe closed [84] 
octahedral 
Fe2oTFt 686 Distorted 2.4 A 5.9 [89] 
octahedral 




Fe-hLF/2N 333 Octahedral 2.0 A 8.0 [91] 
Fe-oTF/2N 332 Octahedral 2.3 A 5.9 [92] 
Apo- 337 2.2 A 5.3 N-lobe open [93] 
hTF/2N 3.2A 
Fe-hTF/2N 337 Octahedral 1.6 A 5.8 Arg124 &carbonate [94] 
1.8A 6.1 distorted 
Fe-hLF/2N, 333 Octahedral 2.05 A 8.0 [95] 
Asp6OSer 
duck 	Fe- 
oTF 249 Octahedral 2.3A 7.8 [96] 
Nil-domain 
fragment 
t hTF- human serum transferrin; hLF- human lactoferrin; rTF- rabbit serum transferrin; oTF; 
Ovotransferrin. 
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(A) 
(B) 
Figure 1.5 (A) X-ray crystal structure of human Fe (.-transferrin 1861. The Globe, 
with Fe" bound. is shown in a closed form (blue) and the apo N-lobe in an open form 
(green). (B) X-ray crystal structure of rabbit serum Fe 2-transferrin 1841, with both 
lobes in the closed form. 
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Figure 1.6 Domain organization of transferrins. The N- and C-terminal lobes are 
divided into domains N 1 , N2 and Ci, C2, respectively. The two lobes are connected by 
a peptide, which is helical in lactoferrin (solid line) and less regular in transferrin 
(dashed line). Taken from ref [81]. 
C 
Figure 1.7 Polypeptide folding pattern in N-lobe of human lactoferrin. A similar 
folding pattern is found in the C-lobe. Helices shown as cylinders are numbered from 
1 to 12 and n-strands shown as arrows are labeled from "a" to "k". The interdomain 
backbone strands are shaded and the position of the hinge is also indicated. Taken 
from ref [88]. 
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All known vertebrate transferrins are glycoproteins except for certain species of 
fish. However, there is no pattern to the sites of attachment of the carbohydrate 
chains on different types of transferrins and for the same transferrins from different 
species, which may suggest that the carbohydrate plays no direct role in function. The 
carbohydrate chains are not required for receptor recognition either [97]. 
At the metal binding site, Fe 3+  coordinates with distorted octahedral geometry to 
two oxygens from two Tyr, one nitrogen from His, one oxygen from Asp and two 
oxygens from a bidentate synergistic anion - carbonate (Figure 1.8). The ligands are 
from four different parts of the protein structure, one from domain 1 (Asp 63), one 
from domain 2 (Tyrl 88) and two from the two polypeptide strands (Tyr95 and 
His249) that cross over between the two domains at the back of the iron site [86]. 
Thus the domains can move apart to form an open conformation, hinged by the 
backbone strands, leading to iron release. At the binding site, the Asp ligand appears 
to play a crucial role in the metal site, as it coordinates to the metal through one 
carboxylate oxygen while hydrogen bonding between the two domains with its other 
oxygen. 
The anion (bi)carbonate occupies a pocket in domain 2. The pocket is formed by 
positively-charged groups, the side-chain of an arginine residue and the N-terminus 
of a helix 5 [98]. The anion fits perfectly between protein and metal (Figure 1.8). 
The synergistic anion has an important role in creating the metal binding site. 
Without this anion, the positively-charged Arg side chain and the N-terminus of helix 
5 could inhibit metal ions from binding in the specific site. This presumably accounts 
for the weak, nonspecific metal binding in the absence of anions. The synergistic 
anion may also play a role in iron release. Protonation of the carbonate ion could 
disrupt the hydrogen bonding pattern and assist in the breakup of the binding site, 
which is essential to ensure reversibility of metal binding. 
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Figure 1.8 Schematic diagram showing the characteristic metal and anion 
binding site in transferrin. Residue numbers are for the N-lobe of human serum 
transferrin, but the same arrangement of ligands is found in the C-lobe [86]. 
1.2.3 Metal-Induced Conformational Changes 
Transferrin undergoes conformational changes during Fe 3+  uptake and release (as 
shown in Figure 1.5), which may be crucial in receptor recognition. X-ray 
crystallographic studies of Fe2-lactoferrin and Fec-lactoferrin (Fe 3+  in the C-lobe 
only) have shown that the binding of Fe 3+  and carbonate causes the N-lobe to change 
conformation from wide-open to closed [83,87,99]. This involves a 54° rotation of 
the N2 domain relative to the N  domain and flexing of the two antiparallel extended 
polypeptide strands which run behind the iron binding site connecting domains Ni 
and N2 (Figure 1.9). There is good evidence from small-angle X-ray scattering that 
loading of transferrin with Fe 3+'  Cu2+ 3+ and In causes a decrease in the radius of 
gyration of the protein consistent with lobe closure [100-102]. The isolated N and C-
lobes undergo structural changes in solution on iron binding and release, similar to 
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those of the corresponding lobes of intact transferrin, despite the fact that the apo C- 
lobe can open only to the equivalent of about 75% of the N-lobe due to the presence 
of an extra disulphide bridge [100]. 
It has been proposed that the mechanism for opening and closing the lobes 
may involve a pH-sensitive interdomain interaction. Uptake of the Fe 3 -transferrin 
complex into an acidic endosome (pH Ca. 5.5) via receptor-mediated endocytosis 
could result in the protonation of both residues Lys 209 and Lys 301, the so-called 
dilysine "trigger" (Figure 1.10), based on the X-ray structure of the N-lobe of hen 
ovotransferrin [92]. The two resulting positive charges on opposite domains may 
provide the driving force to push the two domains apart and expose the Fe 3+  ion and 
facilitate its release. This Lys-Lys arrangement is a common occurrence in the N-lobe 
of the serum transferrins, such as the rabbit and human serum transferrins, which has 
led to the reasonable conclusion that all N-lobe Lys-Lys groupings in the closed Fe 3 -
containing lobes of the serum transferrins will exist in the form of this pH-sensitive 
dilysine trigger [92]. However, there might be a second type of pH-sensitive trigger 
for opening the transferrin domains in the C-lobe, such as the Lys-Asp-Arg sequence 
in the serum transferrins, which would produce an open C-lobe at a pH value 
somewhat lower than that at which Lys-Lys would produce the same result in the N-
lobe [92]. This provides an explanation for the in vitro experiments in which the N-
lobe (with the Lys-Lys couple) releases Fe 3+  at pH ca. 5.7, while the C-lobe (with the 
Lys-Asp-Arg sequence) retains Fe 3+  until pH ca. 4.8 [103,104]. Low-angle X-ray 
scattering studies of the N-lobe recombinant human serum transferrin have suggested 
that Asp63, an iron binding ligand, serves as a trigger for the closure of the two 
domains upon Fe 3+  uptake, and that this trigger is abolished completely by the 
mutation of Asp63 to Ser or Cys, which means that the lobe does not close and 
remains in an open conformation [105]. However recent studies on Asp60Ser 
lactoferrin by X-ray crystallography have shown that the N-lobe is completely closed 
although the Ser side-chain neither binds to the iron atom nor makes any interdomain 
contact as substituted Asp does. This has led to the proposal of an equilibrium 
between open and closed forms in solution with a low energy barrier [106]. 
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Figure 1.9 Open (left) and closed (right) forms of the N-lobe of human lactoferrin. 
The movement of helix 5 in domain N2 appears to pivot on helix 11. The hinge in the 
two backbone strands is indicated with an arrow. Taken from ref [87]. 
Lys3Ol '1% Ser303 
H is250 Ty 
iro TU r, \ 
L y s 209 
Asp6O 	 DII 
Ca32- 	Tyr92 
Figure 1.10 The dilysine trigger, showing the proposed H-bonding between 
the c-amino groups of Lys209 and Lys301. Protonation of this pair may act as a 
trigger for lobe opening and metal release [92]. 
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1.2.4 Cellular Uptake of Iron from Transferrin 
The pathway of iron uptake from transferrin has been elucidated with the 
discovery of receptor-mediated endocytosis of transferrin [107,108] as well as effects 
of pH on both the binding of iron to transferrin [109] and the affinity of transferrin 
for the transferrin receptor [110,111]. The transferrin receptor of iron-requiring cells 
is a dimer of two identical subunits, with molecular weights of about 95 kDa, linked 
by a pair of disulfide bonds [112]. Each subunit is capable of binding one transferrin 
molecule. Receptor-mediated endocytosis of the diferric transferrin complex into an 
acidic endosome, with subsequent release of Fe 3 , is the generally accepted 
mechanism for Fe 3+ delivery to a cell. The diferric transferrin binds strongly to the 
receptor protein on the surface of the cells and is taken up, and inside cell diferric 
transferrin is held in membrane-bound vesicles (endosomes), where the pH is 
lowered from the extracellular value of 7.4 to about 5.5, and Fe 3+  is released. Apo-
transferrin remains bound to its receptor due to its high affinity for the receptor at 
acid pH, and it is recycled back to the surface of the cell. At extracellular 
physiological pH, apo-transferrin dissociates from its receptor due to its low affinity 
at pH 7.4, is released into the circulation, and reutilised [113,114]. This is shown in 
Figure 1.11. 
Besides diferric transferrin, other metal-transferrin complexes have also been 
found to interact with transferrin receptors. Ga 3 , a pharmacologically important 
metal, is also taken up by transferrin receptor-mediated endocytosis [115,116]. Ga2-
transferrin can inhibit transferrin receptor-mediated cellular uptake of iron. It blocks 
the activity of the iron-dependent enzyme ribonucleotide reductase [117,118] and 
also inhibits iron-dependent DNA synthesis [119]. Several studies have shown that 
there is little difference between the binding of Fe2-transferrin and Al 2-transferrin to 
the transferrin receptor [120,121]. Aluminium uptake is enhanced in a variety of cell 
lines by addition of apo-transferrin, which was attributed to receptor-mediated 
endocytosis of the Al 2-transferrin complex [122]. The toxic effects of aluminium, 
particularly the neurotoxicity, are probably related to aluminium binding to 
transferrin, and Al-transferrin is transported and recognised by the transferrin 
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receptor [121]. Elevated aluminium levels in the brain are a possible factor in the 
development of Alzheimer's disease and may also be related to transferrin- receptor 
recognition [123]. 
apohTF 	
Fe2hTF binds to 
receptor 
 




returned ((o receptor complex 
sorting of vesicle 
bearing complex of 
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storage Fe3 
by ferritin 
Figure 1.11 Diagram showing the pathway of cellular uptake of iron from 
transferrin via a cell receptor. Adapted from ref [109]. 
1.3 Metallothionein 
1.3.1 Definition and Classification 
Metallothioneins (MT) were initially discovered by Margoshes and Vallee in 
1957 as a result of efforts to search for tissue constituents responsible for the natural 
accumulation of cadmium [124]. This protein was characterized by the following 
features [125,126]: low molecular weight; high metal content; characteristic amino 
acid composition (high cysteine content, no aromatic amino acids); unique 
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distribution of cysteine residues in the amino acid sequence; spectroscopic features 
characteristic of metal-thiolate complexes and metal clusters. The definition was 
adopted that any protein (polypeptide) which satisfies several of these criteria can be 
designated as "metallothionein" [127]. 
Metallothioneins can be subdivided into three classes [128,129]: class I are 
mammalian metallothioneins with 20 cysteines and closely related metallothioneins 
such as 1 8-cysteine metallothionein of crustaceans; class II are polypeptides, such as 
yeast metallothioneins [130], with locations of cysteines only distantly related to 
mammalian metallothioneins; class III are those peptides enzymatically synthesized 
such as cadystins [131] and the poly(y-glutamylcysteinyl)glycines variously known as 
phytochelatins [132]. 
1.3.2 Occurrence 
Metallothioneins have been reported to occur throughout the animal kingdom 
as well as in plants. They have been isolated from kidney, liver and intestines of a 
variety of animal species [133], from fungi [134,135], from plants [136], and from 
metal-resistant bacteria [137,138]. 
In animals, metallothioneins are most abundant in parenchymatous tissues but 
their occurrence and biosynthesis have been documented in many tissues and cell 
types [139]. For instance, MT concentrations have been found to vary in the adult 
monkey in the order: kidney> liver> intestine> testes> lung> heart [140]. The 
absolute amounts of MT in different species and tissues are highly variable, relevant 
to age, state of development, dietary regime and some other unknown factors [141]. 
However, high concentrations have been found in the liver of all mammalian species. 
Recently, MT III, a growth inhibitory factor (GIF) from human brain tissue 
has been identified as a new member of metallothionein family [142]. This discovery 
has opened a new interest in studying this small protein. 
1.3.3 Biological Functions 
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The biological functions of metallothioneins are not yet fully understood but 
are being investigated actively. They may play an important role in sequestering toxic 
Cd(II) and prevent it from interacting with other cellular targets in mammals and 
other higher organisms [143], and in the metabolism of copper and zinc ions under 
various physiological conditions [144,145], including its ability to donate metal ions 
to apo-Zn-requiring enzymes [146,147]. They may be involved in the transport, 
storage and detoxification of some heavy metals other than Cd(II), such as Hg(II) 
[148], Au(I) [149] and Pt(II) [150,151], and also appear to play a role in radical 
scavenging, the stress response, and the pharmacology of metallodrugs and alkylating 
agents [145,152, 153]. 
The significance of multiple MT isoforms is still unclear, but the specific 
forms may have unique functions. MT-Ill, as a new member of the MT family 
distinguishes itself from other MT isoforms by exerting inhibitory effects on cortical 
neuron growth instead of metal ion buffering and detoxification. MT-Ill is abundant 
in normal human brain but down-regulated in Alzheimer's disease [154]. This 
finding links MT for the first time with a disease process. It is not clear whether its 
mechanism of action as a cellular growth inhibitory factor is a guiding principle for 
similar actions of other metallothioneins. 
1.3.4 Structure 
The best characterized mammalian metallothioneins contain a single 
polypeptide chain with molecular mass about 60008000 Da. There is a total of 61 
amino acids with 20 cysteine residues, distributed in specific sequences of Cys-X-
Cys, Cys-Cys-X-Cys-Cys, and Cys-Cys-X-Cys units, where X represents another 
amino acid residue. However, the polypeptide lengths of MTs are different for 
different species, and for the same species and different isomers. 
Human and mouse MT-Ill resemble other mammalian MTs, containing 20 
cysteines in conserved Cys-X-Cys and Cys-X-X-Cys sequence motifis. However, 
there are two insertions in MT-Ill resulting in a polypeptide length of 68 residues. A 
one-residue (Thr) insertion occurs in a region corresponding to the N-terminal 
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domain of MT- II and a six-residue insertion is present in a sequence corresponding 
to the C-terminal a domain (Figure 1.12) [142]. The C-P-C-P sequence and the Thr 
residue at position 5 in the 3 domain are thought crucial for the bioactivity of MT-Ill. 
Double mutation two Pro residues to either C-S-C-A or C-T-C-T abolishes the 
inhibitory activity of MT-Ill [155]. A deletion of l'hr5 also caused a loss of growth 
inhibitory activity. Furthermore, inserting these MT-Ill residues in a MT-1 backbone 
appears to generate bioactivity in the modified MT-I, indicating that these residues in 
MT-Ill may be the key determinant of bioactivity [156]. Bioactivity of MT-Ill does 
not appear to be related to the metal-binding properties. The mechanism of growth 
inhibition of neurons by MT-Ill remains unresolved. The significance of the insertion 
in the a-domain regarding the biological function of MT-Ill is unknown. 
rMT-II /3 	MDPN CSCATDSGCSCAGSCKCKQCKCTSCK 
hMT-III /3 MDPETCPCPSGGSCTCADSCKCEGCKCTSCKK 
rMT-II a 	KSCCSCCPVGCAKCSQG CICKEA 	SDKCSCCA 
hMT-III a MSCCSCCPAECEKCAKDCVCKGGE 1 1 bi IAEKCSCCQ 
Figure 1.12 Sequences of rabbit liver MT-11 and human brain MT-ILL 1155,1571. 
The X-ray crystal structure of rat liver Zn2Cd 5-MT-II (Figure 1.13) [158], 
and NMR solution structures of rabbit liver Cd 7-MT-II [159], rat liver Cd7-MT-Il 
[160] and human liver Cd7-MT [161] show that metallothionein can be divided into 
two structurally-independent domains a and 13, and linked via two amino acids. The 
seven metal ions are bound in clusters of four and three metals formed by bridging 
and terminal cysteine thiolate ligands with metal to sulthydiyl ratios M4S11 and M3S9 , 
which are associated with two domains, a and 13, respectively [158]. When both zinc 
and cadmium are present, Cd(II) binds preferentially to the cc-domain while Zn(II) 
binds preferentially to the 13-domain [162,158]. The presence of two zinc ions in the 
three -metal cluster of MT in the crystal versus all Cd in this cluster in the solution 
structure does not change the structure of the 13-domain [158]. All 20 cysteine 
residues participate in metal binding, and each of the seven metal ions is bound to 
four thiolate ligands tetrahedrally [163,164] as shown in Figure 1.13. 
27 
(A) 
( /hJj)IC) I I11I1()cIUCli )11 
Figure 1.13 (A) Metal thiolate clusters Zn 2 CdCys9 and Cd 4Cys 11 , and (B) 
X-ray crystal structure of rabbit liver metallothionein (Zn 2Cd 5MT-II). 
Colour code: dark blue-Cd; light blue- Zn; yellow-S [158]. 
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Many efforts have been made toward understanding the structure of MT-Ill. It has 
been suggested that the structure of MT-Ill should differ from that of the other MTs 
despite their high sequence identity (70%), since only MT-Ill exhibits growth 
inhibitory activity in neuronal cell culture studies. EXAFS study of native bovine 
Cu,Zn-MT-III [165,166] shows that both Cu+ 2+ and Zn are exclusively ligated by 
thiolates with primarily trigonal Cu and tetrahedral Zn 2 coordination. There is no 
mixed Cu,Zn-cluster in native bovine Cu,Zn-MT-III. Interestingly, a short Zn-Zn 
distance (3.24 A) was found in this MT-Ill, which is not consistent with the Zn3-
cluster usually found in other mammalian MTs with a Zn-Zn distance of 3.88 A. This 
has led to a putative structure for a Zn-cluster in which there is double bridging 
through sulfur atoms between two Zn 2 (Figure 1.14). It was also confirmed via 
" 3Cd NMR that similar Cd3- and Cd4-clusters exist in human Cd 7-MT-III as that in 
MT-I and MT-II. However, the metals in the n-domain exchange more rapidly [167]. 
The full 3D structure of this protein is so far still unknown. 
ZnZn 3.88A 
	
Zn" Zn 3.24 A 
Mammalian MT 	 MT-Ill 
Figure 1.14 Proposed structure of the Zn 3-cluster in Zn-MT-Ill as compared 
with the 3-metal cluster in mammalian MT. Adapted from Refs [166, 167]. 
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1.3.5 Medical Implications 
Metallothioneins are thought to play an important role in human health and 
disease as well as in therapeutics. It has been reported that MT has a critical role in 
the chemotherapy of certain cancers both in the development of tolerance to 
chemotherapeutics and as an adjunct to reduce toxic side effects [168]. The synthesis 
of MT is induced by various metals and this induction may provide protection from 
toxicity by allowing sequestration of metals. Clinical studies show that pretreatment 
of bismuth salts, specifically bismuth subnitrate (BSN) can induce MT synthesis in 
the kidney, but not in renal or pulmonary tumors. Therefore bismuth can reduce the 
renal toxicity of CDDP without compromising its chemotherapeutic activity 
[169,170]. MT has also been implicated in many cases of acquired cellular resistance 
to CDDP, but the mechanism of resistance is multifactorial and far from clear, 
probably including decreased drug accumulation, increased detoxification by thiol 
containing scavenger molecules (MT), and enhanced DNA repair [171,172]. Possible 
roles for MT in diseases other than cancer are being proposed and create exciting 
areas for further studies. The new form of MT, growth-inhibitory factor (GIF), 
isolated from the brain and inhibits neurotrophic activity in neonatal rat cerebral 
cortical neurons in vitro [142,154]. GIF is abundant in normal human brain, but 
down-regulated in the brain of patients with Alzheimer's disease, which suggests that 
it may be an important factor in the pathogenesis of Alzheimer's disease. 
30 
Chapter 1 Introduction 
1.4 References 
1. J. J. R. Fraüsto da Silva, and R. J. P. Williams, in the Biological Chemistry of the 
Elements: the Inorganic Chemistry of Life Clarendon Press, Oxford 1991, pp538 
2. R. D. Hancock, I. Cukrowski, J. Baloyi, and J. Mashishi, J. Chem. Soc. Dalton 
Trans. 1993, 2895 
3. P. J. Sadler, H. Sun, and H. Li, Chem. Eur. J. 1996, 2: 701 
4. a) F. A. Cotton, and G. Wilkinson, in Advanced Inorganic Chemistry (5th ed.) 
John Wiley & Sons Inc. USA 1988 
b) G. Wilkinson, R. D. Gillard, and J. A. McCleverty, in Comprehensive 
Coordination Chemistry, Pergamon Press, Oxford, United Kingdom 1987 
5. a) L. J., Farrugia, F. J. Lawor, and N. C. Norman, J. Chem. Soc. Dalton Trans. 
1995, 1163 
D. A. Atwood, A. H. Cowley, R. D. Hernandez, R. A. Jones, L. L. Rand, S. G. 
Bott, and J. L. Atwood, Inorg. Chem. 1993, 32: 2972 
C. J. Carmalt, L. J. Farrugia, and N. C. Norman, J Chem. Soc. Dalton Trans. 
1996, 455 
6. F. Lazarini, Cryst. Struct. Comm. 1979, 8: 69 
7. S. Summers, K. A. Abboud, S. R. Farrah, and G. J. Palenik, Inorg. Chem. 1994, 
33: 88 
8. W. Frank, G. J. Reiss, and J. Schneider, Angew. Chem. mt. Ed. Engl. 1995, 34: 
2416 
9. G. Pettit, and L. D. Pettit, JUPAC Stability Constant Database, IUPAC and 
Academic Software, Otley, United Kingdom 1993 
10. L. Odier, I Med. Chir. Pham. (France) 1786, 68: 49 
11. A. Marcet, Mem. Med. Soc. London 1805, 65: 155 
12. F. Balzer, C. R. Soc. Biol. 1889, 41: 537 
13. F. Lazarini, Bull. Bismuth Inst. 1981, 32: 3 
14. A. Slikkerveer, and F. A. de Wolff, Med. Toxicol. Adverse Drug Exp. 1989, 4: 
303 
15. U. Dittes, E. Vogel, and B. K. Keppler, Coord. Chem. Rev. 1997, 163: 345 
16. P. D. Midolo, A. Norton, M. von Itzstein, and J. R. Lambert, FEMS Microbiol. 
Lett. 1997, 157: 229 
17. S. Kirschner, Y. Wei, D. Francis, and J. G. Bergman, I Med. Chem. 1966, 9: 369 
31 
Chapter 1 Introduction 
18. S. M. Skinner, J. M. Swatzell, and R. W. Lewis, Res. Comm. Chem. Pathol. 
Pharmacol. 1978,19: 165 
19. P. Kopi-Maier, and T. Klapotke, Inorg. Chim. Acta 1988,152: 49 
20. N. Mahmood, A. Burke, R. M. Aimer, and B. M. Anner, Antiviral Chem. 
Chemother. 1995, 6: 187 
21. Merck Index 1989, 11: 197 
22. a) P. J. Barrie, M. I. Djuran, M. A. Mazid, M. McPartlin, P. J. Sadler, I. J. 
Scowen, and H. Sun, I Chem. Soc. Dalton Trans. 1996, 2417 
E. Asato, K. Katsura, M. Mikuriya, U. Turpeinen, I. Mutikainen, and J. Reedjik, 
Inorg. Chem. 1995, 34: 2447 
E. Asato, K. Katsura, M. Mikuriya, T. Fujii, J. Reedjik, Inorg. Chem. 1993, 32: 
5322 
23. J. W. Clitherow, UK Patent GB2220937A 1990 
24. A. A. McColm, A. McLaren, G. Klinkert, M. R. Francis, P. C. Connolly, C. J. 
Grinham, C. J. Campbell, S. Seiway, and R. Williamson, Aliment. Pharmcol. Therap. 
1996,10:241 
25. P. J. Sadler, and H. Sun, I Chem. Soc. Dalton Trans. 1995, 1395 
26. J. A. Parkinson, H. Sun, and P. J. Sadler, Chem. Commun. 1998, 881 
27. S. B. Coghill, in Pathogenesis and the Treatment of Peptic Ulcer Disease, 
Proceedings of International Symposium (Ed: A. T. R. Axon), Cairo, Egypt 1985, 7 
28. J. R. Lambert, D. J. Way, R. G. King, B. R. Eaves, and J. Hansky, 
Gastroenterology 1988, 94: A248 
29. K. M. Koch, B. M. Kerr, A. E. Gooding, and I. M. Davis, Brit. .1. Clin. 
Pharmacol. 1996, 42: 207 
30. C. J. Gavey, M-L, Szeto, C. U. Nwokolo, J. Sercombe, and R. E. Pounder, 
Aliment. Pharmacol. Ther. 1989, 3: 21 
31. D., Stiel, D. J. Murry, and T. J. Peters, Gut 1985, 25: 364 
32. J. R. Lambert, D. J. Way, R. G. King, E. R. Eaves, K. Lianeas, and A. Wan, 
Gastroenterology 1989, 96: A284 
33. J. R. Lambert, G. Arena, and L. Nicholson, Gastroenterology 1994, 106: A120 
34. G. A. Russ, R. E. Bigler, R. S. Tilbury, H. Q. Woodard, and J. S. Laughlin, 
Radiation Res. 1975, 63: 443 
35. J. R. Lambert, and P. Midolo, Aliment. Pharmacol. Ther. 1997, 11 (Suppl.):  27 
32 
Chapter 1 Introduction 
S. P. Lee, T. H. Lim, J. Pybus, and A. C. Clarke, Clin. Exp. Pharmacol. Physiol. 
1980,7:319 
D. Ws. Bierer, Rev. Infect. Dis. 1990,12(S): S3 
P. Hillemand, M. Palliere, B. Laquais, and P. Bouvet, Sem. Hop. Paris 1977, 53: 
1663 
J. F. Ross, R. C. Switzer, M. R. Poston, and G. T. Lawhorn, Brain Res. 1996, 
725: 137 
A. A. Meister, in Glutathione: Chemical, Biochemical and Medical Aspects 
(Eds.: D. Dolphin, 0. Avramovic, and R. Poulson), Wiley, New York 1988, pp  
A. Corazza, I. Harvey, and P. J. Sadler, Eur. J. Biochem. 1996, 236: 697 
G. Otiko, M. T. Razi, P. J. Sadler, A. A. Isab, and D. L. Rabenstein., J. Inorg. 
Biochem. 1983, 19: 227 
B. V. Cheesman, A. P. Arnold, and D. L. Rabenstein, .1 Am. Chem. Soc. 1988, 
110:6359 
N. Ballatori, Adv. Pharmacol. 1994, 27: 271 
D. R. Williams, I Inorg. Nul. Chem. 1997, 39: 711 
D. Chaleil, F. Lefevre, P. Allain, and G. J. Martin, J. Inorg. Biochem. 1981, 15: 
213 
N. Rao, and S. Feldman, Pharmaceut. Res. 1990, 7: 188 
M. Garner, J. Reglinski, W. E. Smith, and M. J. Stewart, I. Inorg. Biochem. 
1994, 56: 283 
A. Gyurasics, L. Koszorrus, F. Varga, and Z. Gregus, Biochem. Pharmacol. 1992, 
44: 1275 
G. Alonzo, N. Bertazzi, and M. Consiglio, Inorg. Chim. Acta 1984, 85: 135 
W. A. Herrmann, E. Herdtweck, and L. Pajdla, Chem. Ber./ Recueil 1993, 126: 
895 
E. Asato, K. Kamamuta, Y. Akamine, T. Fukami, R. Nukada, M. Mikuriya, S. 
Deguchi, and Y. Yokota, Bull. Chem. Soc. Jpn 1997, 70: 639 
H. H. Paradies, in Helicobacter Pylon, Gastritis and Peptic Ulcer (Eds: P. 
Malfertheiner, and H. Ditschuneit) Springer-Verlag, New York 1990, pp409 
J. A. Szymanska, and A. J. Zelazowski, Environ. Res. 1979, 19: 121 
33 
Chapter 1 Introduction 
D. W. Thomas, S. Sobecki, T. F. Hartley, P. Coyle, and M. H. Alp, in Chemical 
Toxicology and Clinical Chemistry of Metals (Eds: S. S. Brown and J. Savory), 
Academic Press, London 1983, 391 
H. Li, P. J. Sadler, and H. Sun, J. Biol. Chem. 1996, 271: 9483 
S. P. Lee, Scan. J. Gastroenterol. 1991, 26: 1 
A. Ottlecz, J. J. Romero, S. L. Hazell, D. Y. Graham, and L. M. Lichtenberger, 
Dig. Dis. Sd. 1993, 38: 2071 
W. Beil, C. Birkholz, S. Wagner, and K. F. Sewing, Pharmacology 1995, 50: 333 
W. Beil, S. Bierbaum, K. F. Sweing, Pharmacology 1993, 47: 141 
R. P. Rome, K. S. Salmela, J. Hooknikanne, T. U. Kosunen, and M. Salaspuro, 
Life Sci. 1992, 51: 195 
K. S. Salmela, R. P. Rome, J. Hooknikanne, T. U. Kosunen, M. Salaspuro, Scan. 
.1 Gastroenterolo. 1994, 29: 528 
E. Zeppezauer, J. P. Samama, and H. Eklund, Biochemistry 1982, 21: 4895 
E. Asato, Y. Akamine, R. Nukada, M. Mikuriya, S. Deguchi, and Y. Yokota, .1. 
Inorg. Biochem. 1997, 146 
E. Jabri, M. B. Carr, R. P. Hausinger, and P. A. Karplus, Science 1995, 268: 998 
S. Benini, W. R. Rypniewski, and K. S. Wilson, J. Biol. Inorg. Chem. 1998, 3: 
268 
J. F. Tomb, 0. White, A. N. Keriavage, R. A. Clayton, G.G. Sutton, et al. Nature 
1997,388:539 
J. R. Warren, B. Marshall, Lancet 1983, i: 1273 
T. L. Cover, and M. J. Blaster, Adv. mt. Med. 1996, 41: 85 
A. Labigne, H. de Reuse, Infect. Agents Dis. 1996, 5: 191 
P. Domenico, J. Reich, W. Madonia, B. A. Cunha, I Antimicro. Chemother. 
1996,38:1031 
R. C. Jamroz, J. R. Gasdaska, J. Y. Bradfield and J. H. Law, Proc. Nail. Acad. 
Sci. USA 1993, 90: 1320 
R. M. Palmour, H. E. Sutton, Biochemistry 1971, 10: 4026 
A. Bezkorovainy, in Biochemistry of Nonheme Iron, Plenum Press, New York 
1980, Chap. 4, p 127 
R. T. A. MacGillivray, E. Mendez, S. K. Sinha, M. R. Sutton, J. Lineback-Zins, 
and K. Brew, Proc. Natl. Acad. Sci. USA 1982, 79: 2504 
34 
Chapter 1 Introduction 
R. T. A. MacGillivray, E. Mendez,J. G. Shewale, S. K. Sinha, J. Lineback-Zins, 
and K. Brew, .1. Biol. Chem. 1983, 258: 3543 
J. -M. Jeltsch, and P. Chambon, Eur. I Biochem. 1982, 122: 291 
J. Williams, T. C. Elleman, B. Kingston, A. G. Wilkins, and K. A. Kuhn, Eur. I 
Biochem. 1982, 122: 297 
M. -H. Metz-Boutigue, J. Jollés, J. Mazurier, F. Schoentgen, D. Legrand, G. Spik, 
J. Montreuil, and P. Jollés, Eur. J. Biochem. 1984, 145: 659 
T. M. Rose, G. D. Plowman, D. B. Teplow, W. J. Dreyer, K. E. Hellström, and J. 
P. Brown, Proc. Nat!. Acad. Sci. USA 1986, 83: 1261 
E. N. Baker, Adv. Inorg. Chem. 1994, 41: 389 
B. Magdoff-Fairchild and B. W. Low, Arch. Biochem. Biophys. 1970, 138: 703 
B. F. Anderson, H. M. Baker, E. J. Dodson, G. E. Norris, S. V. Rumball, J. M. 
Waters and E. N. Baker, Proc. Nat!. Acad. Sd. USA 1987, 84: 1769 
S. Bailey, R. W. Evans, R. C. Garratt, B. Gorinsky, S. Hasnain, C. Horsburgh, H. 
Jhoti, P. F. Lindley, A. Mydin, R. Sarra and J. L. Watson, Biochemistry 1988, 27: 
5804 
R. Sarra, R. Garratt, B. Gorinsky, H. Jhoti and P. F. Lindley, Acta Crystallogr. 
1990, B46: 763 
H. J. Zuccola, Ph.D. Thesis, 1993, Georgia Institute of Technology, Atlanta, GA 
B. F. Anderson, H. M. Baker, G. E. Norris, S. V. Rumball, E. N. Baker, Nature 
(London)1990,344:784 
B. F. Anderson, H. M. Baker, G. E. Norris, D. W. Rice and E. N. Baker, I Mo!. 
Biol. 1989,209: 711 
H. Kurokawa, B. Mikami and M. Hirose, I Mo!. Biol. 1995, 254: 196 
M. S. Shongwe, C. A. Smith, E. W. Ainscough, H. M. Baker, A. M. Brodie and 
E. N. Baker, Biochemistry 1992, 31: 4451 
C. L. Day, B. F. Anderson, J. W. Tweedie and E. N. Baker, I Mo!. Biol. 1993, 
232:1084 
J. C. Dewan, B. Mikami, M. Hirose and J. C. Sacchettini, Biochemistry 1993, 32: 
11963 
P. D. Jeffrey, M. C. Bewley, R. T. A. MacGillivray, A. B. Mason, R. C. 
Woodworth, and E. N. Baker, Biochemistry 1998, 37: 13978 
35 
Chapter 1 Introduction 
R. T. A. MacGillivray, S. A. Moore, J. Chen, B. F. Anderson, H. Baker, Y. Luo, 
M. Bewley, C. A. Smith, M. E. P. Murphy, Y. Wang, A. B. Mason, R. C. 
Woodworth, G. D. Brayer, and E. N. Baker, Biochemistry 1998, 31: 7919 
H. R. Faber, T. Bland, C. L. Day, G. E. Norris, J. W. Tweedie, and E. N. Baker, 
I Mo!. Biol. 1996, 256: 352 
H. Jhoti, B. Gorinsky, R. C. Garratt, P. F. Lindley, A. R. Walton and R. W. 
Evans, I. Mo!. Biol. 1988, 200: 423 
A. B. Mason, M. K. Miller, W. D. Funk, D. K. Banfield, K. J. Savage, R. W. A. 
Oliver, B. N. Green, R. T. A. MacGillivray, R. C. Woodworth, Biochemistry 1993, 
32: 5472 
S. Bailey, R. W. Evans, R. C. Garratt, B. Gorinsky, S. Hasnain, C. Horsburgh, H. 
Jhoti, P. F. Lindley, A. Mydin, R. Sarra and J. L. Watson, Biochemistry 1988, 27: 
5804 
M. Gerstein, B. F. Anderson, G. E. Norris, E. N. Baker, A. M. Lesk, C. Chothia, 
I. Mo!. Biol. 1993,229: 1654 
J. G. Grossmann, M. Neu, E. Pantos, F. J. Schwab, R. W. Evans, E. Townes-
Andrews, P. F. Lindley, H. Appel, W. G. Thies, and S. S. Hasnain, I. Mo!. Biol. 
1992,225:811 
J. G. Grossmann, M. Neu, R. W. Evans, P. F. Lindley, H. Appel, and S. S. 
Hasnain, I Mo!. Biol. 1993, 229: 585 
A. C. Castellano, M. Barteri, M. Castagnola, A. Bianconi, E. Borghi, S. Della 
Longa, Biochem. Biophys. Res. Commun. 1994, 198: 646 
J. V. Princiotto and E. J. Zapoiski, Nature 1975, 255: 87 
D. A. Baldwin, D. M. R. de Sousa and R. M. A. von Wandruszka, Biochim. 
Biophys. Acta 1982, 719: 140 
J. G. Grossmann, A. B. Mason, R. C. Woodworth, M. Neu, P. F. Lindley and S. 
S. Hasnain, I. Mol. Biol. 1993, 231: 554 
H. R. Faber, T. Bland, C. L. Day, G. E. Norris, J. W. Tweedie and E. N. Baker, 
I Mol. Biol. 1996, 256: 352 
E. H. Morgan, and E. H. Appleton, Nature (London) 1969, 223: 1371 
A. L. Sullivan, J. A. Grasso, and L. R. Weintraub, Blood 1976, 47: 133 
D. C. Harris, and P. Aisen, In Iron Carriers and Iron Proteins (Ed: T. M. 
Loehr), VCH 1989, p270 
36 
Chapter 1 Introduction 
A. Dautry-Varsat, A. Ciechanover, and H. F. Lodish, Proc. Natl. Acad. Sd. USA 
1983,80:2258 
R. D. Klausner, G. Ashwell, J. van Renswoude, J. B. Harford, and K. R. 
Bridges, Proc. Nati. Acad. Sci. USA 1983, 80: 2263 
S. Jing, and I. S. Trowbridge, EMBOJ. 1987, 6: 327 
A. Dautry-Varsat, Biochimie 1986, 68: 375 
J. N. Octave, Y. J. Schneider, A. Trouet, and R. R. Crichton, Trends. Biochem. 
Sci. 1983, 8: 217 
C. R. Chitambar, and Z. Zivkovic, Cancer Res. 1987, 47: 3929 
C. R. Chitambar, and Z. Zivkovic, Cancer Res. 1990, 50: 1484 
C. R. Chitambar, W. G. Matthaeus, W. E. Antholine, K. Graff, and W. J. 
O'Brien, Blood 1988, 72: 1930 
C. R. Chitambar, J. Narasimhan, J. Guy, D. S. Sem, and W. J. O'Brien, Cancer 
Res. 1991,51: 6199 
R. UI-Haq, and C. R. Chitambar, Biochem. J. 1993, 294: 873 
M. Cochran, V. Chawtur, M. E. Jones, and E. A. Marshall, Blood 1991, 77: 
2347 
A. J. Roskams, and J. R. Connor, Proc. Nati. Acad. Sd. USA 1990, 87: 9024 
C. Exley, and J. D. Birchall, J Theor. Biol. 1992, 159: 83 
R. G. L. Pullen, J. M. Candy, C. M. Morris, G. Taylor, A. B. Keith, and J. A. 
Edwardson,i Neurochem. 1990, 55: 251 
M. Margoshes, B. L. Vallee, I Am. Chem. Soc. 1957, 79: 4813 
J. H. R. Kagi, S. R. Himmelhoch, P. D. Whanger, J. L. Bethune, and B. L. 
Vallee, I Biol. Chem. 1974, 249: 3537 
Y. Kojima, C. Berger, B. L. Vallee, and J. H. R. Kagi, Proc. Natl. Acad. Sci. 
USA 1976,73:3413 
B. A. Fowler, C. E. Hildebrand, Y. Kojim, and M. Webb, in Metallothionein II 
(Eds: J. H. R. Kagi, and Y. Kojima) Birkhauser Verlag, Basel, Boston 1987, p 19 
J. H. R. Kagi, M. Vaák, K. Lerch, D. E. 0. Gilg, P. Hunziker, W. R. Bernhard, 
M. Good, Environ. Health Perspect. 1984, 54: 93 
B. A. Fowler, C. E. Hildebrand, Y. Kojima, and M. Webb, Experientia Suppl. 
1987, 52: 9 
37 
Chapter 1 Introduction 
D. R. Winge, K. B. Nielson, W. R. Gray, and D. H. Hamer, J Biol. Chem. 1985, 
260:14464 
Y. Hayashi, C. W. Nakagawa, and A. Murasugi, Environ. Health Perspect. 
1986, 65: 13 
W. E. Rauser, Annu. Rev. Biochem. 1990, 59: 61 
M. Nordberg, Y. Kojima, in Metallothionein (Eds: J. H. R. Kagi, and M. 
Nordberg), Birkhäuser, Base! 1979, p41 
R. Prinz, U. Weser, Hoppe-Seyler 's Z. Physiol. Chem. 1975, 356: 767 
K. Lerch, Nature (London) 1980, 284: 368 
W. E. Rauser, N. R. Curvetto, Nature (London) 1980, 287: 563 
D. P. Higham, P. J. Sadler, M. D. Scawen, Inorg. Chim. Acta 1983, 79: 140 
D. P. Higham, P. J. Sadler, M. D. Scawen, Science 1984, 225: 1043 
S. Onosaka, K. Tanaka, K., and M. G. Cherian, Environ. Health Perspect. 1984, 
54: 67 
R. Nath, V. K. Paliwa!, R. Prasad, and R. Kambadur, in Metallothionein II (Eds: 
J. H. R. Kgai, and Y. Kojima) Birkhäuser Verlag, Basel, Boston 1987, p631 
R. J. Cousins, and D. E. Coppen, in Metallothionein II (Eds: J. H. R. Kgi, and 
Y. Kojima) BirkMuser Verlag, Base!, Boston 1987, p545 
Y. Uchida, K. Takio, K. Titani, Y. Ihara, and M. Tomonaga, Neuron 1991, 7: 
337 
D. Hamer,Annu. Rev. Biochem. 1986, 55: 913 
M. P. Richards, J. Nutr. 1989, 119: 1062 
M. Karin, Cell 1985, 41: 9 
T. Y. Li, A. J. Kraker, C. F. Shaw III, and D. H. Petering, Proc. Mad. Acad. Sci., 
USA 1980, 77: 6334 
L. Jiang, W. Maret, and B. L. Vallee, Proc. Natl. Acad. Sci. USA 1998, 95: 3483 
M. A. Morcillo, J. Santamaria, Biometals 1996, 9: 213 
S. Saito, M. Kurasaki, Res. Commun. In Mo!. Pathol. & Pharmacol. 1996, 93: 
101 
A. Pattanaik, G. Bachowski, J. Laib, D. Lemkuil, and C. F. Shaw III, .J. Biol. 
Chem. 1992, 267: 16121 
D. C. Lemkui!, D. Nettesheim, C. F. Shaw III, and D. H. Petering, J. Biol. 
Chem. 1994, 269: 24792 
38 
Chapter 1 Introduction 
L. Endresen, A. Bakka, and H. A. Rugstad, Cancer Res. 1983, 43: 2918 
M. Thornally, and M. Vasák, Biochim. Biophys. Acta 1985, 827: 36 
Y. Uchida, and M. Tomonaga, Brain Res. 1989, 481: 190 
A. K. Sewell, L. T. Jensen, J. C. Erickson, R. D. Palmiter, and D. R. Winge, 
Biochemistry 1995, 34: 4740 
L. T. Jensen, J. C. Erickson, R. D. Palmiter, and D. R. Winge, in 
Metallothionein IV (Ed: C. D. Klaassen) Birkhäuser Verlag, Basel, Boston 1999, pSi 
J. H. R. Kgi, and Y. Kojima, Experientia Suppi. 1987, 52: 25 
A. H. Robbins, D. E. McRee, M. Williamson, S. A. Collett, N. H. Xuong, W. F. 
Furey, B. C. Wang, and C. D. Stout, I Mo!. Biol. 1991, 221: 1269 
A. Arseniev, P. Schultze, E. Worgotter, W. Braun, G. Wagner, M. Vaák, J. H. 
K. Kogi, K. WUthrich, I Mo!. Biol. 1988, 201: 637 
P. Schultze, E. Worgotter, W. Braun, G. Wagner, M. Vaák, J. H. K. Kogi, and 
K. WUthrich, .1. Mo!. Biol. 1988, 203: 251 
B. A. Messerle, A. Schäffer, M. Vaák, J. H. K. Kogi, and K. WUthrich, I Mo!. 
Biol. 1990,214: 765 
J. D. Otvos, and I M. Armitage, Proc. Nat!. Acad. Sci. USA 1980, 77: 7094 
M. Vaák, and J. H. R. Kagi, Metal Ions in Biological Systems 1983, 15: 213 
M. Vaák, and J. H. R. Kagi, Proc. Nati. Acad. Sci. USA 1981, 78: 6709 
R. Bogumil, P. Falter, P. Binz, M. Vaák, J. M. Charonock, and C. D. Gamer, 
Eur. I Biochem. 1998, 255: 172 
M. Vaák, R. Bogumil, P. Falter, D. W. Hasler, P. Binz, S. Klauser, A. 
Bruinink, J. M. Charnock, and C. D. Garner, in Metal!othionein IV (Ed: C. D. 
Klaassen) Birkhäuser Verlag, Basel, Boston 1999, p1  5 
G. Oz, D. L. Pountney, I. M. Arimitage, in Metallothionein IV (Ed: C. D. 
Klaassen) Birkhäuser Verlag, Basel, Boston 1999, p 37 
M. P. Waalkes in Metallothionein III (Eds: K. T. Suzuki, N. Imura and M. 
Kimura) Birkhäuser Verlag Basel, Switzerland 1993, pp 243 
M. Satoh, Y. Aoki, and C. Tohyama, Cancer Chemother. Pharmoco!. 1997, 40: 
358 
P. J. Boogaard, A. Slikkerveer, J. F. Nagelkerke, and G. J. Mulder, Biochem. 
Pharmaco!. 1991, 41:369 
39 
Chapter 1 Introduction 
P. Farnworth, B. Hilicoat, and I. Roos, Cancer Chemother. Pharmacol. 1990, 
25: 411 
G. A. P. Hospers, N. H. Mulder, B. de Jong, L. de Ley, D. R. A. Uges, A. M. J. 
Fichtinger-Schepman, R. J. Sheper, and E. G. E. de Vries, Cancer Res. 1998, 48: 
6803 
40 
Chapter 2 Experimental Techniques 
Chapter 2 
Experimental Techniques 
In this chapter, some specific techniques used in this thesis are described. 
These include NMR, ultraviolet and visible (UV) spectroscopy, and stability constant 
calculations for binding of metal ions to macromolecules. 
2.1 NMR 
2.1.1 Basic Theory of NMR 
Nuclei with a spin quantum number of ~! 1/2 possess a magnetic moment and 
can be observed by NMR spectroscopy. Some commonly used nuclei for the study of 
biomolecules and their properties are listed in Table 2.1. 
Table 2.1 Magnetic properties of some useful nuclei 
Property 'H 13C 15N 
Nuclear spin 1/2 1/2 1/2 1/2 
Frequency (MHz)atll.74T 500.0 125.7 50.7 202.4 
Natural abundance% 99.98 1.108 0.37 100 
Relative sensitivity 	 1.00 	1 .59x 1 02 	1 .04x 1 0-3 	6.63x1  0-2 
When a magnetic field 130 is applied, the nuclear moments orient themselves 
with only certain allowed orientations. The nuclear moment is constrained to these 
orientations, but is subject to a torque as a result of the interaction with the applied 
field. The nuclei precess around the direction of the field with a frequency, w , known 
as the Larmor frequency, which is essentially the NMR frequency. The Larmor 
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frequency is related to the field strength, B0 by Equ. 2.1, where y  is the 
magnetogyric ratio. 
Equ.2.1 
Those nuclei with spin 1/2 have two possible orientations: parallel or 
antiparallel to the field, referred to as the a. and 3 spin states, respectively. Since 
there is a slight Boltzmann excess of nuclei aligned with the magnetic field, these 
will give rise to a net magnetization vector M0, which also lies in the same direction 
as B0 (Figure 2.1). 
z, B0 
Figure 2.1 Distribution of the precessing nuclear spins around the magnetic 
field, B0. The net macroscopic magnetization is aligned with the field, and the net 
magnetization vector M0 is shown [1]. 
To fulfill the resonance condition, in the continuous wave (CW) method, 
either variation of magnetic field or the transmitter frequency is required. However, 
this method has been entirely superseded by the pulsed method. 
2.1.2 Pulsed NMR 
In the pulsed method, a short pulse (several ts) of radiofrequency (RF) 
irradiation of duration (tn) provides the simultaneous excitation of all the frequencies 
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in a certain range. If a pulse of radiofrequency irradiation at the Larmor frequency zm, 
along the x axis in the laboratory frame is applied, this would be equivalent to 
applying a static field B 1 along the x' axis of the rotating frame. The bulk 
magnetization M0 will flip through an angle, known as the pulse angle, into the x-y 
plane. The pulse angle 0 is related to the length of the pulse as shown in Equ. 2.2. 
0=yB 1 t 	 Equ.2.2 







y 	x-axis 	) 
Figure 2.2 The effect of a 900  pulse applied along the x axis, adapted from 121. 
After the pulse, the magnetization has coherence in the x-y plane, whereby all 
the spins are aligned along the y axis and are in phase. Since the detector coil lies 
oriented in the x-y plane, as the nuclei relax back to their equilibrium position along 
the z axis, the decay of the transverse magnetization, which is detected in the 
receiver coil, is called the free induction decay (FID), giving rise to time domain 
spectra. The FID can be converted to a frequency signal by Fourier transformation. 
2.1.3 Relaxation 
After removal of the RF pulse, the perturbed spin system will begin to relax 
back towards its equilibrium position by means of two different relaxation processes. 
The relaxation in the applied field direction, which is characterized by the spin- 
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lattice or longitudinal relaxation time T 1 , and relaxation perpendicular to the field 
direction, which is characterized by the spin-spin or transverse relaxation time T 2 . 
Spin-lattice relaxation is associated with a change in the energy of the spin 
system. For protons under high-resolution NMR conditions, the spin-lattice times T1 
are of the order of a second, and do not vary greatly for protons in different bonding 
situations. However, for ' 3 C, T 1 -values vary from milliseconds in large molecules to 
several hundred of seconds in small molecules. It also depends on the types of 
carbons present. T 1 is usually measured by inversion recovery experiments [1]. After 
a 900  pulse, a period of 5*Ti  is required to achieve almost complete T 1 relaxation. 
Spin-spin relaxation is the dephaseing of coherence in the x-y plane, as 
nuclear spins interchange energy whilst processing at different rates. T 2 is measured 
by spin-echo experiments [1]. T 2-values are related to the line-width of observed 
NMR signals. Macromolecules usually relax fast with smaller T 2 values and give rise 
to broad NMR signals. 
23.4 Chemical Shift 
The chemical shift (ö) is defined as follows: 
Vsample V reference 
X101  
observing frequency 
For 1 H NMR the recommended reference is tetramethylsilane (TMS), i.e. 
STMS = 0.0. Other references such as 3-trimethylsilyipropionate 2,2,3,3,d4 (TSP), 
have also been used in aqueous solutions since TMS is insoluble in water. 
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The chemical shifts for 'H are commonly found in the range of 0 to 10 ppm, 
for 13 C they are in the range of 0 to 250 ppm. In proteins, the chemical shifts for 
aromatic and NH protons are normally in the range of 6 to 12 ppm, for aliphatic 
aCH, PCH and PCH2 in the range of 1.0 to 5.8 ppm, and methyl protons are in the 
range of 1.0 to —1.0 ppm [3]. The negative chemical shifts in proteins are often found 
for those protons which are located above or below aromatic rings, such as His, Phe, 
Trp or Tyr. This is attributed to ring current effects. 
When the molecule with its delocalized 7t-electron is placed in a magnetic 
field, the ring current generates an additional magnetic field which is in the opposite 
direction to the external magnetic field above or below the ring plane, and therefore 
the corresponding resonances are shifted to high field (Figure 2.3). Conversely, 
protons located in the ring plane outside the confines of the ring are shifted to low 
field. The extent of the ring current shift is related to the distance and angle of a 
proton from the face of an aromatic ring, Figure 2.3. The ring current shifts are 
much less noticeable for all other nuclei than for 'H. 
A 	 B 
B0 
Z 	




'I6\OA \02 	.1 
0 	1 	2 3 4 p 
Figure 2.3 (A) Qualitative representation of the ring current field of a benzene 
ring generated by the application of an external magnetic field. Inside the cone, 
the local field is opposed to B0, and outside it is parallel to B0. (B) Isoshielding lines 
in a plane perpendicular to the plane of the ring. Taken from [3]. 
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2.1.5 Solvent Suppression 
For biological and biochemical applications, 'H NMR spectra are usually 
recorded in aqueous media, with the addition of only 10% D20 to provide the 
necessary lock signal. The large HOD signal can be suppressed via so-called 
"presaturation" during the relaxation delay between pulses. An irradiating field of 
lesser amplitude is applied at the frequency of the solvent signal before the observed 
pulse as shown in Figure 2.4. The drawback for this technique is that exchanging 
NH protons are also saturated and can therefore disappear from the spectrum. 
90°x 
Figure 2.4 Pulse scheme for a 1D experiment with water presaturation. 
Other techniques, such as the "jump and return" technique [4], and a 
Watergate sequence [5], have also been used for solvent suppression. These methods 
overcome the problem of saturation of exchangeable protons in presaturation. The 
jump and return method has the disadvantage of signals in the dispersion tail of the 
residual water peak. The Watergate (WATER suppression by GrAdient Tailored 
Excitation) technique, which uses pulsed field gradients, is claimed [5] to yield a 
superior suppression of the water signal compared with other methods. 
2.1.6 Two Dimensional NMR 
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21) NMR spectra are obtained by recording a series of 1D NMR spectra. 
These individual spectra differ only by a time increment, which is introduced within 
the pulse sequence. The overall scheme for a 21) experiment is shown in Figure 2.5. 
 -- — — — _
I -- — — — — — - — — — — — — — - — — — — — — — — — — — — — I 
preparation 	: evolution 	: mixing 	detection 
nR 
ii ii \AAA 
I 	 I 	 I 	 I 	J 	V 
dl 	p1 	u t1 	 p2 	i V acq (t2) 
Figure 2.5 General scheme for a 2D NMR experiment 161. 
The preparation period usually consists of a delay time (dl), during which 
thermal equilibrium is reached, followed by one or several RF pulses to create phase 
coherence in the x-y plane. During the evolution period t1 the chemical shifts or spin-
spin couplings evolve and this is the time domain which is incremented during the 
2D experiment. In the mixing period, one or several RF pulses are applied and create 
an observable transverse magnetization. The FID is then recorded during t2, the 
acquisition time. 
The primary 2D matrix consists of a series of FIDs, from which a set of 1 D 
NMR spectra is obtained by Fourier transformation with respect to t2. The signals of 
each transformation may differ in amplitude and/or phase. A second Fourier 
transformation with respect to ti yields the finial 2D matrix with frequency axes F 1 
and F2. The 2D spectrum is commonly displaced by the stacked plot or the contour 
plot as shown in Figure 2.6, with the latter being the most practically used method in 















—* F2 	 —* F2 
Figure 2.6 Schematic representation of a two-dimensional 13C_ 1 H J-resolved 
NMR spectrum of chloroform. (A) Stacked plot and (B) Contour plot [1]. 
2.1.6.1 Homonuclear Correlated NMR Spectroscopy (COSY) 
COSY is one of the most important and most commonly used 2D NMR 
experiments. The basis of the COSY experiment is the process of coherence transfer 
in which magnetization is transferred between coupled spins. The pulse sequence for 





C11 	 t1 	 acq 
Figure 2.7 Pulse sequence for the two-dimensional homonuclear correlated 
NMR experiment COSY [6]. 
Various spin systems can be easily identified from the cross peaks of the 2D 
COSY spectrum and so the protons can be assigned. This experiment is very useful 
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in peptides and proteins in which cross-peaks can be observed within a specific spin 
system (amino acid). Practically, only absolute-value mode is used with low 
resolution, and the phase-sensitive COSY is often not useful due to the 90 0 phase 
difference between the cross-peaks and the diagonal peaks, e.g. cross-peaks are in-
phase and the diagonal peaks are out of phase. An in-phase spectrum for both cross-
peaks and diagonal peaks can be obtained from total correlation spectroscopy 
(TOCSY, see below). 
2.1.6.2 Total Correlation Spectroscopy (TOCSY) 
One of the most popular pulse sequences currently used for resonance 
assignments in high resolution 'H NMR spectroscopy is TOCSY (sometimes 
referred to as HOHAHA) [7,8]. In this experiment magnetization is transferred 
coherently from one spin to another belonging to the same scalar-coupled spin 
system during an extended spin-lock period. During this period an RF pulse 
sequence (such as MLEV 17) is applied that, theoretically, eliminates the chemical 
shift terms from the nuclear spin Hamiltonian and leaves only the isotropic scalar 
coupling interaction. Therefore it can be thought of as an alternative version of 
homonuclear correlated spectroscopy (COSY). 
However, there is an additional important advantage over conventional 
COSY: the correlation observed in TOCSY is from coherence transfer even if there 
is no direct coupling between two nuclei, which is quite different from COSY. The 
advantage of such coherence transfer is that net magnetization transfer occurs, and 
all the peaks in the spectrum can be obtained in pure absorption mode (in-phase). 
This situation is different from that observed in phase-sensitive COSY and DQF-
COSY (anti-phase cross peaks). This is an advantageous feature in cases where the 
linewidth exceeds the size of the active scalar coupling, since then the anti-phase 
multip lets are severely attenuated due to the destructive interference of the anti-phase 
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components. Another advantage of coherence transfer is the appearance of relay and 
multiple relay peaks in the spectrum. The number of relay peaks is related to the 
mixing period (spin-lock time), and the relay peaks are not particularly sensitive to 
spin coupling. This method is even suitable for strongly-coupled systems, and hence 
TOCSY is often preferred to normal COSY. The TOCSY spectrum can provide 
connectivities for a complete network, and is very useful for studies of peptides and 
oligosaccharides. 
2.1.6.3 Heteronuclear Multiple (Single)-Quantum Coherence (HMQC and 
HSQC) 
The heteronuclear multiple-quantum (and single-quantum) coherence 
(HMQC and HSQC) technique belongs to the family of indirect (or inverse) 
detection experiments. The main advantage of this technique is the enhanced 
sensitivity, a theoretical maximum of [17HI/17xI]512  (32 and 306 for ' 3C and ' 5N, 
respectively) can be obtained with respect to direct detection, and relatively short 
repetition time due to short T, of protons [9]. Therefore it is possible to detect 
species at concentrations of physiological relevance (mM or even tM) and aqueous 
solution where no substitution of hydrogen by deuterium occurs, and thus NH 
protons can be observed [10]. By means of selective labeling with ' 3 C and ' 5N, this 
technique can also simplify a complicated spectrum, since it detects only those 
protons which are directly attached to ' 3C and ' 5N atoms in the sample. This is 
especially important for biofluids or large molecules (such as proteins and nucleic 
acids) [11,12]. 
Besides the enhanced sensitivity, the resolution in the 'H dimension is also 
improved via inverse detection. The basic pulse sequence of HMQC (HSQC) is 
shown in Figure 2.8, and can be regarded as a heteronuclear spin-echo difference 
experiment. The BIRD (Bilinear Rotation Decoupling) sequence [13] or 
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presaturation can be inserted before this pulse sequence to eliminate the signals from 
protons attached to 12C, leaving only signals from protons attached to 
contributing to a 13 C - 'H chemical shift correlated spectrum. 
(A) 
















X 	 itI2 
	
702 
ti 	 GARP (dec.) 
Figure 2.8 Basic HSQC (A), and HMQC (B), pulse sequences. The delays d2 are 
1/4J and 1/2J, respectively, where J is the one-bond HX coupling constant. Other 
modifications are usually needed to improve the water suppression and to detect 
resonances close to the water signal. These include techniques such as presaturation 
(+ SCUBA) and WATERGATE (WATER suppression by Gradient-Tailored 
Excitation) [14,15]. 
2.1.6.4 2D Nuclear Overha user Enhancement Spectroscopy (NOESY) and 
Exchange Spectroscopy (EXS19 
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NOESY yields correlation signals, which are caused by dipolar (e.g. 'H) 
cross-relaxation between nuclei (proton-proton) in a close spatial relationship. The 
intensities of the cross-peaks are proportional to the inverse sixth power (ocl/r ij 6) of 
the distances between them. The pulse sequence is shown in Figure 2.9. NOESY is 
the essential method for determining peptide conformations or the tertiary structure 
of proteins. Of key importance in the NOESY experiment is the mixing time -cm. The 
length of time chosen for this mixing period depends dramatically on the properties 
of the molecule being investigated. For small molecules, Tm  is usually chosen as the 
order of 1 5 s whereas for large molecules as the order of 50 200 ms. In contrast 
to phase-sensitive COSY, both the cross-peaks and diagonal peaks in NOESY 
spectra can be obtained with absorption-mode lineshapes. A complicating factor is 
that both peaks caused by cross relaxation and chemical exchange (EXSY) appear on 
the spectra, but can be avoided by using clean-NOESY techniqe.. 
Dynamic processes such as chemical exchange can also be investigated via 
NOESY pulse sequence shown in Figure 2.9. 2D EXSY gives several advantages 
over conventional ID techniques (saturation transfer, selective excitation and 
lineshape analysis etc.). The obvious one is the ability to study networks involving 
multi-sites. A single 2D EXSY spectrum allows determination of all the dynamic 
data simultaneously. The second advantage is the ability to study partially 
overlapping spectra, where selective excitation is impossible, and finally a 2D 
method becomes clear (for multi-site exchange) if the dynamic processes are to be 
monitored as a function of mixing times (Tm). 
7r12 
Figure 2.9 2D NOESYJEXSY pulse sequence. 
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2.2 Ultraviolet and Visible (UV) Spectroscopy 
Absorption of ultraviolet and visible radiation by molecules generally occurs 
in one or more electronic absorption bands, each of which is made up of numerous 
closely packed but discrete lines. Each line arises from the transition of an electron 
from the ground state to one of the many vibrational and rotational energy states 
associated with each excited electronic energy state. Due to the fact that many of 
these vibrational and rotational states have only slight different energies, the number 
of lines contained in the typical band is large. 
Organic molecules absorb radiation in the wavelength region between 180 
and 780 nm resulting from interactions between photons and those electrons that 
either participate directly in bond formation or are localized on atoms such as 
oxygen, sulfur, nitrogen and halogens. Certain functional groups have typical 
absorption bands in UV spectra, for instance, carbonyl groups occur at -180 and 280 
nm, carboxyl at -200 nm, benzene at -200 and 260 nm [16]. Many metal ions and 
their complexes, in particular the first and second transition metal ions, absorb 
radiation in the visible region. Proteins absorb radiation in the region of 230 -'300 
nm due to the aromatic side chains of tyrosine, tryptophan and phenylalanine 
residues. Disulfide bonds display a weak absorption band around 250 nm and peptide 
bonds absorb strongly below 230 nm [17]. 
Many inorganic and organic complexes exhibit charge-transfer absorption. 
These kinds of complexes consist of an electron-donor group bonded to an electron 
acceptor. When this complex absorbs radiation, an electron from the donor is 
transferred to an orbital that is largely associated with the acceptor. In most charge-
transfer complexes involving a metal ion, the metal serves as the electron acceptor, 
for example as Fe 2-transferrin shows a Ligand-Metal-Charge-Transfer (LMCT) band 
at 465 nm[18]. 
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Ultraviolet and visible spectroscopy has a wide applicability, enormous 
numbers of inorganic, organic and biochemical species absorb ultraviolet or visible 
radiation and are thus amenable to direct quantitative or qualitative determination. It 
has a high sensitivity with a typical detection limit from 104  to  10-5  M. It can be used 
to determine the concentration of biological macromolecules in solution and also 
used to determine protein stability and to follow structural transitions such as 
unfolding and refolding under a variety of conditions. By using rapid mixing 
techniques, reactions that occur in the millisecond range can be monitored by UV. 
Moreover, this method is particularly important for those extremely expensive 
complexes such as proteins and enzymes since the measurements can be carried out 
in solution, and only tiny amounts of material are required for analysis. The method 
is non-destructive and the samples can be recovered afterwards. 
2.3 Stability Constant Calculations for Binding of Ligands 
and Metal Ions to Macromolecules 
There are many methods which can be used to study the thermodynamics of a 
reaction. Here, only the method used to calculate the stability constants quoted in this 
thesis is described. 
For a macromolecule P binding to one molecule of ion (metal or ligand) L, 
the reaction can be represented as: 
P + L PL 
	
Ka = {PL]/[P] [L] 	 Equ. 2.3 
Where Ka is the equilibrium constant for this association reaction. Here a new 
quantity Y is introduced and defined as: 
concentration of L bound to P = [PL] 	
Equ. 2.4 
total concentration of all forms of P [P] + [PL] 
From Equ. 2.3, [PL]= Ka[P1[L], thus 
Y= Ka[L]/(1+Ka[L]) 	 Equ. 2.5 
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By taking the reciprocal of Equ. 2.5, then 
1/Y = 1 + l/(Ka[L]) 	 Equ. 2.6 
A plot of 1/Y vs 1/[L] gives a straight line with a slope of 1/K a. 
If a macromolecule has two equivalent binding sites, there will be two 
binding equilibria: 
P + L 	PL 	 Ka i = [PL]/ ([P][L]) 
PL + L PL2 	 Ka2 = [PL2]/ ([PL][L]) 
Similarly a new quantity Y is defined as: 
concentration of L bound to P = [PL] + 2[PL2] 	Equ. 2.7 
total concentration of all forms of P [P] + [PL] + [PL2] 
Since [PL] = Kai[P][L] and [PL2] =K[PL][L], the equation above can be rewritten 
as: 
Kai[L] + 2KalKa2[L] 2 
1+ Kai[L] + KalKa2[L] 2 
Equ. 2.8 
If the two sites of macromolecules are independent and equivalent, K ai and Ka2 are 
related each other by a statistical factor. For the two sites, K ai = 2K and Ka2 =1/2K, 
where K is an intrinsic binding constant. Therefore, the Equ. 2.8 can be written as 
Y = 2K[L]/ (1 + K[L]) 	 Equ. 2.9 
In general, for n equivalent sites, it can be shown that 
Y = nK[L]/ (1 + K[L]) 	 Equ. 2.10 
Equ. 2.10 can be rearranged as 
1/Y = 1/n + 1/(nK[L]) 	 Equ 2.11 
Thus a plot of 1/Y versus 1/[L] gives a straight line of slop 1I(nK) and an intercept 
on the y axis of 1/n, Figure 2.10A. This plot is also known as the Hughes-Klotz plot 
[19]. 
Equ. 2.10 can also be rearranged as: 
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Y/[L]=nK—KY 	 Equ 2.12 
Thus a plot of Y/[L] versus Y gives a straight line of slope —K and an intercept on 





1/Y I 	Slope =1/(nK) 	Y/[L] 
1/n 
1/[L] Y 
Figure 2.10 (A) Plot of 1/Y versus 1/LU, and (B) Plot of Y/[L] versus V. Adapted 
from [19]. 
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Chapter 3 
Complexation of Bismuth by Recombinant N- 
Lobe of Human Serum Transferrin (hTF/2N) 1 
3.1 Abstract 
Interactions of recombinant N-lobe of human serum transferrin (hTF/2N) 
with Bi3 (ionic radius 1.03 A), a metal ion widely used in medicine, have been 
investigated by UV and NMR spectroscopy. The (bicarbonate independent) stability 
constant for Bi3 binding to the recombinant N-lobe of human serum transferrin was 
determined to be log K*  18.9±0.2 at 310 K, 5 mM bicarbonate, 10 mM Hepes buffer 
at pH 7.4. The presence of Fe 3+  in the C-lobe of intact human serum transferrin (hTF) 
perturbed Bi3 binding to the N-lobe, whilst binding of Bi 3 to the C-lobe was almost 
unaffected by the presence of Fe 3+  in the N-lobe. Reactions of Bi3 (as [Bi(NTA)] or 
ranitidine bismuth citrate) with hTF/2N in solutions containing 10 mM bicarbonate 
induced specific changes to high field 'H NMR peaks. The 'H coordination shifts 
induced by Bi3 were similar to those induced by Fe 3+  and Ga3 , suggesting that Bi3 
binding causes similar structural changes to hTF/2N. ' 3C NMR data showed that 
carbonate binds to hTF/2N concomitantly with Bi3 . 
'Abbreviations used in this Chapter are: 
hTF, human serum transferrin; hTF/2N, recombinant N-lobe of human serum 
transferrin; FeN/c-hTF, monoferric transferrin with Fe 3+  in the N/C lobe; K, 
bicarbonate-independent binding constant; NOESY, nuclear Overhauser effect 
spectroscopy; RBC, ranitidine bismuth citrate; NTA, nitrilotriacetate; pH*,  pH meter 
reading for D20 solution; TOCSY, total correlation spectroscopy. 
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3.2 Introduction 
The transferrins are primarily iron-binding proteins, however in human 
serum, transferrin is only about 30% saturated with iron and this is thought to occupy 
the N-lobe [1]. Thus there is a high capacity for binding to other metal ions which 
enter the body and it is thought that transferrin may play an important role in the 
transport and delivery of a variety of metal ions of diagnostic, therapeutic and toxic 
importance. Indeed about 30 metal ions have already been reported to bind transferrin 
reversibly with either bicarbonate or oxalate as synergistic anions. This includes first 
transition series metal ions, group 13 metal ions, lanthanides and actinides [2]. 
Binding of the first transition series metal ions to transferrins has been studied 
extensively. Like Fe 3+'  Mn 3+' CO3+ and Cu2+  give intensively-coloured complexes 
with transferrins because of the presence in the visible region of the phenolate (it) -0.  
metal (dit)  LMCT bands [3]. The binding of the first transition series elements to 
tansferrins is more complicated due to their variable oxidation states. Vanadium can 
bind to transferrins in three different oxidation states, V(III), V(IV) and V(V) [4,5,6]. 
Generally, trivalent oxidation states are highly favored to form thermodynamically 
more stable complexes than divalent metal ions. Since most of the first transition 
elements are essential in biological systems, transferrins may be involved in their 
binding and translocation. It has been reported that transferrin is the main carrier for 
manganese in blood [7], and thermodynamic studies suggest that transferrin is also 
capable of competing with serum albumin for zinc under the conditions that prevail 
in circulation [8]. 
The group 13 metals have a characteristic 3+ charge, just like Fe'. This 
group of metal ions can form very stable complexes with transferrin with binding 
constants ranging from 10' (A1 3 ) [9] to l0' 9(Ga3 ) [10] similar to Fe 3+ (1020) [11]. 
This binding is particularly important since several metal ions in this group are 
medically important. Aluminum has been linked with various diseases such as 
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dialysis encephalopathy and Alzheimer's disease [12,13]. Gallium (67Ga) and indium 
(11 1 1n) are used as imaging agents in diagnostic medicine and transferrin is likely to 
be the main carrier for these metal ions. 
The lanthanide and actinide ions are substantially larger. It has been reported 
that only smaller lanthanide ions bind to transferrin at both sites, whereas larger ions 
such as Pr 3+  and Nd3 bind only at one site [14]. It has been suggested that one of the 
specific transferrin sites is too small to accommodate the larger lanthanides and 
actinides. However, Harris [15] has reported that for Sm 3 and Nd3 , two metal ions 
can bind. Contradictory results have also been obtained for Gd 3 binding to human 
transferrin [16,17]. Hf1 binds to transferrin at both sites, but appears not to have the 
same closed configuration as transferrin complexes of smaller cations [18]. 
Recently it was found that Bi 3 , a large metal ion of ionic radius 1.03 A, 
which is widely used in medicine in antibacterial and antiulcer drugs [19,20], binds 
to human serum transferrin strongly with (bicarbonate independent) stability 
constants of log K*l  and log K*2  of 19.4, 18.6 (37 °C 10 mM Hepes buffer, 5 mM 
bicarbonate pH 7.4) [21]. This binding ability is of potential importance for the 
transport and delivery of bismuth-containing drugs and control of bismuth levels in 
the body, since the distribution of bismuth in blood plasma and other biofluids is still 
not well understood. 
There is currently much interest in the functional difference between the two 
lobes of transferrin. Half-molecules offer the chance to examine the properties of 
single-sited molecules without the complications of seeing the "averaged" 
characteristics of the two sites. In this Chapter, the complexation of Bi 3 by 
recombinant N-lobe of human serum transferrin is studied. The stability constant for 
Bi3 binding to recombinant hTF/2N is determined and is compared to that for Bi 3 
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binding to intact hTF. The effect of Fe 3+  on binding of Bi 3 to hTF/2N is also studied 
by selectively loading Fe 3 in either the N- or the C-lobe. Bi 3 -induced structural 
changes are investigated by NMR spectroscopy and compared with those induced by 
3+ 	3+ Fe andGa 
3.3 Experimental Procedures 
3.3.1 Materials 
Apo-hTF was purchased from Sigma (catalogue no: T05 19). Recombinant N-
lobe of human serum transferrin (hTF/2N) was prepared by Dr. A. B. Mason 
(University of Vermont College of Medicine, U.S.A.). It was expressed in the 
methylotrophic yeast, Pichia pastoris, by placing the hTF/2N cDNA under the 
control of the methanol-inducible alcohol oxidase promoter, and purified as 
previously described [22]. The Fe 3+  was removed by addition of metal removal buffer 
(1 mM NTA, 1 mM EDTA and 0.5 M-sodium acetate, pH 4.9) [23], followed by 
ultrafiltration three times in a Centricon 10 (Amicon, 1 h each). Finally the protein 
was washed four times with 0.1 M KC1 to remove low molecular mass impurities via 
ultrafiltration (Centricon 10). For apo-hTF, a similar procedure was used to remove 
low molecular mass impurities (Centricon 30). Monoferric transferrins (selective 
loading of Fe 3+  in either N- or C-lobe of transferrin) were prepared as previously 
described [24]. Use of the reported procedure for selective Fe 3+  loading of the N-lobe 
(using [Fe(NH4)2(504)21) appears to provide > 80% selective N-lobe loading [11], 
although under NMR conditions it was found that the selectivity is slightly lower 
[25]. Crystalline [Bi(NTA)] was synthesized according to a literature procedure [26] 
and had a satisfactory elemental analysis. Ranitidine bismuth citrate (RBC) was 
supplied by GlaxoWellcome. NaHCO3, KC1, H3NTA and Hepes were purchased 
from Aldrich Chemical Co., and NaH' 3CO3 (99% enriched-' 3 C) was from MSD 
Isotopes. 
3.3.2 Preparation of NMR Samples 
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To allow H-D exchange, apo-hTF/2N was dissolved in 0.1 M KC! in D 20, 
and after adjustment of the PH*  (pH meter reading for D20 solution) to 7.8, was left 
for 4 h at ambient temperature. After lyophilization, the sample was redissolved in 
D20 containing 10 mM NaHCO 3 . The pH*  was then readjusted to 7.80 ± 0.05, when 
necessary, using NaOD and DC! (0.2 M). The pH*  values of NMR solutions were 
recorded before and after NMR measurements. 
3.3.3 Samples for Electronic Absorption Spectroscopy 
These were prepared by diluting aliquots of stock apo-hTF/2N or mono ferric 
transferrin solutions to Ca. 10 M with 10 mM Hepes buffer, pH 7.4. The 
concentrations were determined spectrophotometrically on the basis of E280  38,600 
and 103,000 M'cm' for hTF/2N and monoferric transferrins, respectively [22,27]. 
Immediately before addition of Bi , an aliquot of a concentrated solution of 
NaHCO3 (0.25 M) was added to give 5 mM HCO3. The spectrum of the apo-hTF/2N 
solution (containing 5 mM bicarbonate) was recorded after equilibration at 310 K for 
10 mm. Aliquots of the stock solution of bismuth (usually 5-20 p.! of [Bi(NTA)] 
solutions) were then added to the apo-hTF/2N curvette and spectra were recorded 
after at least 0.5 h equilibration at 310 K. A similar procedure was used for titration 
of monoferric transferrins with [Bi(NTA)]. 
3.3.4 NMR Spectroscopy 
'H NMR spectra were recorded on a Bruker DMX 500 or Varian Unity 600 
spectrometers at 500 and 600 MHz, respectively. Spectra were acquired using 0.7 ml 
of solution in 5-mm tubes (0.9 mM hTF/2N) at 310 K, and 400-1200 transients, 6 p.s 
(500) pulses, recycle time 2 s, 16 K data points, and water suppression via 
presaturation. The chemical shift reference was dioxane via endogenous formate 
(8.465 ppm, pH*>  7) which was always present in the samples as a minor impurity. 
Resolution enhancement of the spectra was achieved by processing the free induction 
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decays with a combination of unshifted sine-bell and exponential functions (line 
broadening of 1.5-5 Hz) on a Silicon Graphics computer using Varian VNMR 
software (VNMR, 4.3) and XW1NNMR 2.0. 2D TOCSY and NOESY spectra 
(mixing time 60 and 50 ms, respectively) of hTF/2N at pH * 7.3 were acquired using 2 
K data points in the f2 dimension, acquisition time 0.12 s, 48 scans and 256 
increments in the fi dimension, in a total time of 14 h. Unshifted Gaussian functions 
were used in both dimensions for processing 2D spectra. The 2D NMR experiments 
were carried out with help from Dr. Hongzhe Sun. 
The 'H-decoupled 13 C spectrum was recorded at 310 K on a Bruker DMX 500 
MHz NMR spectrometer equipped with a 5-mm broadband probe at a resonance 
frequency 125 MHz. Typically, 20,000-40,000 transients were collected using a 
pulsewidth of 8 is (50°), relaxation delay 2 s, 16 K data points. The spectra were 
processed using an exponential function (8-10 Hz) prior to Fourier transformation. 
3.4 Results 
3.4.1 Electronic Absorption Spectroscopy 
The complexation of metal ions to the phenolic groups of the tyrosine 
residues in the specific metal-binding sites of apo-transferrin leads to the production 
of two new absorption bands at 241 and 295 nm [28]. These new bands are readily 
apparent in difference UV spectra of metal-transferrin and apo-hTF. 
The recombinant N-lobe of transferrin (hTF/2N) was titrated with [Bi(NTA)] 
(x-- I, 10), and the absorbance at 241 nm was monitored. The UV difference spectra 
and titration curves are shown in Figure 3.1 and Figure 3.2, respectively. For the 
NTA : Bi = 1: 1 curve, M increases linearly with increase in ratio of Bi: hTF/2N, and 
from the initial slope of the curve the molar absorptivity of Bi-hTF/2N was obtained 
as 22,000 M'cm'. Due to NTA competition, the titration curve for NTA : Bi = 10 :1 
roll 
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Figure 3.1 UV difference spectra for Bi 3 binding to the recombinant N-lobe of 
transferrin. [Bi(NTA)] (0.2, 0.4, 0.6, 0.8, 1.0, 1.4 mol equiv) was added to 1.09x10 
M recombinant hTF/2N in 10 mM Hepes buffer at pH 7.4 containing 5 mM 
bicarbonate, 310 K. The two absorption bands at 241 and 295 nm are indicative of 
Bi3 binding to the specific binding site of hTF/2N. 
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Figure 3.2 Titration curves for bismuth binding to recombinant hTF/2N. 
Addition of [Bi(NTA)] to 1 .09x10 5 M recombinant hTF/2N in 10 mM Hepes buffer 
at pH 7.4 containing 5 mM bicarbonate, with x- 1 and 10. AE equals the absorbance at 
241 nm divided by the transferrin concentration. The insert is based on the titration of 
[Bi(NTA)io] with hTF/2N and allows determination of log K a= 1.40, R= 0.997. 
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leveled off, and Bi 3 was loaded only partially into the metal-binding site of hTF/2N. 
This curve was used to calculate the stability constant of Bi-hTF/2N. 
The stability constant determination was based on the competition reaction of 
NTA and hTF/2N with Bi3 and the following equations were used: 
Bi(NTA) + hTF/2N Bi-hTF/2N + NTA 
Ka = { [Bi-hTF/2N] [NTA] }/{ [Bi(NTA)] [hTF/2N] } 	Equ. 3.1 
Bi3 + hTF/2N Bi-hTF/2N 
K = [Bi-hTF/2N]/{ [Bi 3 ] [hTF/2N] } 
K Bi(NTA) Ka 	 Equ. 3.2 
Ka was obtained from the Hughes-Klotz plot (see Chapter 2): 
1/Y = 1 + 1/Ka [NTA]/[Bi(NTA)] 	 Equ. 3.3 
where Y = [Bi-hTF/2N]/[hTF/2N] totai , and the concentration of Bi-hTF/2N was 
calculated by assuming that full loading of hTF/2N with Bi 3 gives a molar 
absorbitivity of 22,000 M' cm'. By plotting l/Y vs [NTA]/[Bi(NTA)] (Figure 3.2 
insert), log Ka was obtained from the slope as 1.40 ±0.2. The reported (log) stability 
constant of Bi(NTA) is 17.75 [29], therefore the stability constant of Bi-hTF/2N is 
log K = 19.15±0.2 (310 K 10 mM Hepes and 5 mM bicarbonate pH 7.4). The 
bicarbonate-independent binding constant (log K) was calculated from the 
relationships [30] in the following equations: 
log KS = log K + log a 	 Equ. 3.4 
where (x, represents the fractional saturation of the hTF/2N binding sites with 
bicarbonate, and 
a {K[HCO3]}/ {l +K[HCO3]} 	Equ. 3.5 
With 5 mM bicarbonate, pH 7.4, a c =0.6, giving log K*  as 18.9 ±0.2. 
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The effect of bound Fe 3+  on the uptake of Bi 3+  into the N- or C- lobe of intact 
human serum transferrin was studied. Apo-transferrin was selectively loaded with 
Fe 3+  in the C- or N- lobe and then titrated with Bi 3 . The results are shown in Figure 
3.3. When Bi3 (as [Bi(NTA)]) binds to the vacant C-terminal site of FeN-hTF, the 
initial slope of the curve (A6 21,740 M' cm) is close to that observed for 
apotransferrin (M 21,900 M' cm') [21]. In contrast, binding of Bi 3 to the vacant N-
terminal site in Fec-hTF gave a much lower molar absorptivity of 12,600 M cm, . 
For recombinant N-lobe transferrin (hTF/2N), the titration curve is almost identical 
to that of N-terminal monoferric transferrin (Fe N-hTF) with a molar absorptivity of 
22,000 M' cm. 
3.4.2 Ligand Competition 
Citrate: Competition between hTF/2N and citrate for Bi 3 binding was 
investigated. Large excesses of citrate removed Bi 3 from the binding site. The i 
value appeared to decrease almost linearly with increase of citrate concentration 
(Figure 3.4 A). From the linear range, it was calculated that an approximately 125-
fold molar excess of citrate (1.36 mM) is required to remove Bi 3 from hTF/2N 
completely. However for the intact protein Bi 2-hTF, such an excess of citrate 
appeared to remove only about half of the bound Bi 3 from the protein. 
CF: This experiment was performed by addition of 1 mol equiv of Bi 3 to 
hTF/2N in the presence of 5 mM bicarbonate, followed by titrating with KC1 
solution. Large excesses of Cl - only slightly decreased the UV absorbance 
corresponding to removal of Bi 3 from the hTF/2N binding site (Figure 3.4 B). For 
the intact protein there was almost no effect of Cl - on the Bi2-hTF complex. 
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Figure 3.3 Titration curves for bismuth binding to monoferric transferrins. 
Addition of [Bi(NTA)] to 1 .09x 1 0 M mono ferric transferrins in 10 mM Hepes 
buffer at pH 7.4 containing 5 mM bicarbonate. AF, equals the absorbance at 241 nm 
divided by the transferrin concentration. The titration curve for hTF/2N is included 
for comparison. 
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Figure 3.4 Graphs showing changes in extinction coefficient at 241 nm of 
bismuth transferrin with increasing concentrations of citrate (A) and chloride 
(B), at 310 K, pH 7.4. This experiment was carried out by first adding Ca. 1 mol 
equiv Bi(NTA) to hTF/2N to form Bi-hTF/2N, followed by titration with citrate and 
chloride. Each solution was allowed to equilibrate for 30 min before recording the 
absorbance. The data for hTF were obtained under similar conditions for comparison. 
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3.4.3 'CNMR 
These experiments were carried out to investigate whether the binding of 
Bi3 to hTFI2N also involves concomitant binding of (bi)carbonate as synergistic 
anion. Proton decoupled ' 3 C NMR spectra of a solution containing hTF/2N and 10 
MM ' 3 C-enriched bicarbonate (> 99% in 13 C) in the absence and presence of Bi 3 are 
shown in Figure 3.5. In the absence of Bi 3 , the sharp signal at 161.1 ppm can be 
assigned to free bicarbonate, and the broad envelope at 168--182 ppm to backbone 
and side-chain carbonyls of the protein. After addition of 1.0 mol equiv of Bi 3 (as 
Bi(NTA)), a new peak at 165.7 ppm is observed which can be assigned to bound 
carbonate [21,31,32]. 
Figure 3.5 Carbonate binding to bismuth N-lobe transferrin. 13 C{'H} NMR 
spectra (125 MHz) of (A) hTF/2N (1.8 mM, 80% H 20, 20% D2 0, pH 7.6) in the 
presence of 10 mM NaH' 3 CO3, and (B) with addition of 1.0 mol equiv of [Bi(NTA)]. 
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3.4.4 1  HNMR 
These experiments were carried out to investigate bismuth-induced structural 
changes in recombinant N-lobe of human serum transferrin by comparison with those 
induced by Fe 3+  and Ga3 . Additions of Bi 3 were made (0.6 and 1.0 mol equiv of 
[Bi(NTA)]) to hTF/2N in the presence of 10 mM bicarbonate. Specific resonances in 
both high- and low-field regions of the spectrum progressively disappeared and new 
resonances appeared, indicative of strong binding of Bi 3 and slow exchange between 
apo-hTF/2N and Bi-hTF/2N on the 'H NMR chemical shift time scale. Peaks A, B 
and C in the high field region (Figure 3.6 A) gradually decreased in intensity and 
new peaks A', B' and C' appeared and increased in intensity on addition of 0.6 and 
1.0 mol equiv of Bi 3 . Peaks A (-0.602 ppm) and B (4339 ppm) have previously 
been assigned as Ile 132 7CH2 and Leu 122 8CH3, respectively, on the basis of ring-
current calculations and with the aid of Trp128 mutation [33,34]. 2D TOCSY and 
NOESY (Figure 3.7) spectra of apo-hTF/2N and Bi0 5-hTF/2N were also recorded. 
Analysis of most of the resonances was impossible due to the large number of 
overlapping cross-peaks. However, the 2D spectra were well resolved in the high-
field region. Peaks A ('yCH 2 of lie 132) and B (CH 3 Leu122) had associated cross-
peaks at 0.100, 0.400, 0.830 and 1.378 ppm, and 0.413, 0.543, 1.143 and 1.457 ppm, 
respectively, which are consistent with intramolecular NOEs for lie and Leu spin 
systems. Similar patterns of cross-peaks for A and A', B and B', C and C' in the 
NOESY spectrum of this aliphatic region strongly suggested that A' is the bound 
form of A, and B' and C' are the bound forms of B and C, respectively. With 1.0 mol 
3-4- 	
i equiv of Bi present, the new resonances further increased their ntensities, while the 
resonances for hTF/2N disappeared almost completely. Notable shifts induced by 
Bi3 binding are those for peak A, 0.120 ppm to high-field, peak B, 0.063 ppm to 
low-field, and peak C, 0.128 to low-field (Table 3.1, Figure 3.9). 
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Figure 3.6 (A) The high field region of 500-MHz 'H NMR spectra of hTF/2N 
(1.0 mM) in 0.1 M KC1, pH*  7.8, before (bottom) and after addition of 0.6 
(middle) and 1 (top) mol equiv of [Bi(NTA)]. 
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Figure 3.6 (B) The His C2H region of resolution-enhanced 500-MHz 1 H NMR 
spectra of hTF/2N (1.0 mM) in 0.1 M KC1, pH*  7.8. From bottom to top: apo-
hTF/2N, addition of 10 mM carbonate, addition of 0.6 and 1 mol equiv of 
{Bi(NTA)]. 
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Figure 3.6 (C) The Met SCH3 region of resolution-enhanced 500-MHz 'H NMR 
spectra of hTF/2N (1.0 mM) in 0.1 M KCI, pH*  7.8, before (bottom) and after 
addition of 0.6 (middle) and 1 (top) mol equiv of [Bi(NTA)J. 
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Figure 3.7 The high field region of 2D NMR spectra of hTF/2N. (A) TOCSY 
(tm=60 ms); (B) NOESY (tm=50 ms) and (C ) Bi3 half-loaded hTF/2N ('t m =60 
MS) 
In the His C2H region (Figure 3.6 B), a notable change is the appearance of 
peaks at 7.613 and 6.626 ppm (J'). Peaks D, G, H, I decreased in intensity, and new 
peaks K', H', and I' also appeared after addition of Bi 3 . Peaks H' and I' appeared to 
undergo low-field shifts of 0.085 and 0.076 ppm, respectively, on addition of 1.0 mol 
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equiv of Bi 3 although again unambiguous correlations between peaks cannot be 
made. A sharp resonance at 5.995 ppm, which is sensitive to oxalate and insensitive 
to bicarbonate, decreased in intensity and appeared to shift to 6.004 ppm (broad 
peak) when 1.0 mol equiv of Bi 3 was added. 
Changes were also observed in the region 1.9 2.3 ppm, which contains 
resonances for Met CH3 and carbohydrate (Figure 3.6 Q. Resonances at 2.096, 
2.074, 2.059 ppm have not been observed previously for hTF/2N samples, and are 
thus assigned to the two carbohydrate residues which are attached to the protein in 
the yeast expression system [22]. The presence of carbohydrate was also confirmed 
by the intense resonances from 3.0 to 4.5 ppm. Peaks at 2.218, 2.165, 2.143 and 
1.967 ppm have been assigned previously [35] to S-CH3 ofMet3l3, Met309, Met256 
and Meti 09/Met26, respectively. Upon addition of 0.6 mol equiv of Bi 3 , the broad 
resonances assigned to Meti 09/Met26 decreased in intensity and a broad shoulder 
appeared at 1.982 ppm. On addition of 1.0 mol equiv of Bi 3 , the peak increased in 
intensity further and that for Meti 09/Met26 disappeared. Similarly, the Met309 
resonance also disappeared whereas peaks for Met256 and those for carbohydrate 
remained unchanged. 
The recombinant N-lobe of transferrin was also titrated with the new bismuth 
antiulcer agent, ranitidine bismuth citrate. This gave rise to NMR spectra identical to 
those obtained with [Bi(NTA)] in the presence of 10 mM bicarbonate at pH 7.8, 
apart from peaks due to added ligands. 
In order to compare 1 H chemical shifts induced by Bi 3 with those induced by 
Fe3 , a titration of hTF/2N with Fe 3 (added as Fe(NTA)2) in the presence of 10 mM 
bicarbonate at pH*7.8  was also carried out. Although 'H NMR spectra are broadened 
upon addition of Fe 3 due to the paramagnetic effects of bound high-spin Fe 3 , the 
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appearance of new peaks in the high-field (Figure 3.8 A) and methionine regions 
was still observable. The chemical shifts induced by Fe 3 appeared to be almost 
identical to those induced by Bi 3 in these regions, indicative of a similar binding 
mode and similar structural changes. Notable coordination shifts induced by Fe 3+  
complexation are those of peak A (Tie 132), 0.22 ppm to high field, peak B (Leu 
122), 0.039 ppm to high field, and peak C, 0.087 ppm to low field (Table 3.1, Figure 
3.9). In the His C2H region (Figure 3.8 B), peaks at I (8.052 ppm), H (7.920 ppm) 
and D (7.682 ppm) became significantly broadened on addition of 0.5 mol equiv of 
Fe3 , and disappeared almost completely after addition of slightly less than 1.0 mol 
equiv of Fe 3+ (to avoid excess of non-protein-bound Fe) 
X16 
X16 
I 	I 	I 	I 	 I 	I 	I 
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Figure 3.8 (A) Bottom: the high field region of 500-MHz 1 H NMR spectra of 
hTF/2N (1.0 mM) in 0.1 M KCI, pH*  7.8; middle: after addition of 0.5; and top: 
1 mol equiv of [Fe(NTA) 2 ]. 
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Figure 3.8 (B) The His C2H region of resolution-enhanced 500-MHz 'H NMR 
spectra of hTF/2N (1.0 mM) in 0.1 M KC1, pH*  7.8. From bottom to top: apo-
hTF/2N, addition of 10 mM carbonate, addition of 0.5 and 1 mol equiv of 
[Fe(NTA)2]. 
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Table 3.1 Chemical shifts for 'H NMR resonances of hTF/2N and its metal 
complexes' 
Protein pH* Leu 122 (B) lie 132 (A) C 
hTF/2N -0.333 -0.605 -0.173 
ox-hTF/2N 7.25 -0.343 -0.617 -0.166 
Ga-ox-hTF/2N -0.308 -0.897 -0.044 
A (Ga)b 0.035 -0.28 0.122 
hTF/2N -0.335 -0.601 -0.178 
CO3-hTF/2N 7.55 -0.335 -0.589 -0.173 
Ga- CO3-hTF/2N -0.413 -0.846 -0.014 
A8 (Ga)b -0.078 -0.257 0.159 
CO3-hTF/2N -0.333 -0.635 -0.110 
A1-0O3-hTF/2N 8.8 -0.401 -0.839 -0.042 
EsS (Al) b -0.068 -0.204 0.068 
CO3-hTF/2N -0.339 -0.603 -0.178 
Fe-0O3 -hTF/2N 7.8 -0.378 -0.825 -0.081 
A (Fe) b -0.039 -0.222 0.097 
CO3 -hTF/2N -0.339 -0.603 -0.170 
Bi-0O3-hTF/2N 7.8 -0.280 -0.703 -0.044 
6(Bi)b 0.059 -0.100 0.126 
a Connectivities were obtained from DQF-COSY, TOCSY and NOESY, and 
assignments are based on previous work [23,33]. For peak labels see Figure 3.6 A. 
bCoordination  shift. hTF/2N was expressed in the methylotrophic yeast Pichia 
pastoris and contains two carbohydrate residues which are not present in the N-lobe 
of the intact serum protein [22]. 
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Figure 3.9 Stack plot illustrating the changes in shifts of the high field 
resonances on metal binding to Ga3, A1 3+  , Fe 3+ and Bill. 
3.5 Discussion 
Bi3 (ionic radius 1.03 A) is a much larger ion than Fe 3+  (radius 0.65 A, high-
spin state), but binds to human transferrin almost as strongly as Fe 3 , a feature which 
can be correlated with its high acidity (low pK a of bound H20) [29]. 
The stability constant for Bi 3 binding to the recombinant N-lobe of human 
transferrin was determined to be log K (bicarbonate independent constant [30]) 
18.9±0.2. Thus Bi3 binds to the N-lobe almost as strongly as to the intact protein 
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(log Kl*  19.4, log 1(2*  18.6 [21]). This appears to be the first determination of a 
binding constant for any metal ion for the isolated N-lobe of human serum 
transferrin. 
The effect of Fe 3+  loading of the N- or C-lobe on the binding of Bi 3+  to the 
other lobe was also investigated. With Fe 3+  in the N-lobe of hTF (FeN-hTF), Bi 3+ 
binds to the C-lobe as strongly as it does in the apo-protein (N-lobe vacant), whereas 
the binding of Bi 3 to the N-lobe of hTF with Fe 3+  in the C-lobe (Fec-hTF) is much 
weaker than binding to the isolated N-lobe. Previous work on the titration of 
monoferric transferrins have shown that A1 3 , Zn2 , Nd3 and Sm3 also have a higher 
affinity for the C-lobe compared to the N-lobe [9,8,15], but there are no previous 
studies on binding of these metal ions to isolated N-lobe. Calorimetric studies of the 
. binding of Fe 3+  to ovotransfernn have shown that the two binding sites are not 
independent, but communicate to each other in a way which increases the 
thermodynamic binding constant of Fe 3+  to the N-lobe site and decreases the binding 
constant to the C-lobe site [36]. Similarly, the two lobes of transferrin are not isolated 
but in communication as can be seen in this study and a previous study in which Ga 3 
binding to the N-lobe of transferrin is communicated to the C-lobe [35]. 
Since a large excess of citrate is required to remove significant amounts of 
Bi3 from transferrin (Figure 3.4A), it seems likely that citrate will not be a major 
competitor for Bi 3 in blood plasma (citrate concentration ca. 100 M, hTF : citrate 
Ca. 1:3). Comparison of the curves in Figure 3.4A suggests that citrate is much less 
effective in removing Bi 3 from the C-lobe compared to the N-lobe. In blood, hTF is 
normally saturated to a level of only ca. 30% with Fe 3+'  which occupies the N-lobe 
[1], although it has been suggested that this switch from C- to N-lobe preference may 
be related to the presence of a receptor protein [37]. 
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Non-synergistic anions such as Cl -, C104 , HP20 73 have been reported 
previously to affect the thermodynamic stability of metal-transferrin complexes and 
also to play a role in promoting and modulating iron release. The thermodynamic 
stability constant of iron binding to the N-terminal site relative to the C-terminal site 
has been reported to increase with increasing concentration of NaF, NaCl, NaBr, Nal, 
and this effect was enhanced as the pH increased in the range 7 to 8.4 [38]. Recently, 
the UV titration of anions with apo-transferrin and mutant recombinant N-lobe of 
transferrin have led to the conclusion that the anion binding sites are near to the metal 
binding sites [39,40]. In the present work, it was shown that a large excess of 
chloride slightly decreases the absorbance of Bi-hTFI2N and has little affect on the 
absorbance of Bi2-hTF, suggesting that two lobes of transferrin are not isolated. 
In general, the 'H NMR spectrum of hTF/2N consists of a large number of 
broad overlapping resonances. However, reasonable assignments have been proposed 
previously for several peaks in the high field region, specifically for Leu-122 and lie-
132 which are above and below Trp-128 in the hydrophobic patch of helix 5 (Figure 
3.10). This helix makes contact with the anion and metal binding site via its amino 
terminal end. Therefore these resonances are sensitive to metal binding, Figure 3.6A, 
and the shift changes may arise from small movements of the side-chains of Leu-122 
and Ile-132 relative to Trp-128. On titration of hTF/2N with Bi .3+ 
 
these peaks show 
NMR shifts characteristic of slow Bi 3 exchange (on the NMR time scale), indicative 
of strong Bi3 binding. As can be seen from Figure 3.9 the shift changes for these 
resonances induced by Ga 3+ , A13+  and Bi3-i-  are all of the same sign and similar in 
magnitude suggesting that all the metal ions induce a similar conformational change 
in this part of the protein. Interestingly, the sign of the shift change for Leu-122 
(Figure 3.9) for Bi3 is opposite to that for Ga3 , A13 and Fe 3+, although similar to 
that seen for Ga 3 with oxalate as synergistic anion. Therefore this may be a 
consequence of the large size of Bi 3 (ionic radius 1.03A) in comparison to Ga 3 
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2 	3+ 	2 	 3+ 	2 (0.62 ), Al (0.54 A) or Fe (0.65 ii), and the large size of oxalate compared to 
carbonate. It has been shown previously [34] that oxalate binding causes shifts of the 
hTF/2N resonance at 5.995 ppm. No such shifts were observed in the present work 
with bicarbonate as the synergistic anion, which may be indicative of a different 
binding mode or affinity for these two anions before addition of metal. 





Figure 3.10 Model of hydrophobic patch of the N-lobe of transferrin, showing 
the residues which give the largest high-field ring-current-induced 'H NMR 
shifts [23]. 
The shift changes for the Met S-cCH3 resonances of hTF/2N on Bi 3 binding 
are similar to those observed previously for Ga 3 [34]. The Met residues are well 
spread out through the protein and their behavior is probably a good indication for 
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the similar binding mode of these metal ions. In view of this it will be interesting to 
investigate the binding of Bi3 -transferrin to the transferrin receptor. 
It was also shown that Bi3 in the form of the antiulcer drug ranitidine 
bismuth citrate is also readily transferred to hTf/2N, forming the same transferrin 
adducts as for [Bi(NTA)]. Citrate is readily displaced from Bi3 by hTF/2N and could 
act as a transfer agent in blood plasma. Further experiments on blood plasma are 
required to establish whether this is the case. 
3.6 Conclusion 
The first determination of a stability constant for metal binding to the 
recombinant N-lobe of human transferrin was made. The metal ion used, Bi3 , is 
important because it forms the basis of widely-used antiulcer drugs. Bi3 binds 
strongly to hTF/2N, log K*  18.9 ± 0.2 at 310 K, 5 mM bicarbonate, 10 mM Hepes 
buffer at pH 7.4. The presence of bound synergistic anion (C03 2 ) was confirmed by 
' 3 C NMR, and 'H NMR studies suggested that the conformational changes induced 
by Bi3 binding are similar to those induced by Fe 3 , A13 and Ga3 , probably from 
lobe-open to lobe-closed form. Studies on monoferric intact human transferrins (hTF) 
suggested that occupation of the C-lobe by Fe 3+  perturbs Bi3 binding to the N-lobe, 
but Fe 3+  occupation of the N-lobe has little effect on Bi3 binding to the C-lobe. It 
will be interesting to investigate the biological activity of bismuth transferrin. 
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Chapter 4 
NMR Investigations of Bi 3 Binding to E-'3C- 
Met Labelled and 1132M Mutated Transferrin: 
Recognition of Bi 3 by Transferrin in Plasma 
4.1 Abstract 
2D ['H, ' 3 C] NMR studies of recombinant - ' 3C -Met-hTF' allow the order 
of lobe-loading with Bi 3 and various metal ions, including Fe 3+,  to be determined. In 
particular, the resonance for Met464, a residue in the hydrophobic patch of helix 5, is 
very sensitive to metal binding in the C-lobe. The selectivity of lobe-loading with 
3+ 	2+ 	 3+ Bi is compared to loading with Fe , Fe (which binds as Fe ), A1 3+, and Ga3+  
Similar changes in shifts of the Met residues are observed for these metal ions, 
suggesting that they induce similar conformational changes in the protein. A site-
specific mutant 1132M in the recombinant N-lobe of transferrin was made in order to 
provide a metal sensitive indicator in the N-lobe and to study the differences between 
.3+ 	 13 the two lobes of transferrin. Loading of Bi into 1132M c- C-Met-hTF/2N caused 
similar chemical shifts as that of Fe 3 , indicative of similar conformational changes. 
However, the chemical shifts of Met464 and Meti 32 in both apo- and metal-bound 
forms are different both in the 1 H and ' 3 C dimensions, suggesting that local structures 
of the N-lobe and the C-lobe are not identical. Significantly, using the chemical shift 
'The abbreviations used in this Chapter are: 
DTNB, 5,5'-dithio-bis(2-nitrobenzoic acid); HSA, human serum albumin; HSQC, 
heteronuclear single-quantum coherence; hTF, human serum transferrin; hTF/2N, 
recombinant N-lobe of hTF; pH*,  pH meter reading in D20; RBC, ranitidine bismuth 
citrate; rHA, recombinant albumin. 
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changes of Met residues of 1132M c-' 3C-Met-hTF/2N and wild type hTF induced by 
metal ions as probes, a possible target site for bismuth antiulcer drugs in intact blood 
plasma was identified. Surprisingly, it was found for the first time that bismuth is 
recognized preferentially by transferrin in the presence of a large excess of albumin 
(biologically relevant concentrations) and even in intact blood plasma although 
albumin has been previously thought to be a potential target site for bismuth due to 
its free cysteine residue (Cys34). Gel filtration chromatography showed that bismuth 
associates with albumin only weakly, and can readily be extracted by a tripeptide 
glutathione (GSH). Furthermore, for the first time, a direct detection of metallodrug 
binding to proteins at biologically relevant concentrations without separation was 
achieved. 
4.2 Introduction 
Transferrin, with a concentration of ca. 35 tM in blood, serves the functions 
of transport and delivery for a variety of metal ions, not only for the natural metal ion 
Fe 3+, but also for therapeutic, diagnostic or toxic ions including Ga 3 , Ru3 and Al3 
[1-3]. It contains two structurally-similar lobes, the N- and the C-lobe, and in each 
lobe there is an iron binding site. Although the two sites have remarkably similar 
thermodynamic and spectroscopic properties, they are different in their ability to 
donate iron to reticulocytes [4]. In blood plasma, transferrin is only about 30% 
saturated with iron, which occupies the N-lobe [5]. There is much interest in the 
functional differences between the two binding sites and numerous experiments in 
which metal ions are thought to load either the N- or C-lobes have been reported and 
these are summarized in Table 4.1. 
There appear to be few methods which currently allow a direct determination 
of the order of lobe loading of transferrin with metal ions. Methods such as EPR [6], 
differential scanning calorimetry (DSC) [7, 8] and heteronuclear NMR spectroscopy 
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[9-15] can often distinguish two stages of loading, but comparison with isolated 
individual lobes is necessary before each step can be assigned to specific lobes. This 
method is reliable only if the behaviour of the isolated lobe is the same as that of the 
same lobe in the intact protein. A direct determination of which lobe is loaded using 
gel electrophoresis is possible for some metal ions, but the procedure involves the 
use of 6 M urea which allows examination only of metals which bind tightly, such as 
Fe3 [16, 17]. 
Table 4.1 Order of lobe loading of human serum transferrin with various metal 
ions using different techniques. 
Metal donor Synergistic PH Method Preference References 
anion 
(NH4)2Fe 11(SO4)2 Bicarbonate 7.4-8.5 Electrophoresis N-lobe [18] 
Fe"1 (NTA)2 Bicarbonate 6-8.5 Electrophoresis C-lobe [16,19] 
Calorimetry [7, 8] 
Fe"1 -citrate Bicarbonate 7.4-8.5 Electrophoresis N-lobe [18] 
Fe"-oxalate Bicarbonate 7.4-8.5 Electrophoresis N-lobe [18] 
Cr"-citrate Bicarbonate 7.5 EPR Both [20] 
5.9 N-lobe  
A1" (SO4)3 Bicarbonate 8.8 'H NMR N-lobe  
Ga"(NTA)2 Oxalate 7.2 'H, ['H, ' 3 C] NMR C-lobe [22, 23] 
Bicarbonate 7.2-7.4 NMR Both 
In"-citrate Bicarbonate 7.25 NMR C-lobe  















Bicarbonate 7.4 NMR N-lobe  
Bicarbonate 7.4-8.5 EPR C-lobe  
Bicarbonate 6.0 EPR C-lobe  
Bicarbonatea 7.5-9.0 5 'V NMR N-lobe  
Bicarbonate 7.3-7.8 205T1 NMR C-lobe [9] 
a 
v02+ can bind without a synergistic anion. 
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Bismuth compounds have long been associated with medicine for the 
treatment of a variety of gastrointestinal disorders including diarrhea, constipation, 
gastritis and ulcers [30-32], and compounds containing radioactive bismuth isotopes 
have also been used as targeted radiotherapeutic agents. However, the mechanisms of 
action of bismuth drugs are still poorly understood. Neurotoxicity (encephalopathy) 
of bismuth drugs is generally diagnosed by the detection of bismuth in blood, plasma 
or serum. It is not clear how bismuth is transported into the brain. In blood, bismuth 
is thought to be primarily present in red blood cells, possibly binding to glutathione 
inside the cells, and with a small fraction in serum or plasma [33, 34]. The speciation 
of bismuth in blood plasma, in particular the binding of Bi 3 to plasma proteins, is 
not well understood. This is partially due to the lack of proper separation techniques 
to identify bismuth-bound protein and the lack of proper techniques to accurately 
detect bismuth contents. 
Previously, it has been suggested that serum albumin is a potential major 
target for bismuth in plasma, since there is a free group Cys34 in this protein. Human 
serum albumin (HSA) is the most abundant protein in the blood serum with a 
concentration of ca. 40 mg ml -1 ('-0.63 mM). It is a single polypeptide chain of 585 
amino acid (66.5 kDa) with a largely a-helical triple-domain structure (Figure 4.1) 
[35]. It contains 17 disulfide bonds and one free thiolate group at Cys34. It is the 
major transport protein for unesterified fatty acids, but is also capable of binding an 
extraordinarily diverse range of metabolites, drugs, organic compounds and even 
metal ions (e.g. Cu 2+  and Ni )[36,37]. 
Transferrin is thought to be a metal ion-mediator in the blood, and apart from 
Fe 3+,  other metal ions, such as Ga3 , A13 , Mn3 and Ru3 , are believed to be 
transported at least partially by transferrin via receptor-mediated endocytosis and this 
has been reviewed recently [38]. An unexpectedly strong binding of bismuth to 
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Figure 4.1 X-ray crystal structure of human serum albumin 1391. The side-chain 
of Cys34, in a crevice, is shown in red. 
,Ji 
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human serum transferrin (hTF) and the recombinant N-lobe of transferrin [25,40] has 
provided a new potential pathway for the transport and delivery of bismuth in the 
human body. However, so far it still has not been clarified whether bismuth drugs are 
recognised and transported by transferrin or by albumin in blood plasma. 
In this Chapter, by isotope labelling of -' 3C-Met residues of human serum 
transferrin, the order of lobe loading is determined directly under conditions of 
physiological relevance via 2D [ 1 H, 13 C] NMR spectroscopy. Using chemical shift 
changes of Met residues of 1132M mutant recombinant N-lobe induced by metals as a 
probe, competition reactions of bismuth between transferrin and large excess of 
albumin in biologically relevant conditions were investigated without separation. The 
possibility that transferrin is a major target of bismuth drugs in blood plasma is 
considered. 
4.3 Experimental Procedures 
4.3.1 Materials 
Recombinant hTF and its N-lobe (hTF/2N) (residues 1-337) were prepared by 
Dr. A. B. Mason (University of Vermont College of Medicine, U.S.A.). They were 
expressed in baby hamster kidney cells using a pNUT plasmid with -L-' 3C-
methionine in the growth medium and purified as described previously [41, 42]. A 
gene for a mutant 1132M protein was created by site-directed mutagenesis. Iron was 
removed from proteins by treatment with a buffer containing 1 mM NTA, 1 mM 
EDTA and 0.5 M sodium acetate at pH 4.9, followed by ultrifiltration in a Centricon 
30 and Centricon 10 (Amicon) for hTF and hTF/2N, respectively. Human serum 
albumin (HSA) was purchased from Sigma as essentially globulin-free and fatty-
acid- free and was purified by ultrifiltration (Centricon 10) using 0.1 M KC1 washing 
3 times each time for 1 h, and then it was freeze-dried. Recombinant human albumin 
(rHA) was prepared by Delta Biotechnology Ltd (batches GA 950202 and R 970103). 
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Samples of rHA were dialyzed against 100 mM ammonium bicarbonate at pH 7.9, 
and freeze-dried. Ranitidine Bismuth Citrate (RBC) and bismuth citrate [Bi(Hcit)] 
were provided by GlaxoWelicome plc. NaHCO 3, KC1, [Al2(SO4)3], ferrous 
ammonium sulfate ([Fe(NI-1 4)2(SO4)2]), 5,5 '-dithio-bis(2-nitrobenzoic acid) (DTNB) 
and other chemicals were purchased either from Aldrich or Sigma as the highest 
quality and used as received. 
A 50 mM stock solution of [Bi(Hcit)] was prepared by addition of the 
minimum amount of dilute ammonia solution to a suspension of [Bi(Hcit)] until the 
solution became clear. The finial pH of this solution was Ca. 7 and it was then diluted 
before use. Solutions of [Fe(NTA)2] and [(Ga(NTA) 21 were prepared from atomic 
absorption standard solutions (1000 ppm in 1% HNO3, Aldrich) by adding 2 mol 
equiv of H3NTA (Aldrich) followed by pH adjustment to 6.0-'7.0, freeze-drying and 
redissolution in D20 before use. Fresh Fe 2+  solutions were prepared directly by 
dissolving known amounts of ferrous ammonium sulfate in D20. A [Bi(NTA)] 
solution was prepared by dissolving a known amount of tiny [Bi(NTA)] crystals 
synthesized using a literature procedure [43] in D20. 
4.3.2 Preparation of NMR Samples 
NMR samples of 6- 13C-Met-hTF (ca. 0.3 mM) and 1132M c- 13C-Met hTF/2N 
(0.15 mM) were prepared in 0.1 M KC1 in D20, and pH*  values were adjusted to 
7.4±0.1 and 7.8±0.1, respectively, using NaOD or DC1. Sodium bicarbonate in D20 
(0.25 M) was added to transferrin solution to give a concentration of 10 mM. 
Addition of metal complexes was made to protein samples containing bicarbonate to 
give metal: protein ratios of up to 2.0 :1 or 1.0 :1 and the PH*  was readjusted to 
7.4±0.1 or 7.8±0.1 (8.8±0.1 for A1 31) after each addition; the samples were left 30 
min for equilibration. For the competition reaction between transferrin and albumin, 
1132M E- 13C-Met hTF/2N (0.15 mM) was added to either rHA (1.8 mM) or HSA (1.8 
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mM) solution in 0.1 M KC1 in D20 followed by adjustment of pH values to 7.8±0.1. 
Prior to titration of Bi 3 , an aliquot of a concentrated NaHCO 3 (0.25 M) was added to 
the samples to give a final concentration of 10 mM and pH values were readjusted to 
ca. 7.8 using NaOD or Dcl. For the intact blood plasma experiments, blood from a 
male healthy volunteer was collected by venipuncture into lithium heparinized 
vacutainers, and the plasma was separated by centrifugation at 277 K, frozen prior to 
NMR measurement. Isotopically enriched proteins were added to plasma to give final 
concentrations of either 100 p.M (or 50p.M) 1132M c-' 3 C-Met-hTF/2N or 35 p.M s-
13 C-Met-hTF in 1.2 ml of intact blood plasma and the concentration of this sample 
was doubled by freeze-drying and reconstituting in 0.6 ml D20, followed by addition 
of concentrated NaHCO3 to a final concentration of 20 mM. The pH*  was checked 
and adjusted to 7.8. After titration with Bi 3 , samples were left to equilibrate for ca. 
30 min at 310 K, and p11*  was readjusted to 7.8. 
4.3.3 NMR Spectroscopy 
NMR spectra were recorded on Varian Unity 600 or Bruker DMX500 
spectrometers at 600 and 500 MHz, respectively, at 310 K. For 1 D 'H NMR spectra, 
400 1200 transients were acquired with 6 p.s (50 °) pulses and 16 k data points with 
a 2 s pulse delay. The water peak was suppressed via presaturation. For 2D ['H, ' 3C] 
heteronuclear single quantum coherence spectra (HSQC), the sequence was 
optimised for 'J ('H-' 3C) = 140 Hz, and 16 32 transients were acquired using 2 k 
points in f2 dimension ('H), 32 - 64 increments of t,, 13 C frequency width of 3 kHz 
and relaxation delay of 1.6 s giving a total ca. 30 min for the acquisition of each 
spectrum. The ' 3C spins were decoupled using the GARP sequence [44]. After zero 
filling to 4 k x 1 k points, unshifted Gaussian functions were used for processing in 
both dimensions. The water suppression was achieved by a combination of 
presaturation and pulsed-field gradients. 1D HSQC (or ' 3 C edited 'H NMR) spectra 
were recorded using the first increment of the 2D HSQC sequence. Resolution 
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enhancement was achieved using a combination of exponential (1.5 10 Hz line-
broadening) and unshifted sine-bell functions [45]. Peaks were referenced to sodium 
3-(trimethylsiiyl)propionate-2,2,3,3-d4 (TSP) via the E-CH3 peak of external L-
methionine (15.14 ppm) for ' 3C and via formate (8.465 ppm, a minor impurity 
always present in the protein) for 'H. The 2D HSQC NMR experiments were set-up 
with help from Dr. Hongzhe Sun. 
4.3.4 Determination of Bismuth Content 
HSA (concentration ca. 0.1 mM) was incubated with different mol ratios of 
RBC in 0.1 M Tris-HC1 buffer, pH 7.4 overnight at 310 K. Unbound RBC was 
separated via chromatography using gel filtration on a column of Superose 12 on an 
FPLC system (Amersham Pharmacia Biotech). The concentration of the albumin 
samples was ca. 6 mg/mi and 500 jii of the protein solution was loaded onto the 
column. Elution conditions were 0.1 M Tris-HC1, pH 7.4, and flow rate was 0.5 
ml/min. Each fraction was collected from 10 ml to 14 ml and the Bi 3 content was 
determined using a Microneb 2000 direct injection nebulizer (CETAC Technologies, 
Omaha, NE, US) coupled with a VG PiasmaQuad PQ2 ICP-MS (VG Elemental, 
Winsford, Cheshire, UK). Details of optimization of the DIN-ICP-MS system and 
measurement conditions for Bi 3 have been described previously [46]. The 
instrumental optimization was carried out with help from Ms. B. M. Keohane. 
4.3.5 Determination of Free -SH Groups 
The free -SH content of albumin was determined after incubation with either 
RBC or [Bi(Hcit)] using Ellman's reagent, 5, 5'-dithio-bis(2-nitrobenzoic acid). HSA 
or rHA were incubated with different mol ratios of RBC or [Bi(Hcit)] overnight (>12 
h) in 0.1 M Tris-HC1 buffer at 310 K, pH 7.4, and free RBC or [Bi(Hcit)] were 
removed by ultrafiltration with Centricon 10 (Amicon). The concentration of albumin 
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was measured using 6279  =37,000 Mcm 1 [47], and the amount of generated p-
nitrothiolate was calculated using 6412  =13,600 M'cm' [48]. 
4.4 Results 
4.4.1 Metal Ion Binding to e-' 3C-Met-hTF: 2D ['H,' 3CJ NMR 
Determination of the Order of Lobe Loading 
There are totally nine methionine residues in human serum transferrin, and 
they are wide spread throughout the protein and occupy several types of environment, 
Figure 4.2 and Table 4.2. Recombinant non-glycosylated human transferrin with> 
95% c-' 3CH3 enrichment at all nine Met residues was prepared according to 
published procedures [23]. 2D ['H, ' 3 C] NMR spectra of the labelled protein at low 
concentration (ca. 300 jiM) were obtainable within a short time (ca. 0.5 h) using 
inverse detection techniques. Cross-peaks for 8 Met residues were readily observed, 
and that for the ninth appeared when the temperature was raised from 310 to 318 K, 
or when bicarbonate was added. Reasonable assignments of these cross-peaks, as 
deduced from a single-site specific mutation and 2D NMR data [23,49], are shown in 
Figure 4.3. The chemical shifts are constant over the range pH*  6.8 to 8.8. 
Detection of Fe 3+ Binding to Transferrin and Order of Lobe-Loading: 2 
Fe 3+, as [Fe(NTA)2], was added to hTF at pH*  7.4 to give Fe : hTF mol ratios of 0.5:1 
and 2.0:1(0.5 mol equiv steps). The addition of the first mol equiv of Fe 3+  led to the 
dramatic disappearance of the cross-peak for Met464 and was accompanied by the 
appearance of a new broad peak shifted by ca. 2 ppm to low field in the 13C 
dimension and ca. 0. 2 ppm to high field in the 'H dimension, Figure 4.3. The cross-
peak for Met499 also disappeared and a new peak appeared which is shifted slightly 
to low field in both dimensions, Figure 4.3. When the second mol equiv of Fe 3+  was 
added, there was no further change to these peaks (Met464 and Met499), but shifts 
2 This experiment was done with collaboration from Drs. Mark C. Cox and Hongzhe Sun. 
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were observed for the cross-peaks of N-lobe residues Met26, Met 109, Met309 and 
Met313. In addition, a shift of the peak for Met382, which is in the C-lobe, was 
M26 
M256 	 M499 
Figure 4.2 Distribution of the nine Met residues in human serum transferrin, 
based on the X-ray crystal structure of Fe-hTF 1501. The lobe with an open 
interdomain cleft is on the left-hand side. The Met side-chains are shown in purple, 
and the residue numbers are indicated. Fe  3+  in the C-lobe is shown in red. 
Chapter 4 Recognition of bismuth by hTF in plasma 
Table 4.2 'H and ' 3C NMR chemical shifts of apo-hTF, iron(III)-induced 
coordination shifts 08 = 8Fe2hTF - apo-hTF) for the Met-(c)- 13CH3 residues of hTF 
at 310 K, their locations, and distances between Met-*- 13CH3 and Fe3 . 
Residue 
(lobe) 
Location E- 13 CH3 distance 
from Fe 3+  (A) 
Nlobea 	C1obeb 




Met26(N) Buried 23.1 1.99/14.61 -0.011-0.10 
Met 109 (N) Partially buried 16.5 1.98/16.02 0.03/0.13 
Met256 (N) Completely exposed 30.0 2.13/15.54 0.00/0.00 
Met309 (N) Mostly buried 17.1 2.27/17.52 -0.05/0.28 
Met313 (N) Partially exposed 21.4 2.29/15.22 0.05/0.24 
Met382 (C) Partially exposed 22.1 21.5 2.07/15.23 0.03/420 
Met389 (C) Completely buried 12.2 2 . 01/15 . 48c 
Met464 (C) Above Trp460 in 16.1 1.38/16.30 0•2011•90d 
hydrophobic patch 
of helix 5 
Met499 (C) Mostly exposed 21.8 1.86/15.40 0.04/0.11 
a  Data from crystal structure of Fe-hTF/2N [51]. 
b  Data from the X-ray structure of Fec-hTF [50]. 
C  Peak appears at 318 K or after addition of bicarbonate at 310 K. 
d - 
— 8Fe2-hTF °apo-hTF 
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observed. The chemical shift changes are listed in Table 4.2, and coordination shifts 
are calculated on the assumption that the peaks for the iron-loaded protein are close 
to those for the apo-protein. Although the peak for Met464 is markedly broadened by 
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Figure 4.3 2D ['H, 13C] HMQC spectra of E- 13 C-Met-apo-hTF, and after 
addition of 10 mM bicarbonate at pH*  7.4, and 1.0 and 2.0 mol equiv of Fe 3 as 
an NTA complex. The assignments for Met resonances are based on refs [23,49]. 
The specific shifts of cross-peaks for the Globe residue Met464 and Met499 on 
binding the first equiv of Fe 3 and N-lobe residues Met309 and Met313 on binding 
the second equiv are notable. The cross-peak for Met464 is broadened. The solid 
boxes indicate initial peaks and dotted boxes show new peaks. 
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Detection of Bi 3 Binding to Transferrin and the Order of Lobe-Loading: 
This experiment was performed under similar conditions. Bi 3 both added as a NTA 
complex or the antiulcer drug ranitidine bismuth citrate (RBC) induced similar 
changes on 2D HSQC spectra. Addition of 1 mol equiv of Bi 3 led to disappearance 
of peaks for C-lobe residues (Met464, Met499, Met389 and Met382) and appearance 
of new peaks characteristic of Bi-hTF, Figure 4.4. Again the large shift of the peak 
for Met464 to 1.17/18.20 ppm was notable, with no changes in shift for the N-lobe 
peaks. Addition of the second mol equiv of Bi 3 caused the disappearance of peaks 
for N-lobe residues, particularly Met3 13 and Met309 and the appearance of new 
peaks with shifts similar to that of Fe 2-hTF. 
Uptake of Fe 2 , Ga3 and A13 by Transferrin: 3 The binding of these metal 
ions to apo-hTF was also studied by 2D ['H, ' 3 C] NMR under similar conditions. 
After addition of 1 mol equiv of Fe 2+ (added as a solution of ferrous ammonium 
sulfate) in the presence of 10 mM bicarbonate and after equilibration for Ca. 30 mm, 
cross-peaks for both N- and C-lobe Met residues decreased in intensity and new 
peaks appeared with the same chemical shifts as those observed for Fe(III)2-hTF, 
Figure 4.5 and Table 4.2. The disappearance of peaks for apo-hTF and the 
appearance of these new peaks for Fe2-hTF was complete after addition of 2 mol 
equiv of Fe2 . Similar spectra were obtained after leaving the same mixture overnight 
(>12 h) at 310 K showing that equilibrium had indeed been reached. 
On addition of [Ga(NTA)2], the behaviour of the cross-peaks was similar to 
2+ . . 	 3+ that observed for Fe , with addition of 1 mol equiv of Ga causing a decrease in 
intensity of the initial peaks for apo-hTF and appearance of a new set of peaks for 
both the N- and the C-lobe Met residues, Figure 4.5. However there was less 
broadening of peaks for Met464 than in the case of the reaction with Fe 2+  (or Fe3 ). 
These experiments were carried out with collaboration from Drs. Mark C. Cox and Hongzhe Sun. 
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2.4 	2.0 	1.6 	1.2 
Figure 4.4 2D HSQC spectra of -' 3C-Met-hTF in the presence of 10 mM 
bicarbonate, after addition of 1.0 and 2.0 mol equiv of ranitidine bismuth citrate 
(RBC) at pH*  7.4. The solid boxes indicate initial peaks and dotted boxes show new 
peaks. 
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Figure 4.5 2D HSQC spectra of E-' 3C-Met-hTF in the presence of 10 mM 
bicarbonate, after addition of 1.0 mol equiv of ferrous ammonium sulphate at 
p11* 7.4, 1.0 mol equiv of [Ga(NTA) 2 1 at pH*  7.4, and 0.5 mot equiv of A1 3 at 
pH* 8.8. The solid boxes indicate initial peaks and dotted boxes show new peaks. 
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Addition of the second mol equiv of Ga 3 led to a further increase in intensity of the 
peaks for Ga2-hTF and almost complete disappearance of peaks for apo-hTF. The 
chemical shifts changes observed were identical to those observed for binding of 
Fe' . 
No changes to the 2D ['H, ' 3C] NMR spectrum were observed on reaction of 
apo-hTF with A1 3+  (added as Al 2(SO4)3) at pH
* 
 7.4 in the presence of 10 mM 
bicarbonate. However, on increasing the pH*  to 8.8, peaks for the N-lobe resonances 
Met26, Met309, Met313 and interlobe Met382 decreased in intensity and new cross-
peaks appeared (Figure 4.5). On addition of the second equiv of A1 3 , peaks for 
Met464, Met389 and Met499 were perturbed. The new cross-peak for Met464 
appeared at 1.17/18.20 ppm, a similar shift change to that observed for Fe 3+  binding 
to the protein. This similarity in magnitudes of the shift changes was also true for the 
other Met peaks in the spectrum. The lobe preferences of metal ion binding to hTF 
detected via 2D [ 1 H, 13 C] are shown in Table 4.3. 




pH* Anion Lobe preference 
N-lobe 	C-lobe 
Fe Fe"(NTA)2 7.4 CO + 
Fe' 1(NH4)2(SO4)2 7.4 CO + 	 + 
Ga Ga ... (NTA)2 7.4 C032 + 	 + 
Al Al"2(SO4)3 8.8 C032 + 
Bi Bi 1"(NTA) 7.4 CO  
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4.4.2 NMR Studies of Bi3 Binding to 1132M e-13C-Met-hTF12N: 
Comparison with Fe3+  
In the recombinant N-lobe of transferrin, Ilel 32, which is the analogue 
residue of Met464 in the C-lobe, was mutated to Met using site-directed mutagenesis 
techniques, and 6- 13 CH3 groups of all six Met residues were enriched (> 95%). This 
allows the similarity of local structures between the two lobes of transferrin to be 
studied and metal binding in the N-lobe to be probed. It also serves as a model of 
hTF in searching for a target site for bismuth antiulcer drugs in blood plasma using 
inverse NMR detection techniques. 
'H NMR: It has been shown previously that the 'H NMR spectrum of human 
serum transferrin is severely broadened due to the high molecular weight of this 
protein. However, the spectrum in the high-field-region is relatively well resolved. 
Those resonances are thought to arise from the residues around Trp128, e.g. Leu122 
and Ile 132 [21]. The mutation of Ile 132 to Met would be expected to lead to the 
disappearance of the resonance at -0.603 ppm (peak A in Chapter 3) which was 
assigned as yCH2 of 11e132. Indeed, this is the case as seen from Figure 4.6A. Other 
changes have also been observed in the spectrum of the mutant in comparison with 
that of the wild-type N-lobe of transferrin, e.g. the resonance at -0.170 ppm (peak C 
in Chapter 3) from hTF/2N disappeared and Leu122, -0.339 ppm (peak B in Chapter 
3) in hTF/2N shifted to -0.324 ppm (B). Addition of 0.5 mol equiv of Bi3 (added as 
[Bi(NTA)]) caused appearance of new peaks at -0.160 (C'), -0.255 ppm (B') and the 
peak at -0.324 ppm decreased in intensity and on further addition of Bi 3 (1.0 mol 
equiv) the resonances at -0.160 and -0.255 ppm increased but the resonance at -0.324 
ppm decreased significantly (Figure 4.6A). For comparison, titration of Fe 3+  (added 
as [Fe(NTA)21) with the mutant protein was also performed under similar conditions 
(pH*  7.8, 310 K and 10 mM bicarbonate) and the results are shown in Figure 4.6B. 
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1.0 Bi 3 C " A 
BB 
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0.2 -0.2 -0.6 -1.0 
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Figure 4.6 (A) The high-field region of 500-MHz 'H NMR spectra of 1132M 
hTF/2N in 0.1 M KC1, pH*  7.8 in the presence of 10 mM bicarbonate, before 
(bottom) and after addition of 0.5 (middle) and 1.0 (top) mol equiv of [Bi(NTA)]. 
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Figure 4.6 (B) The high-field region of 500-MHz 'H NMR spectra of 1132M 
hTF/2N in 0.1 M KC1, pH*  7.8 in the presence of 10 mM bicarbonate, before 
(bottom) and after addition of 0.5 (middle) and 0.9 (top) mol equiv of 
[Fe(NTA)21. 
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Upon addition of 0.5 and 0.9 mol equiv of Fe 3+'  the resonance at -0.324 ppm 
decreased in intensity and completely disappeared and broad new peaks at -0.392 
(B') and -0.004 (C') ppm appeared and increased in intensity. It is reasonable to 
assume from these titration studies that the resonance at -0.324 ppm actually consists 
of two overlapped peaks, one is the peak B which was probably Leu 122 as adjudged 
from the change in the pattern of this residue on titration of metal ions (Bi 3 and 
Fe 3+)for both wild-type and mutant protein (Figure 4.7), and the other peak C cannot 
be assigned currently. This is supported by 2D TOCSY and NOESY experiments 
(Figure 4.8). It can be seen clearly that the peak B has identical associated cross-
peaks for both wild-type (Chapter 3) and mutant hTF/2N in NOESY spectra which 
suggests that peak B belongs to 5CH3 of Leu122. B and B' and their cross peaks are 
in slow exchange on the NMR time scale indicates that B' is the bound form of B. 
Interestingly, metal ions (Bi 3 and Fe 3+)  induced a large chemical shift change (0.164 
and 0.320 ppm for Bi3 and Fe 3+, respectively) in the peak C, which is different from 
that in the case of wild type of hTF/2N (0.126 and 0.097 ppm for Bi 3 and Fe 3+' 
respectively, Chapter 3). 






Figure 4.7 Bar chart showing the changes in shift of the methyl protons of 
Leu122 on Bi3 and Fe3 binding to wild-type hTF/2N and its mutant 1132M 
hTF/2N. 
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Figure 4.8 The high-field region of 2D TOCSY (-v =60 ms) and NOESY (tm=50 
ms) spectra of 1132M hTF/2N and NOESY spectrum of Bi 3 half-loaded 1132M 
hTF/2N (-u =50 ms). 
In the histidine C2H region, a notable change is the appearance and further 
increase in intensity of peaks at 7.606 (J'), 7.825 (K'), 7.996 (H') and 8.147 ppm (I') 
upon addition of 0.5 and 1.0 mol equiv of Bi 3 , (added as [Bi(NTA)]) (Figure 4.9A). 
Peaks at 7.679 (D), 7.770 (G), 8.056 (I) and 7.880 ppm (H) decreased in intensity and 
peaks I and H completely disappeared on addition of 1.0 mcl equiv of Bi 3t Peaks I' 
and H' appeared to undergo low-field shifts of 0.090 and 0.116 ppm, respectively, 
although unambiguous correlations between peaks cannot be made. Upon addition of 
0.5 mol equiv of Fe 3+ (added as [Fe(NTA)2]), peaks I, H and D became significantly 
broadened and almost completely disappeared after addition of 0.9 mol equiv of Fe 
3+ 
(Figure 4.9B). However, the peak at 7.770 ppm (G) remains constant throughout 
W. 
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titration of Fe 3+'  which is different from titration of hTF/2N with Bi 3 . Significantly, 
two peaks at 7.770 and 7.721 ppm remain very sharp even after addition of 0.9 mol 
equiv of Fe 3+'  in contrast to the same peaks for wild-type hTF/2N (Chapter 3). 
J' 
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Figure 4.9 (A) The His C2H region of resolution-enhanced 500-MHz 'H NMR 
spectra of 1132M hTF/2N in 0.1 M KC1, pH*7.8.  From bottom to top: 1132M apo-
hTF/2N, addition of 10 mM bicarbonate, addition of 0.5 and 1.0 mol equiv of 
[Bi(NTA)]. 
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Figure 4.9 (B) The His C2H region of resolution-enhanced 500-MHz 'H NMR 
spectra of 1132M hTF/2N in 0.1 M KCI, pH*7.8.  From bottom to top: 1132M apo-
hTF/2N, addition of 10 mM bicarbonate, addition of 0.5 and 0.9 mol equiv of 
{Fe(NTA)2]. 
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['H, 13  C] HSQC: The 2D ['H, ' 3 C] HSQC NMR spectra of 1132M hTF/2N 
and addition of 0.5 and 1.0 mol equiv of Bi3 , in the presence of 10 mM bicarbonate, 
pH 7.8, 310K are shown in Figure 4.10. As expected, six cross peaks were observed 
for the apo-protein with five of them also being seen for the wild-type protein 
(hTF/2N) and these have been assigned previously on the basis of single-site 
mutations in combination with NMR spectroscopy techniques [23,49]. Thus the sixth 
peak at 1.51/17.98 ppm can obviously be assigned as Met132. On addition of 0.5 mol 
equiv of Bi3 (added both as RBC and [Bi(NTA)]), a notable change is the decrease 
in intensity of Met132 and appearance of a new peak shifted by 0.05 and 0.06 ppm 
to high field in the 'H and ' 3C dimensions, respectively. This was thought to arise 
from the metal-bound form of 1132M hTF/2N. Other cross-peaks such as those for 
Met109 and Met309 also shifted in both 'H and ' 3 C dimensions (Figure 4.10A, and 
Table 4.4). Addition of 1.0 mol equiv Bi 3 caused almost complete disappearance of 
the peaks from the apo-protein and resulted in further increases in intensity of 
resonances for the bound-form of the protein (e.g. Meti 32, Met309 and Metl 09). 
These changes can be also observed clearly from one dimensional ' 3C edited 'H 
NMR (Figure 4.1013). 
On addition of [Fe(NTA) 2] in the presence of 10 mM bicarbonate, the 
behavior of the cross-peaks was similar to that observed for Bi 3 , upon addition of 
0.5 mol equiv of Fe 3+  with a decrease in intensity of the initial peaks for apo-hTF/2N 
and appearance of a new set of peaks for the bound-form as shown in Figure 4.11. 
However, there was much more broadening of the peak for Metl 32 in the bound 
form than was the case for the reaction with Bi 3t Addition of 0.9 mol equiv of Fe 3+  
(to avoid the presence of free Fe 3 ) led to a further increase in intensity of the peaks 
for Fe-hTF/2N and almost complete disappearance of peaks for apo-hTF/2N. 
However, the peak for Met 132 in the bound-form was severely broadened and almost 
undetectable. 
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Figure 4.10 (A) 2D I'H,' 3C1 HSQC spectra of 1132M 6- 13C-Met-hTF/2N in the 
presence of 10 mM bicarbonate at p11*  7.8, and after addition of 0.5 and 1.0 mol 
equiv of Bi 3 . The solid boxes indicate initial peaks and dotted boxes show new 
peaks. 
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Figure 4.10 (B) Slices through 2D ('H,' 3C] HSQC spectra of 1132M c-' 3 C-Met-
hTF/2N in the presence of 10 mM bicarbonate at pH*  7.8, and after addition of 
0.5 and 1.0 mol equiv of Bi 3 . 
Table 4.4 'II and 13C chemical shifts of apo- and Bi-bound- form of Met-(c)-
' 3CH3 residues of 1132M hTF/2N at pH*  7.8, 310 K. 
Residues Apo-1132M hTF/2N (ppm) 
6 ('Hi' 3 C) 
Bi-bound (ppm) 
6 ('1-{/' 3 C) 	AS ('H/ 13C) 
Met i 32 1.51/17.98 1.45/17.93 -0.061-0.05 
Met26 1.97/14.65 1.97/14.60 0.00/-0.05 
Met 109 1.94/16.15 1.97/16.22 0.03/0.07 
Met256 2.13/15.54 2.13/15.54 0.00/0.00 
Met309 2.15/16.16 2.14/16.10 -0.011-0.06 
Met313 2.21/15.76 2.20/15.75 -0.01/-0.01 
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Figure 4.11 (A) 2D ['H,' 3C1 HSQC spectra of 1132M 6- 13 	in the 
presence of 10 m bicarbonate at pH*  7.8, and after addition of 0.5 and 0.9 mol 
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Figure 4.11 (B) Slices through 2D ['H, 13C]  HSQC spectra of 1132M - 13C-Met-
hTF/2N in the presence of 10 mM bicarbonate at pH 7.8, and after addition of 
0.5 and 0.9 mol equiv of [Fe(NTA)21. 
4.4.3 Binding of Bi3 to 1132M h TF12N in the Presence of Excess of 
Albumin 
Since chemical shift changes of Met residues were induced by metal ions (e.g. 
Fe 3+  and Bi 3 ) in the 2D HSQC spectra, they were used as finger-prints to allow 
studies of competition of Bi 3 binding between transferrin and other proteins such as 
albumin. These experiments were performed using only 150 iM 1132M hTF/2N in 
the presence of 12 mol equiv of human serum albumin (HSA, 1.8 mM) or 
recombinant albumin (rHA, 1.8 mM) at pH' 7.8, 10 mM bicarbonate at 310 K. The 
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ratio of [albumin]/[transferrin] was chosen as 12:1 to mimic the biological condition. 
In blood plasma, the concentration of albumin (ca. 0.63 mM) is Ca. 18 times higher 
than that of transferrin (Ca. 35 tM). However, considering the metal carrying 
capacity of hTF (30% saturated with Fe), and the fact that albumin was considered to 
have one metal binding site, the ratio of albumin concentration over hTF should be 
ca. 12:1. The 2D HSQC NMR spectrum of a mixture of the two proteins shows sharp 
resonances from labelled Met residues of transferrin and broad resonances from 
albumin (Figure 4.12). It can be seen that addition of RBC led to a decrease in 
intensity of cross-peaks for Met residues of apo-hTF/2N, in particular Meti 32, and 
those for the Bi-bound form appeared and increased in intensity with further addition 
of RBC. However, a quantitative study of Bi 3 competition reactions between 
transferrin and albumin using the shift changes of Metl 32 as a probe was hampered 
due to overlapping of the Meti 32 peak with broad peaks from albumin, Figure 4.12. 
Since there are only six peaks from labelled 1132M hTF/2N at a low concentration, 
one dimensional ' 3C-edited 'H NMR spectra were recorded. Figure 4.13A shows the 
' 3C edited 'H NMR spectrum of 1132M hTF/2N with and without the presence of 
HSA or rHA. Broad resonances at 1.70 and 1.45- 1.10 ppm were from albumin and 
can be filtered out with resolution enhancement as shown in Figure 4.13B, e.g. prior 
to Fourier transformation, using a combination of un-shifted sine-bell and 
exponential functions. 
The new antiulcer drug, ranitidine bismuth citrate (RBC), was added in 0.25 
mol equiv stepwise to 1132M hTF/2N without and with the presence of either 
12* rHA or  12*HSA,  and resulting 'H{ ' 3 C} spectra are shown in Figure 4.14. With 
the increase of Bi 3 , a new peak at 1.45 ppm assigned as a bound form of Met132 
increased in intensity gradually and reached a maximum after addition of Ca. 1 mol 
equiv of RBC with respect to hTF/2N, while the peak for Met132 in the apo-form 
decreased in intensity and finally disappeared, Figure 4.14. The change in intensity 
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Figure 4.12 2D ['H,' 3C] HSQC spectra of 1132M c- 13C-Met-hTF/2N in the 
presence 12*rHA with 10 mM bicarbonate at pH*  7.8, and after addition of 
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Figure 4.14 (A) Resolution-enhanced 500-MHz 'H{ 13C} spectra of 1132M E) 3C-
Met-hTF/2N in 0.1 M KCI, 10 mM bicarbonate, at pH*  7.8 before and after 
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Figure 4.14 (B) Resolution-enhanced 500-MHz 'H{' 3C} spectra of 1132M - 13C-
Met-hTF/2N in the presence of 12*rHA  in 0.1 M KCI, 10 mM bicarbonate, at 
pH* 7.8 before and after addition of different mol ratios of RBC with respect to 
1132M hTF/2N. 
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of the peak for Met309 (2.15 ppm) can be seen more clearly in the 'H{' 3 C} 
dimension due to the increased resolution: it decreased in intensity gradually with the 
addition of Bi3 and disappeared finally due to overlap of the new signal with 
Met256 (2.14 ppm) as judged from the increase in intensity of Met256 and from 2D 
HSQC spectra (Figure 4.10A). Metl09 also shifts to low field by 0.02 ppm and 
becomes overlapped with Met26, Figure 4.14 and Figure 4.10A. The chemical shift 
changes of Met residues induced by Bi 3+  were identical in the presence of albumin to 
those observed for Bi 3 binding to hTF/2N. The integration changes for the peak of 
Met132 in apo- and bound-form in the presence and absence of albumin (HSA and 
rHA) with mol ratios of Bi3 added are shown in Figure 4.15. It can be seen from 
Figure 4.14 and Figure 4.15 that the presence of large excess of albumin does not 
cause a significant decrease in intensity of the Met132 resonance for the Bi-bound-
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Figure 4.15 Titration curves for addition of RBC to 1132M hTF/2N without and 
with the presence of 12*rHA  or  12*HSA  in 0.1 M KC1 at pH*7.8,  10 mM HCO3. 
Graphs showing gradual increases in intensity of the cross-peak for Met132 in Bi 3 -
bound form (filled symbols) and decreases in intensity of resonances for Met132 in 
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Since the albumin concentration was more than ten times higher than that of 
transferrin, the peaks in the 'H NMR spectrum are almost exclusively from albumin. 
The spectra of this mixed protein solution (hTF/2N+12*rHA or +12*HSA)  in the 
aromatic region are virtually identical with and without addition of Bi 3 , particularly 
the resonance at 7.632 ppm which was previously assigned to His3 of albumin 
(Figure 4.16). 
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Figure 4.16 The aromatic region of resolution-enhanced 500-MHz 1 H NMR 
spectra of 150 jtM 1132M hTF/2N in the presence of 12*HSA  in 0.1 M KC1, pH* 
7.8, before (bottom) and after addition of 0.48 (middle) and 0.96 (top) mol equiv 
of RBC with respect to hTF/2N. 
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4.4.4 Uptake of Bi3 by Transferrin in Intact Blood Plasma  
The concentration of transferrin in human plasma is ca. 35 LM, and it is only 
about 30% saturated with iron and therefore there is ca. 50 .LM capacity for binding 
to other metal ions. In order to determine if transferrin is the main target for bismuth 
in vivo and in vitro, 1132M hTF/2N was added directly to human plasma to give a 
final concentration of 100 jtM. The whole plasma concentration (including the added 
transferrin) was doubled by freeze-drying the sample and re-dissolving so as to give 
half the volume of the original plasma solution. 
The resonance of Met 132 is very broad and overlapped with other peaks from 
plasma in ' 3C edited 'H NMR spectra even with resolution enhancement, Figure 
4.17. Titration with RBC caused a decrease in intensity of only the resonance for 
Met309, which shifted and finally overlapped with Met256. However, the 2D HSQC 
spectrum of this sample in 100 mM KC1, 20 mM bicarbonate at pH*  7.8 is reasonably 
resolved and is shown in Figure 4.18. Surprisingly, the Metl09 cross-peak was 
severely broadened and the remaining Met cross-peaks from labelled transferrin can 
be clearly observed. There are many other cross-peaks which are difficult to assign 
partially due to a limited frequency width (12 ppm in the ' 3C dimension). However, 
some of them can be easily identified, such as ca. 1.46/17.2 ppm and 1.67/15.8 ppm, 
from Ala and Lys (folded from 23 ppm) residues of albumin, respectively, and Ca. 
1.24/19.2 ppm from lipid in plasma. Addition of 0.5 mol equiv of RBC with respect 
to the total binding capacity of transferrin, i. e. 1132M hTF/2N added (2x100 LM) 
and unlabelled transferrin in plasma (2x50 jiM), caused a decrease in the intensity of 
the Met132 peak in the apo-form (1.51/17.98 ppm) and the appearance of a peak for 
the bound form at 1.45/17.93 ppm. Similarly, Met109 (1.94/16.15 ppm) low-field 
shifts slightly and Met309 (2.15/16.16 ppm) high-field shifts, Figure 4.18. The 
cross-peak for Met 13 2  in the apo-protein almost disappeared and that for the bound- 
"Collaboration with Dr. Hongzhe Sun 
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form further increased in intensity upon further addition of 1.0 mol equiv of RBC. 
The chemical shift changes of cross-peaks for Met residues induced by Bi 3 in the 
presence of blood plasma are identical to those observed for isolated transferrin 
(1132M hTF/2N) or in the presence of albumin under the same conditions. 
In order to more closely mimic biological conditions, experiment in which 
113 2M hTF/2N was added to intact blood plasma to give a final concentration of 50 
tM, then reconstituted similarly as before was also performed. All the Met cross-
peaks were observed clearly except those for Met26 and Meti 09, which became 
significantly broadened, Figure 4.19. A similar change in the pattern of resonances 
occurred in the 2D HSQC spectra upon addition of 1.0 mol equiv of RBC with 
respect to the total binding capacity, e.g. peaks for Met132, Metl09 and Met309 in 
the apo-form almost disappeared and new peaks for the bound-form appeared. The 
slices from 2D HSQC spectra clearly show peaks for Met132 in the apo- and bound-
forms. Interestingly, Met26 now became sharper and observable. 
Similarly, -' 3C-Met hTF was added to intact plasma to give a final 
concentration of 35 pM and the concentration was doubled by freeze-drying and 
reconstitution in half the volume of 100 mM KC1 in D20. The 2D HSQC spectra of 
this solution before and after addition of 1.0 mol equiv of RBC at the presence of 20 
mM bicarbonate, 310 K, pH*  7.8 are shown in Figure 4.20. The spectra are largely 
from plasma due to a very low concentration of labelled transferrin, however, cross-
peaks for Met256, Met499 and Met464 still can be identified. Addition of 1.0 mol 
equiv of RBC with respect to total concentration of transferrin led to the 
disappearance of the cross-peak for Met464 and the appearance of a peak assignable 
to Met464 in the bound-form at 1.18/18.2 ppm. The cross-peaks for Met499 in the 
apo-protein also decreased in intensity and a cross-peak for the bound-form appeared 
after addition of RBC, Figure 4.20. Again, the shift changes of these residues 
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(Met464 and Met499) induced by Bi 3 are similar in magnitude to those for isolated 
hTF. 
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Figure 4.17 'H{ 13C} spectra of 1132M hTF/2N (200 pM) in plasma (2x 
concentrated) containing 20 mM bicarbonate at pH*  7.8, before (bottom) and 
after addition of 0.5 (middle) and 1.0 (top) mol equiv of RBC with respect to the 
total binding capacity of transferrin. NAC, N-acetyls of glycoproteins; LDL, low 
density lipoprotein. 
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Figure 4.18 2D ['H, 13C] HSQC NMR spectra of 200 tM 1132M E- 13 C-Met 
hTF/2N in plasma (2x concentrated) containing 20 mM bicarbonate pH*  7.8. 
(A) the apo-form of protein; (B) after addition of 0.5 mole equiv of RBC. The solid 
boxes indicate initial peaks and dotted box shows a new peak. 
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Figure 4.19 2D ['H, 13  C1 HSQC NMR spectra of 100 j.tM £- 13C-Met 1132M 
hTF/2N in plasma (2x concentrated) pH*7.8  and 20 mM bicarbonate. (A) the 
apo-form of protein; (B) after addition of 1.0 mol equiv of RBC and (C) slices 
through 2D ['H, 13C] spectra in 'H dimension (corresponding to 13C signal of - 
SCH3 of Met 132. The solid boxes indicate initial peaks and dotted box shows a new 
peak (Bi 3 bound form). 
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Figure 4.20 2D ['H, 13 C] HSQC NMR spectra of 70 p.M -' 3C-Met hTF in 
plasma (2x concentrated) at pH*7.8 and 20 mM bicarbonate, 310K. (A) the apo-
form of protein, (B) after addition of Bi 3 (corresponding to a total of 1 mol equiv of 
RBC with respect to total hTF). The solid boxes indicate initial peaks and dotted 
boxes show new peaks (Bi 3 bound form). 
128 
Chapter 4 Recognition of bismuth by hTF in plasma 
The normal 1 H NMR spectrum of plasma in the presence of labelled 
transferrin is identical in the His region with and without addition of Bi 3 , Figure 
4.21, especially the peak for His3 of albumin (7.632 ppm) which has previously been 
used as an indicator for drug binding at Cys34 [52]. 
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Figure 4.21 The aromatic region of resolution-enhanced 500-MHz 'H NMR 
spectra of 1132M hTF/2N (100 pM) in plasma, pH*  7.8, before (bottom) and 
after addition of 1.0 (top) mol equiv of RBC. 
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4.4.5 Interactions of Bismuth Complexes with Albumin 
Effect of Bi3 on the Free Thiol Content of Albumin: It is known that there 
is a free thiol group in albumin (Cys34), Figure 4.1, and this should be a potential 
binding site for Bi 3t The free thiol content of two albumin samples: serum albumin 
and recombinant albumin, before and after incubation with bismuth citrate 
complexes in 0.1 M Tris-HC1 buffer at pH 7.4 was determined by the DTNB-method. 
rHA samples contained 0.77±0.01 mol of free thiol/mol of protein, while for FISA 
samples the amount of free thiol was significantly lower, only 0.29±0.01 mol SW 
mol protein (Table 4.5). After 12 h of incubation of HSA or rHA (0.1 mM) with 
different mol ratios of either RBC or [Bi(Hcit)], the free SH content did not decrease 
significantly (less than 12% change, Table 4.5). This suggests that Bi 3 is unlikely to 
be bound by Cys34 in albumin. 
Table 4.5 The free thiol content (mol/mol albumin) of HSA and MA before and 
after 12 h of incubation with bismuth complexes in 0.1 M KCI at pH 7.4 (data 
presented as mean ±S.D. values of three measurements). 
Albumin 
samples 
Bi: albumin Bi complexes Free thiol (-SH) Changes (%) 
0:1 0.77±0.01 
1:1 RBC 0.74±0.02 -4 
rHA 5:1 RBC 0.71±0.01 -8 
10:1 RBC 0.68±0.02 -12 
5:1 Bi(Hcit) 0.73±0.02 -5 
0:1 0.29±0.01 
1:1 RBC 0.26±0.04 0 
HSA 5:1 RBC 0.26±0.02 -3 
10:1 RBC 0.23±0.03 -10 
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Weak Binding of Bi 3 to Human Serum Albumin: Different mol ratios of 
ranitidine bismuth citrate were added to albumin solutions (0.1 M Tris-HC1 buffer at 
pH 7.4) and equilibrated overnight at 310 K, followed by separation of albumin-
bound-bismuth from free bismuth via gel filtration chromatography. Bismuth 
contents in albumin fractions were measured by DIN-ICP-MS and are shown in 
Figure 4.22. The bismuth concentrations in the albumin fractions increased almost 
linearly with increase in ratio of RBC over HSA and did not saturate even at 25 mol 
equiv of RBC added, indicative of a weak association of bismuth with albumin. In 
separate experiments, the gel-filtration chromatograms of control albumin and its 
complex with bismuth are found to be very similar both in intensity and retention 
time (Figure 4.23), suggesting that bismuth does not cause aggregation of albumin. 
When 40 mol equiv of glutathione (vs bismuth concentration measured) was added to 
the albumin fraction containing 60 1tM Bi, a new broad band centered at ca. 350 am, 
which was assigned as a Bi-S band, gradually increased in intensity with multi-phasic 
steps, and reached a maximum intensity over 12 h (Figure 4.24). This is in contrast 
to the reaction of bismuth with glutathione, which is extremely fast, Figure 4.24. 
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Figure 4.22 Titration curve for Bi 3 weak binding to HSA. Graph showing the 
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Figure 4.23 Gel filtration chromatography of human serum albumin complexes 
with [Bi(Hcit)]. FPLC traces for HSA control (top) and after 24-h incubation with 5 
mol equiv of [Bi(Hcit)] (bottom) in 0.1 M Tris-HC1 pH 7.4. 
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Figure 4.24 Dependence of absorbance at 350 nm on time for the reactions of 40 
mol equiv of glutathione with Bi3 bound albumin and bismuth citrate. 
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4.5 Discussion 
Transferrin is a major transport protein for iron and perhaps other metal ions 
(e.g. A13 , and Ga3 ) in blood. It possesses two similar metal binding sites in the N-
and C-lobes which differ slightly in their affinities, but the factors which direct metal 
ions to specific lobes of hTF are poorly understood. Only when hTF is loaded with 
metal ions in both lobes does it bind strongly to the receptor and so the 
conformational changes which accompany metal binding are of direct relevance to its 
recognition by cells. The 2D ['H, ' 3 C] NMR method studied in this Chapter appears 
to be one of the few methods reported so far which allows the direct determination of 
the order of loading of the lobes of intact hTF with metal ions. Moreover, for the first 
time using NMR, it is possible to compare directly structural changes induced by 
Fe 3+  in comparison to other metal ions. 
Using recombinant hTF labelled specifically with 8-' 3 C-Met, it is possible to 
detect peaks for eight (and sometimes all) of the nine Met residues in hTF at 
micromolar concentrations, and although the protein is expensive to produce, it can 
be demetallated and recycled for studies under different conditions. The recombinant 
hTF is non-glycosylated, but there is no evidence that glycosylation affects metal 
uptake [42]. The SCH3 peaks are convenient for NMR studies since they are singlets, 
and moreover the Met residues are well spread throughout the protein and occupy 
several types of environment, Table 4.2 and Figure 4.2. Since the (carbon atoms of 
the) SCH3 groups are all over 12 A from Fe3 , it is a reasonable assumption that the 
SCH3 cross-peaks are little affected by the paramagnetism of Fe 3 (high-spin S=5/2 
[6], since dipolar shifts oc 1/ r3 , dipolar broadening cc 1/ r6, where r is the distance 
between Fe 3+  and nucleus of interest [53]). 
Previously 'H NMR has been used to determine the order of lobe-loading of 
hTF with A13 and Ga3 [21,22,54]. This required studies on the isolated N-lobe 
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alone and the use of specific resonances as finger-prints. Although His 1 H NMR 
resonances were useful for finger-printing, they are difficult to follow on account of 
their sensitivities to pH near pH 7. This is not the case with 6- 13 C-Met resonances, 
and, moreover, the resonance for Met464 is a specific and sensitive indicator for C-
lobe binding. Other methods, e.g. heteronuclear NMR, DSC and EPR [6,7] have also 
been used successfully to determine the order of loading, but again comparison with 
the isolated N-lobe is necessary. Although apo-hTF can sometimes be separated from 
mono- (Fec or FeN) and di-metal transferrin by electrophoresis, the method requires 
harsh conditions (6 M urea) and is successful only for very tightly-bound metal ions 
[16,17,55]. 
Importantly the present study has allowed for the first time determination of 
the order of lobe loading of hTF with Fe 3 (as an NTA complex in the presence of 
HCO3 as synergistic anion) using NMR methods, and, in agreement with previous 
reports, the C-lobe is occupied preferentially. The results obtained in this Chapter for 
the order of lobe loading with Bi 3 , Ga3 and A13 agree with previous reports. The 
behavior of Bi 3 resembles that of Fe 3+  (as NTA complexes) with preferential binding 
to the C-lobe, whereas Ga 3 shows little preference for either lobe. However, A1 3 
does not load either the N-lobe or the C-lobe at pH*  7.4, but at pH*  8.8, preferentially 
loads the N-lobe, in contrast to Fe 3+  and Bi3+ at pH
* 
 7 (Table 4.3). The difference 
may be related both to the presence of NTA as a bound ligand on the loading Fe 3+  
and Bi3 complexes, and to the change in charge of the protein (and especially the 
charge in the interdomain cleft) at high pH. It was also found that reaction of one mol 
equiv of Fe 2+  with apo-hTF led to the occupation of both lobes with iron, in contrast 
to previous reports in which it was concluded that this method of loading with iron 
leads to selective loading of the N-lobe [16,17]. It seems likely that the high 
concentration of Cl - ions used in the present work (0.1 M) influences the distribution 
of iron between the two lobes [56], and this will be an interesting topic for further 
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study. The shifts and broadening of ['H, ' 3C] NMR resonances upon loading apo-
hTF with 2 mol equiv of Fe 2 were the same as that with Fe 3 , therefore, it can be 
concluded that Fe 2+  is oxidized as it is taken up. The detailed mechanism of this 
process appears to be unknown but probably involves 02 as oxidant. 
Although the chemical shift changes for Met resonances induced by Fe 3+  are 
similar to those induced by Ga 3 , A13 and Bi3 , implying that these metals all induce 
similar conformational changes on binding, Fe 3+  markedly broadens the cross-peak 
for Met464, Figure 4.3. The contribution of paramagnetic effects to peak broadening 
remains to be determined, but may be negligible at such a large distance (> ca. 12 A) 
from Fe3t It is therefore possible that iron causes a reduction in mobility of this 
group, or a change in its dynamic exchange behaviour, which is different from that 
induced by the other metals studied. 
The present study shows that the cross-peak for Met464 is a sensitive 
indicator of metal binding to the C-lobe since metal binding induced significant 
chemical shift changes of this residue in both the 1 H and ' 3C dimensions. In the N-
lobe of intact hTF, however, there is a lack of this kind of sensitive indicator. Met464 
is situated in the hydrophobic patch of helix 5 in the C-lobe, consisting of Va1454, 
Trp460 and Met464, Figure 4.25, which backs onto the metal binding sites and H-
bonds to the synergistic anion [50,57]. In the N-lobe there is a similar hydrophobic 
patch in helix 5 near the metal binding site, consisting of Leu122, Trp 128 and lie 132, 
Figure 4.25. The analogue residue of Met464 is 11e132 in human serum transferrin, 
but Met 132 in cow and pig transferrin [58]. Thus, particular amino acid residues may 
play a different role amongst different species. In order to provide a possible 
sensitive indicator for metal ions binding in the N-lobe of human serum transferrin 
and to investigate the similarity between the two lobes of transferrin, Ile 132 was 
135 

















N-Lobe 	 Leu122 
Figure 4.25 Hydrophobic patches of transferrin in the C- lobe 1501 and the N-
lobe 1511. Ile 132 in the N-lobe corresponds to the Met464 in the C-lobe, and both of 
these residues are on the top of the tryptophan ring (3- 4 A away). 
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mutated to a Met residue by site-directed mutagenesis of the recombinant N-lobe of 
transferrin. 
The 'H NMR spectrum of 1132M hTF/2N was similar to that of wild type 
hTF/2N both in the high-field and His C2H regions of its NMR spectra, except for 
the disappearance of the 'yCH 2 of lie 132. Both Bi 3 and Fe 3+  induced a similar 
chemical shift change for the peak of Leul 22 in the mutant as for wild type hTF/2N, 
Figure 4.7, which indicates that the overall structure of the mutant is similar as that 
of wild type, although the local structure may be slightly different. This is also 
confirmed by molecular modeling, which shows that the protein backbone of 1132M 
hTF/2N is the same as native hTF/2N although the side-chains conformations of 
certain residues are slightly different (Figure 4.26). Energy minimization gave rise to 
ten structures for mutant Ii 32M hTF/2N with a similar energy, and amongst the ten 
structures, six of them have the side-chain of Met132 above Trp128, Figure 4.26, a 
position in which Met132 would be affected by the Trp indole ring and undergo a 
ring-current shift. 
Indeed, in 2D ['H,' 3C] NMR spectra of 1132M 8- 13CH3-hTFI2N, the SCH3 of 
Met 13 2  exhibits a noticeably high-field shift in the 'H dimension compared with the 
rest of other Met residues, similar to Met464, but with different magnitudes in both 
'H and ' 3C dimensions. Only small changes in shifts of the Met132 resonance 
occurred when Bi 3 and Fe 3+ bind to the mutant 1132M hTF/2N, in contrast to 
Met464 for which considerable shifts were observed upon loading metal ions, 
indicating that the local structure of N- and C-lobe of transferrin are similar but not 
identical. This may also be related to the difference of domain closure after loading 
metal ions which, in the solid state of lactoferrin, involves the pivoting of helix 5 on 
helix 11 and a 540 domain movement in the N-lobe and a possible 150  movement in 
the C-lobe [59]. Consequently, this will affect the distance and angle between the 
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Figure 4.26 (A) Secondary structures of 1132M hTF/2N overlaid from molecular 
modelling together with native hTF/2N, (B) Hydrophobic patch around Trp128 
in 1132M hTF/2N. (modeling carried out by John Parkinson) 
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SCH3 of Met and the Trp indole ring (W128 and W460 in the N and C-lobe, 
respectively). Similarly, Fe 3+  markedly broadens the cross-peaks for both Met464 and 
Met132, which suggests that iron may cause a reduction in mobility of these groups 
or a change in their dynamic exchange behaviour in the same manner in both the C-
and N-lobes of transferrin. 
It has been shown in Chapter 3 that the strength of Bi 3 binding to the 
recombinant N-lobe of transferrin is similar to that in the N-lobe of the intact protein 
(log K*  18.9 vs 18.6 at pH 7.4 310 K). Moreover, the chemical shifts of most of the 
Met residues of 1132M -' 3 CH3-hTF/2N in 2D HSQC spectra are similar to those for 
the N-lobe of intact E-' 3 CH3-hTF, except those in the interlobe hinge region (Met309 
and WOO). Therefore, it appears that 1132M E- 13CH3-hTF/2N can be used to be 
good model for intact hTF and was used in the present work to probe binding of the 
bismuth antiulcer drug (RBC) to transferrin under biologically relevant conditions 
using inverse NMR detection techniques. 
2D HSQC NMR spectroscopy has been used successfully to probe the 
changes of Met residues of transferrin in which the concentration of this protein is 
more than ten times lower than that of albumin. The shift changes of Met residues of 
1132M hTF/2N induced by Bi 3 in the presence of biologically relevant 
concentrations of albumin are essentially identical to those for isolated hTF/2N, 
which indicates that binding of Bi 3 to hTF/2N may cause a similar conformational 
change, e.g. from lobe-open to lobe-closed. Although the titration curves (Figure 
4.15) show a slightly decreased intensity (less than 20%) of cross-peaks for bound 
1132M when either 12*HSA  or  12*rHA  are present, this can perhaps be partially 
attributed to a broadening of peaks since viscosity of the solution is marginally higher 
in the presence of the high concentration of albumin (1.8 mM). Moreover, the use 
resolution enhancement to filter out broad signals from albumin leads to a loss in 
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sensitivity of NMR signals, which may also account for the small differences in the 
titration curves (Figure 4.15) in the presence of albumin. However, the possibility of 
a small amount of Bi 3 binding to albumin can not be excluded. 
Previously, it has been speculated that albumin, the most abundant protein in 
blood serum, should be a target site for bismuth drugs, since there is a free thiol 
group at Cys34. Usually Bi 3 shows a higher affinity for thiol sulfur than for 0 and N 
[32], and glutathione (GSH) can easily displace Bi 3 from its complexes with citrate 
and EDTA at biological pH values [34]. However, recent reports have shown that 
only 2% albumin molecules are bound to Bi3 if binding of bismuth to albumin 
occurs at the free thiol group of Cys34 (with pK a only Ca. 5) [60], which is unlikely 
to be true for strong binding. It is shown, in this work, that binding of Bi 3 to albumin 
is very weak, since even 25 mol equiv of Bi 3 do not saturate albumin, and this weak 
binding does not occur at Cys34, which was evidenced by only a slight decrease 
(<12%) in thiol content of albumin after incubation with different mol ratios of 
bismuth citrate complexes. Furthermore, 'H NMR has been shown previously as a 
sensitive method to monitor drug binding to the free thiol group of Cys34 of albumin 
e.g. the gold drug auranofin and its derivatives, [52,61]. It has been proposed that 
gold binding or oxidation to form a disulfide at Cys34 induces a structural transition, 
and leads to the movement of Cys34 from a buried to an exposed environment. These 
effects can be easily observed in the 'H NMR resonances of His3 of the protein both 
for isolated albumin and for albumin in blood plasma [52,61]. However, 'H NMR 
spectra in the His region are essentially identical before and after addition of bismuth 
drugs to labelled transferrin (both 1132M hTF/2N and intact hTF) in the presence of 
either biologically relevant concentrations of albumin or in blood plasma, Figure 
4.16 and Figure 4.21. This is in line with measurements of the free thiol content 
which show that the binding of Bi3 to albumin is not at Cys34. In the crystal 
structure of albumin, Cys34 is protected in a crevice where it interacts with other 
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side-chains, probably His39 and G1u82 [35]. Thus the stabilized deprotonated thiol 
may not be available for bismuth complexes to react at this position. Therefore, the 
binding sites for Bi 3 on albumin remain unclear and further study is warranted. 
Remarkably, on addition of biologically relevant concentrations of 1132M 
hTF/2N to intact blood plasma, all the six cross-peaks for Met residues were resolved 
and gave rise to identical chemical shifts compared with those from isolated protein 
in the 2D HSQC spectrum, Figure 4.18. However, Met109 was severely broadened. 
The reason for this is not clear, but is probably due to the interaction of transferrin 
and other proteins from blood plasma. On addition of the bismuth antiulcer drug 
RBC, similar changes in shift of Met residues for 1132M hTF/2N were observed in 
blood plasma compared to those observed for the isolated protein, suggesting a 
similar binding mode and similar conformational changes on binding of Bi 3 . 
Furthermore, binding of Bi 3 to the C-lobe of intact transferrin also caused a similar 
conformational change in blood plasma as judged from similar shift changes of 
Met464 and Met499 when a biologically relevant concentration of e- 13 CH3-hTF was 
added to blood plasma (Figure 4.20). Consequently, it can be concluded that Bi 3 
binding to both the N-lobe and C-lobe of transferrin occurs in a similar mode in 
blood plasma as for the isolated protein and binding also induces a conformational 
change, e.g. from lobe-open to lobe-closed, which is crucial for transferrin cell 
receptor recognition. However, the possibility of Bi binding to other thiol-
containing molecules present at low concentration in plasma cannot be excluded. 
The discovery of the recognition of Bi 3 by transferrin in blood plasma may 
have implications for the mechanism of neurotoxicity of bismuth drugs 
(encephalopathy). For a long time, it has not been clear how bismuth is transferred to 
the brain, although it is generally accepted that the diagnosis and symptoms of 
bismuth encephalopathy is confirmed by detection of Bi 3 in blood, serum and 
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plasma. It is likely that bismuth is transported by transferrin once it has entered into 
blood, which is similar to A1 3t It is known that the deposition of A1 3 in the brain 
can cause dialysis encephalopathy and this neurotoxicity is relevant to transferrin 
transportation and transferrin receptor recognition in the brain [62]. Further studies 
are required to verify whether bismuth-transferrin can be recognised by transferrin 
cell receptors. Furthermore, binding of Bi 3 to transferrin may also have implications 
for the anti-bacterial action of bismuth-containing drugs. H. pylon, like other Gram-
negative bacteria, needs Fe 3+  for survival [63]. Strong binding of Bi 3 to Fe 3+  sites in 
transferrin or transferrin-like proteins (e.g. lactoferrin, and ferric-ion-binding protein) 
and block Fe 3+  uptake pathways may be for one of the mechanisms of bismuth anti-
bacterial activity. 
Selective labelling combined with inverse NMR detection is a powerful 
method for probing the structure and dynamics of high-molecular-mass proteins. This 
approach provides a way to investigate the translocation not only of metallodrugs 
(and other drugs) between proteins and enzymes at concentrations of biological 
relevance without separation but also protein-ligand interactions, and even protein-
protein interactions. It should be interesting to use this approach to study the 
recognition of transferrin by its receptor, since it is still not clear which lobe and 
which part of transferrin binds to the receptor. 
4.6 Conclusion 
2D ['H, ' 3 C] NMR provides a rapid method of determining the order of lobe 
loading of transferrins with metal ions via the use of 6- 13C-Met labeled recombinant 
transferrin. Under the conditions used (10 mM bicarbonate, 0.1 M KCI at pH' 7.4), 
NTA complexes of Fe 3+  and Bi3 preferentially load the C-lobe, whereas Ga 3 shows 
little preference, and A1 3 does not bind at pH' 7.4 but preferentially loads the N-lobe 
at pH' 8.8. Reaction of hTF with Fe 2+  gave rise to both the N- and C-lobe loading 
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(with Fe 3)under the conditions used, in contrast to previous reports [55,17]. The 
Met residues of hTF are well distributed throughout the protein, and the changes in 
shift of their ['H, ' 3C] NMR resonances can be used as finger-prints of 
conformational changes induced by various metal ions. Fe 3+, Ga3 , A13 and Bi3 all 
induce similar conformational changes as judged from the changes in shifts of Met 
SCH3 resonances. 
Mutation of Ile 132 to Meti 32 in recombinant N-lobe hTF/2N gave rise to a 
similar structure as the wild type protein as illustrated by molecular modelling and 'H 
NMR spectroscopy. Meti 32 in both apo- and bound-forms exhibited a significant 
difference in chemical shifts in 2D ['H, ' 3C] HSQC compared with Met464, implying 
that the local structures of the two lobes of transferrin are not identical although they 
share ca. 40% sequence identity. Thus, the two lobes of transferrin may function 
differently in vivo. Significantly, by use of the chemical shift changes of Met 
resonances induced by metal ions as probes, a direct detection of bismuth antiulcer 
drug binding to transferrin in the presence of a large excess of albumin or even in 
blood plasma was achieved for the first time via inverse NMR detection techniques. 
The antiulcer drug RBC preferentially binds to transferrin in the presence of 
biologically relevant concentrations of albumin or in blood plasma, and also induces 
conformational changes of transferrin as in the case of isolated transferrin, e.g. from 
lobe-open to lobe-closed form, which is crucial for the transfenmn cell receptor 
recognition. Recognition of bismuth drugs by transferrin in plasma could be 
significant in their mechanism of action and neurotoxicity. The interaction of 
bismuth with albumin is much weaker than with transferrin, non-specific, and can be 
reversed by addition of glutathione, which suggests that binding of metallo-drugs to 
protein and enzymes is not only dependent on affinity for specific sites but also on 
their availability. Selective labelling combined with inverse NMR detection is a 
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potentially useful approach which can be applied to a wide range of studies related to 
large proteins. 
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Chapter 5 
Rationalization of the Strength of Metal 
Binding to Transferrin: Prediction of a New 
Metal (Ti4 ) Binding to Transferrin 1 
5.1 Abstract 
A wide range of metal ions of natural, therapeutic, diagnostic and toxic 
interest are transported by serum transferrin. It is therefore very important to 
understand the factors which control the strength of metal binding. It is shown in this 
Chapter that even though Sc 3 has only slightly larger ionic radius than Fe 3+  (0.75 A 
vs 0.65 A), it binds to the C-lobe and N-lobe sites much more weakly with log K1 
(bicarbonate-independent binding constant) 14.6±0.2 and log K2 t 13.3±0.3, 
respectively (10 mM Hepes, 310 K). It is shown that the strength of binding of 
variety of metal ions to human serum transferrin correlates with metal ion acidity 
(and therefore with the strength of binding to hydroxide, K 1 (OH)). These correlations 
are of predictive value for a range of other metal ions. Significantly, this approach 
allowed the discovery of a new metal ion (e.g. Ti 4 ) which binds to transferrin. The 
plot of log K 1 t (hTF) versus log K 1 (OH) has a negative intercept consistent with 
unfavorable entropy effects due to lobe closure of apotransferrin on binding of metal 
' Abbreviations used in this chapter are: 
CA, carbonic anhydrase; CP, carboxypeptidase; hTF, human serum transferrin; Kt, 
carbonate-independent binding constant; NTA, nitrilotriacetate; pH t , pH meter 
reading in D20 solution; [Sc(NTA)], Sc 3 with x mol equiv NTA present (does not 
imply all x mol of NTA bound to Sc); TSP, sodium trimethylsilyl-d4-propionate. 
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ions. This interpretation is proved by comparison with similar correlations of the 
strength of metal binding to the enzymes carbonic anhydrase (CA) and 
carboxypeptidase (CP) with that for the low M r ligand imidazole. These plots have 
positive intercepts consistent with the preorganized state of these metalloenzymes 
(favorable entropy effects on metal binding). 
5.2 Introduction 
It has been reported that about 30 metal ions bind to transferrin [1]. But the 
factors which determine the strength of metal binding to transferrin are still not fully 
understood. It has been suggested that for strong metal binding to transferrin, the size 
of the metal ion must be matched to the size of the binding cleft, being optimum for 
Fe3 (ionic radius 0.65 A), weaker for slightly smaller (Ga 3 , 0.62 A) or slightly 
larger (In 3 , 0.80 A) ions, and much weaker for much smaller (A1 3 , 0.54 A), or much 
larger (lanthanides, 0.86-1.03 A) ions. This argument has been used to rationalize the 
recent finding that lactoferrin promotes oxidation of the large metal ion Ce 3 (1.10 
A) to the smaller ion Ce4 (0.87 A) [2]. However, recently the large metal ion Bi 3 
(ionic radius 1.03 A), an ion widely used in medicine as an antiulcer drug [3], has 
been found bound very tightly to human transferrin with log K*l  19.64 and log K2 
18.86 (10 mM Hepes 310K and bicarbonate independent) [4]. In Chapter 3, it was 
also shown that Bi 3 binds to the recombinant N-lobe of transferrin very strongly 
with log K2 18.9. Moreover, there appears to be no overall correlation between the 
strength of metal binding and metal size (Figure 5.1). Therefore, new correlations 
need to be investigated. 
Titanium is in group 4 in the periodic table with an electronic configuration 
of 3d24s2 . It has three oxidation states, +2, +3, and +4, with +4 being the most stable 
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Figure 5.1 Dependence of the first binding constant of human serum transferrin 
for trivalent metal ions on the ionic radius of the metal. The radii are taken from 
Shannon [5] for coordination number six. 
state. Ionic radii (6 coordination) are 0.81 and 0.75 A for Ti3 and Ti4 , respectively, 
and most titanium compounds adopt octahedral geometries. Biological interest in 
titanium arises from the two titanium complexes, titanocene dichloride [Ti 4 Cp2Cl2] 
(1), where Cp is cyclopentadienyl and budotitane [Ti 4 (bzac) 2(OEt) 2] (2), where bzac 
is 1-phenylbutane-1,3-diketonate, which are currently on phase II clinical trials as 
anticancer agents [6,7]. Titanocene dichloride is active against a diverse range of 
human carcinomoas, including gastrointestinal and breast carcinomas, but not against 
head and neck cancers. It has also been shown recently that titanocene dichloride can 
significantly overcome cisplatin resistance in ovarian carcinoma cell lines [8], and 
has also been proved to exhibit pronounced antiviral, anti-inflammatory and 
insecticidal activities [9]. In addition, there is an enormous amount of titanium in a 
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variety of biomaterials such as artificial teeth, bones, and titanium is also present in 
many foods as whitening pigment. Moreover, 45  Ti has been reported recently to have 
potential radiopharmaceutical usage [10]. Thus there are abundant opportunities for 
Ti to enter into biochemical pathways in living systems. However, very little is 
known about the biological chemistry of Ti. There appear to be no reports of specific 










It is shown in this Chapter that the strength of metal binding to human apo-
transferrin correlates well with the stability constants for the binding of metal ions to 
small R0 ligands such as hydroxide and phenolates. These correlations were tested 
further by investigation of Sc 3 -hTF: the binding constant of Sc 3thTF as determined 
by UV spectroscopy is in a good agreement with the predicted value. Such 
correlations between metal binding constants for proteins and low molecular mass 
ligands appear to provide information about the preorganization of metal binding 
sites in proteins, as illustrated by comparisons with the metalloenzymes carbonic 
anhydrase (CA) and carboxypeptidase (CP). 
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The discovery of the formation of Ti-hTF, the first specific Ti-protein 
complex, was made on the basis of these new correlations. Ti 4 , a metal ion present 
in potentially important anticancer drugs, forms a strong complex with human serum 
transferrin by binding to the specific Fe 3 binding sites in this protein. This finding 
may provide an insight into the mechanism of action of the titanium anticancer 
drugs. 
5.3 Experimental Procedures 
5.3.1 Materials 
Apo-hTF was purchased from Sigma (Catalog No. T05 19) and was washed 
three times with 0.1 M KC1 to remove low-molecular-mass impurities using 
Centricon 30 ultrafilters (Amicon). Scandium atomic absorption standard solution 
(1,005 pg/m1 in 1% HNO3, Aldrich), NaHCO3 (Aldrich), H 3NTA(Aldrich) and 
Hepes (Aldrich), TiC13 (Sigma), sodium citrate (Sigma), titanocene dichloride 
(Aldrich), and NaH' 3 CO3 (MSD isotopes, >99% enriched) were used as received. 
A solution of [Sc(NTA)] was prepared from the scandium atomic absorption 
standard solution and 1 mol equiv of Na3NTA. The pH was carefully raised to 4 - 6 
with microlitre amounts of NaOH (1 M), and this solution was then diluted to 0.5 or 
1.0 mM. Solutions containing Sc: NTA = 1: 20 and 1: 40 were prepared by addition 
of an appropriate amount of NTA to the [Sc(NTA)] solution. A fresh 200 mM 
purple solution of [Ti 3 (cit)i.25] was prepared under N2 by addition of sodium citrate 
(1 ml of 250 mM) to a known amount of TiC1 3 , and the pH was adjusted to Ca. 6.0 by 
addition of solid NaHCO3 [11]. After bubbling with 02 for a few minutes, a 
colourless solution of Ti 4 citrate was obtained which was then diluted to Ca. 3.3 mM 
for UV experiments. A 10 mM yellow titanocene solution was prepared by 
dissolving a known amount of TiCp2C12 in a sodium citrate solution (Ti:cit=1 :1.2) 
and the pH was adjusted to 4.5 (1 M NaOH). 
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5.3.2 UV Spectroscopy 
Apo-hTF solution was prepared by diluting aliquots of a stock apo-hTF 
solution to ca. 10-5  M with 10 mM Hepes buffer, pH 7.4. The hTF concentrations 
were determined spectrophotometrically using £280  93,000 M'cm [12,13]. UV 
difference spectra upon addition of Sc 3 or Ti4 to apo-hTF were recorded. 
Immediately before addition of Sc 3 or Ti4 , an aliquot of a solution of NaHCO3 
(0.25 M) was added to the solution of apo-hTF (— 10- 5 M in 10 mM Hepes buffer pH 
7.4) giving a 5 mM concentration of bicarbonate. After addition of Sc 3 or Ti4 (2-20 
fl of [Sc(NTA)] or Ti 4 citrate complex), the solution was left to equilibrate at 310 K 
(2.5 and 12 h for Sc3 and Ti4 , respectively, due to slow reactions). The binding was 
monitored by the increase in absorbance at 241 rim and the binding constants for Sc2-
hTF were calculated from titration curves via a modified Hill-plot as described in the 
Chapter 3. The data were fitted using the program Kaleidagraph (Synergy Software). 
All the UV experiments were performed on a computer-controlled Perkin-Elmer 
Lambda 16 spectrometer. The temperature of the cells was maintained at 310 ± 0.1 K 
using a PTP- 1 Peltier temperature programmer. 
5.3.3 Determination of Stoichiometry for Ti4 -hTF 
The titanium content of purified titanium-transferrin was measured using 
ICP-AES (Thermo Jarrell Ash IRIS, at 323.40 rim) with help from Dr. David White. 
The Ti2-hTF samples for ICP-AES were prepared as follows: Ti 4 citrate (2.2 mol 
equiv) was added to apo-hTF (in 10 mM Hepes buffer, pH 7.4, 10 mM bicarbonate) 
and left to equilibrate for over 24 h at 310 K. The protein was then purified by 
ultrafiltration (Centricon 30, Amicon) washing four times with 0.1 M KC1 and twice 
with water. An aliquot of the final solution was diluted with concentrated HNO3 (ca. 
6 M) and the titanium content was measured without any digestion of the sample 
[14]. The transferrin concentration in this sample was determined by titrating with 
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Fe 3+  (added as [Fe(NTA) 21) and then measuring the absorbance at 465 nm (= 4950 
M_ 1 cm- 1 for diferric transferrin) [15]. 
5.3.4 NMR Spectroscopy 
To allow H-D exchange, apo-transferrin was dissolved in 0.1 M KC1 in D20, 
and after adjustment of the pH to 7.25, was left for 4 hours at ambient temperature. 
After lyophilization, the sample was redissoved in D20 containing 10 mM NaHCO3. 
The pH was then readjusted to 7.25 ± 0.05, when necessary, using NaOD and DO 
(0.2 M). The pH*  values of NMR solutions were recorded before and after NMR 
measurements. 
'H and 'H-decoupled ' 3 C NMR spectra were recorded on a Bruker DMX 500 
spectrometer at 500 and 125 MHz, respectively, using 0.7 ml of hTF solution (0.6 
mM for 'H and 1.0 mM for 13C) in 5-mm tubes at 310 K, using ca. 1000 and 20,000-
40,000 transients for 'H and 13C spectra, respectively, 6 j.is (50 0) pulses, recycle time 
1.8 s, 16 K data points, and water suppression via presaturation. The chemical shift 
reference for 'H was TSP via endogenous formate (8.465 ppm, pH*>  7) which was 
always present in samples as a minor impurity, and for 13C the reference was TSP via 
added internal dioxane (67.4 ppm). Resolution enhancement of the spectra was 
achieved by processing the free induction decays with a combination of unshifted 
sine-bell and exponential functions (line broadening of 1.5-5 Hz) on a Silicon 
Graphics computer using XW1NNMR software. 
5.4 Results 
5.4.1 Correlations between the Strength of Metal Binding to hTF and 
Small Ligands 
It has been shown previously that linear free energy relationships exist 
between the strengths of binding of a range of oxygen and nitrogen donor ligands 
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(including transferrin) to Fe 3+  and other trivalent metal ions such as Bi 3 [4], Ga3 
[16], In 3+  [17], and A13+[  18]. It seemed reasonable to assume that the types of amino 
acid side-chain donors in transferrin may determine the strengths of metal binding 
rather than the size of the binding cleft. An attempt has been made to correlate the 
strength of metal binding to human serum transferrin with a range of oxygen and 
nitrogen donor ligands [19], e.g. NTA (nitrilotriacetate), glycine, oxalate, lactate, 
histidine and acetate (Figure 5.2). These correlations are poor with R (correlation 
coefficient) values less than 0.9, and only 0.57 for the nitrogen-donor ligand 
histidine. 
Previously the binding constants for some divalent and trivalent metal ions 
with carbonate as anion have been determined by UV-difference spectroscopy based 
on monitoring the new absorption bands at 240 and 295 nm generated by metal 
ion binding in the interdomain Fe 3+  site with Tyr deprotonation [4,16-21]. Thus 
tyrosine residues may play a major role in determining the strength of metal binding 
to transferrin. Correlations between the strength of metal binding to hTF and 
tyrosinate-like ligands R0, e.g. hydroxide (OH) and 1 ,2-dihydroxybenzene 
(catechol) were made and are shown in Figure 5.3. Here, correlations of only the 
first metal binding constants of human transferrin for divalent and trivalent metal 
ions with the binding constants for R0 are shown. A similar correlation holds for 
the second metal-transferrmn binding constants. The values for hydroxide and 1,2-
dihydroxybenzene complexes are chosen for aqueous solutions at 298 K, I = 1.0 M, 
and were averaged as necessary when there are several reported values in the 
database [19]; log K*l  (hTF) values are from refs [4,16-22]. It can be seen from 
Figure 5.3 that there are excellent correlations between the strength of metal-
transferrin and the strength of metal binding to hydroxide and 1 ,2-dihydroxybenzene 










2+ • Cd2 ' N j2+ 41 
Fe 	i 1 












0 	 'I 
0 2 4 6 8 10 
log K(glycine) 
25 	y-2.90+5.80x R=0.893 
U 
U- 	 S 
1— 
a 	15 
0  10 
Chapter 5 Rationalization Metal-hTF binding constants & Ti-hTF 
25 	y=-1.37+5.81x R0.882 










10  G 3d 
C 
o 




0.5 	1.5 	2.5 	3.5 
log K(acetate) 
	
25 	y-12.63+2.00x R0.893 
SI 
20. 
• /5 U- 
I— 




/5 - 	 S 
0-. 	 I 
0 5 	10 15 20 
log K(nta) 





p 10 . / 
5. 	
•5• 
0 1 	I 	 I 	 I 
0 2 4 6 8 10 
log K(oxalate) 
0 -f 
0 1 	23 	4 
log K(lactate) 
Figure 5.2 Correlation of the strength of metal binding to transferrin with 
binding to some oxygen and nitrogen donor ligands. 
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Figure 5.3 Correlation of the strength of transferrin and Rif binding to metal 
ions. (A) Hydroxide (log K 1 (OH) = 14 pKa where Ka is the hydrolysis constant), and 
(B) 1 ,2-dihydroxybenzene. Closed circles (•) are for experimental data, open circles 
(0) and squares (0) represent predicted values, the latter predicted from correlation 
(A); (A) represents the value determined for Sc-hTF in this Chapter. 
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The correlation noted above (Figure 5.3) can be used to predict unknown 
stability constants for metal-hTF complexes. The stability constant for Sc-hTF can be 
predicted from the log K 1 (OH) correlation to be log KI*  15.6±1.6, and T13 is 
predicted to bind to transferrin even more strongly than Fe 3 , while the lanthanide 
ions are predicted to bind only weakly with e.g. La 3 -hTF log K 1 5.6±1.3, and Yb3 -
hTF log KI*  8.4 ±1.3. Cr3 and Co 3+  bind strongly to transferrin with log K 1 17±1.6 
and 21.4±1.6, respectively. 
5.4.2 Sc-hTF 
Sc3 has a similar ionic radius to Fe 3+  and previous UV [23] and NMR [24] 
data have shown that it binds to transferrin, although the binding constants and order 
of lobe loading have not been determined. Both in vivo and in vitro experiments have 
shown that transferrin is the major binding agent for Sc 3 in plasma [23]. Here the 
binding constant for Sc-hTF was calculated and compared with the value predicted 
from the correlation above (Figure 5.3) to test whether the log K(OH) correlation 
can be used to predicte stability constants for other unknown metal-transferrin 
complexes in general. 
Determination of Stability Constants: Scandium solutions containing 
various ratios of NTA:Sc were used to titrate apotransferrin. By monitoring the 
aborbance at 241 nm, the titration curves were obtained as shown in Figure 5.4. & 
increases linearly with increase in Sc:hTF ratio (r) until a value of r = ca. 1.3 is 
reached, showing that all the added scandium is bound to apo-hTF at low values of r. 
Beyond r1 .3, the absorbance increases further but the plot curves downward 
indicative of the occupation of a second site with a lower binding constant, and of 
competition between free NTA and hTF. With increasing NTA:Sc ratios (20:1 and 
40:1), the plots (Figure 5.4) show more pronounced downward curvature at high r 
values due to competition for Sc 3 binding between hTF and NTA. 
158 








0 	0.5 	1 	1.5 	2 	2.5 
r [Sc]/[hTF] 
Figure 5.4 Titration curves for scandium binding to apo human serum 
transferrin. Addition of [Sc(NTA)] to 1.12 x 10 M apo-hTF in 10 mM Hepes 
buffer at pH 7.4 containing 5 mM bicarbonate, with x = 1, 20, and 40. Ac equals the 
absorbance at 241 nm divided by the transferrin concentration; r is the ratio of [Sc] 
to [hTF]. 
The slope of the initial linear portion of these curves is 22,000 (±850 ) M' 
cm and can be equated to the molar absorptivity of transferrin with one site 
saturated with Sc 3 (AE;,). Hence, if the two sites are equivalent, a Ac value of Ca. 
44,000 M-1 cm- I  would be expected when both the sites are filled. The absorbance 
data obtained at different mol ratios of NTA:Sc were used to calculate the binding 
constants for Sc-hTF complexes as described previously in Chapter 3. By assuming 
that two binding sites of transferrin are independent and equivalent, then the 
following equation can be used to fit the experimental data: 
11 	1 	[NTA] = + 
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where the fractional saturation Y = [Sc-bound]/[hTF] totai , and n = average 
number of scandium ions bound per transferrin molecule. The concentration of metal 
bound to transferrin was calculated by assuming that for transferrin with two fully-
loaded sites the absorptivity is 2Ac 1 . Ka is the intrinsic binding constant, and 
	
Kai =2K a ,Ka Ka /2. 	 (Eq. 5.2) 
For the 40:1 NTA:Sc titration curve, the maximum Ac observed was near the 
calculated molar absorptivity (Ac 1 =22,000 M'cm'), Figure 5.4, even at r = 2.5. This 
suggests that only one Sc 3 ion binds to hTF under these conditions with NTA 
present in large excess, and so these data were used to calculate K ai. The slope of the 
plot of l/Y vs [NTA]/[Sc(NTA)] gave log Kai = 2.2±0.05 (correlation coefficient R = 
0.99 , n= 1.1, Figure 5.5A). 
From the 20:1 NTA:Sc titration curve, it was possible to use a similar plot to 
calculate log Kai = 1.9±0.05 (in agreement with that obtained from the 1:40 titration 
curve, R 0.99, n =1.93, Figure 5.513). 
(A) 	y = 0.89059 + 0.005878x R= 0.99029 
	 (B) 	
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Figure 5.5 Plots for determination of Ka i (A) apo-hTF titrated with Sc(NTA)40 
and (B) apo-hTF titrated with Sc(NTA)20. 
160 
Chapter 5 Rationalization Metal-hTF binding constants & Ti-hTF 
Using the known value [19] for the stability constant of [Sc(NTA)] (log 
KsCTA)=12.7), a pH independent binding constant of log K,= 14.8±0.2 was 
calculated for Sc-hTF. The bicarbonate-independent binding constant (K) was 
calculated as log K,= 14.6±0.2 as described in Chapter 3. This is in reasonable 
agreement with the value predicted from the log K(OH) correlation (15.6±1.6). 
The second binding constant needed to be recalculated due to inequivalence 
of the two metal binding sites on transferrin. An iterative fitting procedure was used 
as described previously [4,17]. The log K2 value was calculated as 13.5±0.3, giving 
log K2*  13.3±0.3. log Kl*  log K2*=  1.3 which is greater than would be the case if 
both lobes bound Sc3 equally strongly (iMog K=  0.6). Therefore it can be concluded 
that one lobe has a higher affinity for Sc 3 than the other. 
Selectivity of Sc 3+  Binding to the N- and Globes in hTF: It has been 
shown previously by 45  S NMR spectroscopy [24] that Sc 3 (and carbonate) binds to 
both lobes of ovotransferrin at pH 7.6 with a similar affinity and gives distinct 45 Sc 
NMR signals, but for serum transferrin only one 45 Sc peak was observed and the 
order of lobe loading was not determined. Here, 'H NMR was used to investigate 
which lobe of hTF binds Sc 3 preferentially. The most intense peaks in the region of 
the spectrum from ca. 2.0 - 2.2 ppm arise from the N-acetyl groups of the glycan 
chains in the C-lobe of hTF. On addition of the first equivalent of Sc 3 to apo-hTF, a 
new apparent singlet peak appeared at 2.098 ppm, the peak at 2.081 ppm split into 
two, and the shoulder at 2.038 ppm decreased in intensity (Figure 5.6). These 
changes occurred progressively from 0 to 1 mol equiv of Sc 3 and almost no further 
changes occurred in this region on addition of the second equivalent. Therefore it can 
be concluded that preferential binding of Sc 3 occurs to the C-lobe of hTF in the 
presence of bicarbonate as synergistic anion, as has been found for several other 
metal ions [4,25,26]. 
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2.2 	2.1 	2.0 
Figure 5.6 Detection of scandium binding to apo human transferrin by NMR. 
Resolution-enhanced 500 MHz 'H NMR spectra of apo-hTF (0.59 mM) in the N -
acetyl region in 0.1 M KC1, 10 mM bicrbonate, and pH 7.40, before and after 
addition of I and 2 mol equiv Sc3 . 
5.4.3 Ti-hTF 
Ti 4 is a highly acidic metal ion; it forms a stronger complex with hydroxide 
than Fe 3+  (log K(OH) >13, and 11.3 for Ti 4 and Fe 3+, respectively [24]). Based on 
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the correlations discussed above (Figure 5.3), a strong binding of Ti 4 to transferrin 
was predicted and was studied by UV and NMR spectroscopy. 
Electronic Absorption Spectroscopy: The reaction of Ti 4 citrate with 
human serum apotransferrin was investigated. When Ti 4 citrate was added to an 
aqueous solution of apo-hTF, three new bands gradually appeared in the UV 
difference spectrum and increased in intensity over a period of 12 h (Figure 5.7). 
The two sharp bands at 241 and 295 rim are typical of phenolate groups generated by 
binding of metal ions to Tyr residues in the specific iron binding sites [20]. The third 
broader band at 315 nm (Ac 4,700±300 M 1 cm 1 ) is likely to be a ligand-to-metal-
charge-transfer (LMCT) band. Similar LMCT bands (325-390 nm) have been 




240 	320 	400 	
nm 
Figure 5.7 Dependence of UV difference spectra of apo-hTF (13 tM in 10 mM 
Hepes, 5 mM HCO3, pH 7.4, 310 K) on time after addition of 2 mol equiv of 
Ti4 citrate. Reaction times from bottom to top: 1, 5, 10, 20, 40, 150 and 720 mm. 
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The titration curve for reaction of apo-hTF with Ti 4 citrate complex is 
shown in Figure 5.8. It can be seen that the As increases linearly with the increasing 
ratio of [Ti]/[hTF] up to 2, which suggests that two Ti4 ions bind strongly to 
transferrin (i.e. one in each lobe). The slight increase in As values for [Ti]/[hTF] > 2 
is due to absorbance of excess of Ti 4 citrate complex at 241 nm. A similar 
stoichiometry of Ti : hTF = 1.9(±O. 1): 1 was obtained from the measurement of the 
titanium content of purified titanium transferrin by ICP-AES. The value of the 
extinction coefficient for the first step of Ti 4 binding to transferrin (occupation of 
one lobe), &, is 17,000±400 M'cm' at 241 nm, The resulting yellow Ti2-hTF 
solution was stable at ambient temperature. 
TO 4 
El 
0.0 	1.0 2.0 3.0 4.0 
r [Ti]/[hTF] 
Figure 5.8 Titration curve for addition of Ti 4 citrate to apo-hTF (13 j.tM in 10 
mM Hepes, 5 mM HCO3, pH 7.4, 310 K). Each solution was left> 12 h to reach 
equilibrium. M is the absorbance at 241 nm divided by the transferrin concentration. 
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NMR Investigation of Binding of the Anticancer Drug [T1CP 2Cl2] to 
hTF2: Attempts to study the reaction of the anticancer drug [TiCp2C12] by UV 
spectroscopy were hampered due to the absorption of the drug itself. Therefore 'H 
and ' 3 C NMR were used to investigate this interaction. The reactions were carried 
out with drug solubilized by ca. 1 mol equiv of citrate since in blood plasma 
[TiCp2Cl2] may be present as a citrate adduct in view of the high concentration of 
plasma citrate (ca. 100 tM). The exact nature of this complex was not established 
and is referred to as {TiCp2} 2 . 
'H NMR spectra of hTF are complicated by the overlap of a large number of 
resonances, however, it was clear that Ti 4+  (added as Ti 4-f  -citrate or -titanocene 
dichloride) binding caused characteristic changes in certain regions of the spectra. In 
the high field region (Figure 5.9), new peaks at 0.284, 0.050 and -0.073 ppm 
appeared and a peak at -0.031 ppm decreased in intensity. In the N-acetyl region 
(Figure 5.10), new peaks appeared at 2.066 and 2.055 ppm, which are slightly 
different from those induced by Bi 3 [4] suggesting a possible difference in structure 
compared to Bi 3 -hTF. 
In the 13 C spectrum, a new peak assigned to bound ' 3C032 appeared at 166.1 
ppm (Figure 5.11), which is almost identical to peaks observed on the reaction of 
hTF with Ti4 citrate in the presence of H' 3CO3. The chemical shift of this bound 
anion is close to that observed previously for other metallo-transferrins, e.g. 165.4 
ppm for A13 , 166.5 ppm for Ga 3 , 166/166.2 ppm for T1 3 [28,29], 166.8/167.2 ppm 
for Sc3 [30], and 165.8 ppm for Bi 34 [4]. However, the intensity of this peak (166.1 
ppm) is relatively low compared to those observed for other metallo-transferrins. It is 
not clear whether this is due to a difference in the extent of lobe closure of Ti 4thTF 
or a different anion exchange rate. 
2 Collaboration with Dr. Hongzhe Sun 
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—0.073 




0.0 	 —0.5 	ppm 
Figure 5.9 The high field region of resolution-enhanced 500-MHz 'H NMR 
spectra of apo-hTF (0.59 mM) in 0.1 M KC1, pH*  7.4, 10 mM bicarbonate, 
before (bottom) and after addition of 1 (middle) and 2 (top) mol equiv of 
{TiCp2 } 2 . 
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2.040 
2.15 	2.10 	2.05 	2.00 ppm 
Figure 5.10 The N-acetyl region of resolution-enhanced 500-MHz 1 H NMR 
spectra of apo-hTF (0.59 mM) in 0.1 M KCI, pH*  7.4, 10 mM bicarbonate, 
before (bottom) and after addition of 1 (middle) and 2 (top) mol equiv of 
{TiCp2 } 2 . 
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Free HCO, 
185 180 175 170 165 160 ppm 
Figure 5.11 125 MHz 13C NMR spectrum of (A) apo-hTF (1.6 mM, 10 mM 
H' 3 CO3 , 0.1 M KCI, 70% H 20/30% D 2 0, pH 7.5) (B) in the presence of 2 mol 
equiv of Ti4  added as an aliquot of a 10 mM aqueous solution of [TiCp 2CI2 1 
solubilized by addition of 1.2 mol equiv of sodium citrate. 
5.5 Discussion 
Transferrin, as a serum iron transport protein, binds a variety of metal ions. 
However the factors which determine the strength of metal binding are still not fully 
understood. The size or the oxidation state of metal ions has been used previously to 
explain the strength of metal ions binding to transferrin. For instance, lanthanide ions 
bind only weakly to transferrin, and even only in one lobe [12,19], and trivalent 
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metal ions bind stronger than divalent ions [20]. Recently, it has been found that Bi 3 
(ionic radius 1,03A) binds to transferrin almost as strongly as Ga 3 (ionic radius 
0.63A) [4], whereas if the strength of binding of metal ions to transferrin is 
optimised to the size of the interdomain binding site, then Bi 3 should bind as weakly 
as the lanthanide ions. Furthermore, a divalent metal ion, Cu 2+, binds more strongly 
than some trivalent metal ions (e.g. Nd 3 , Sm3 ) [21,22] which also does not follow 
the previous assumption. Therefore investigations of possible new kinds of 
rationalization were needed. 
In Figure 5.3A, the constants (log K i ) for metal binding to the first lobe of 
transferrin are plotted against the stability constants for hydroxide binding (log 
K i (OH )). Only in the case of Ga 3+ 3+ , In , Sc3+  and Bi.3-4-  can log K 1
* 
 be equated with 
C-lobe binding, for the others the order of lobe loading is unknown. However since 
log K1 and log K2 values usually differ by < 2 log units, the plot would not be 
significantly affected if it contains a mixture of C-lobe and N-lobe binding constants 
since the range of values is large ca. 20 log units, Figure 5.3A. log K 1 (Off) values 
are related to pK a values by log K 1 (OH) = 14 - pKa, and hence it can be seen from 
Figure 5.3A that the most readily hydrolyzed (most acidic) metal ions bind most 
strongly to transferrin. Such a correlation also holds for 1,2-dihydroxybenzene 
(catechol) a chelating ligand containing two R0 groups, Figure 5.3B. Therefore, it 
is not surprising that highly acidic metal ions such as Bi 3 and T13 , bind strongly to 
transferrin. It is also understandable that Cu 2+  binds more strongly than other 
divalent, even some trivalent, metal ions since Cu 2+  is more acidic than the others 
2+ + (pKa i 7.5 for Cu 2+  in comparison with 9.5 for Fe , 10 for Cd 2+ 	 2 , and 9.2 for Zn ). 
Other correlations for transferrin binding constants with those for a range of oxygen 
and nitrogen donor ligands were also examined but they are poorer than for R0. 
Thus, tyrosinate side-chains are likely to dominate the strength of metal binding to 
transferrin. 
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When small ligands alone are considered, log K correlations of this type are 
well known, as discussed by Hancock and Martell [31,32]. For example, excellent 
linear relationships have been found between the binding of hydroxide and 
negatively-charged 0-donor ligands to a wide range of divalent, trivalent and 
quadrivalent metal ions, showing that the design of strongly-binding negatively-
charged ligands can be based on metal ion acidity. In this respect, transferrin is not 
an exception. 
The correlation between the strength of metal binding to transferrmn and metal 
acidity may provide a basis for the prediction of other unknown stability constants 
for metal-transferrin complexes and this has been verified by the good agreement 
between the calculated (log K 1 14.6±0.2) and predicted (log K1 15.6±1.6) stability 
constant for Sc-transferrin. This correlation may also hold for metal binding to other 
members of the transferrmn family, e.g. lactoferrmn and ovotransferrmn, which contain 
the same ligands in the binding sites. Thus the stability constants for metal binding to 
lactoferrmn or ovotransferrin might also be predictable, which would be very useful 
since few stability constants for metal binding to these two proteins are currently 
available. 
Possible correlations between the strength of metal binding to proteins with 
the strength of metal binding to small molecules were tested further for generality by 
considering the two enzymes carbonic anhydrase (CA) and carboxypeptidase (CP) 
since there are sufficient stability constant data available for a range of divalent metal 
ions binding to these two enzymes. It is very important to study the thermodynamics 
of metal ion binding to these enzymes since Zn 2 binding at their active sites is 
dominated by the imidazole group of histidine side chains (Figure 5.12). 
Replacement of Zn2 by other metal ions (e.g. Hg 2 , Cd2 ) can result in a decrease or 
loss of enzyme activity. The functions of CA and CP are to catalyse the hydration of 
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carbon dioxide and the hydrolysis of certain C-terminal peptide bonds of proteins 
and polypeptides, respectively. Figure 5.13 shows that good correlations exist 
between the strength of metal binding to CA [33] or CP [34] and the strength of 
metal binding to imidazole- a nitrogen donor ligand, which is a part of the side-chain 
of His. This suggests that nitrogens from the side-chains of His residues dominate 
the strength of binding in these enzymes. From Figure 5.13, binding constants can 
be predicted for Fe  2+  of log K 1 6.2 and 7. 1, respectively for CA and CP, and for Pb 2 
8.9 and 9. 1, respectively. The lack of success of previous attempts to establish such 
correlations is due to the fact that limited data on the stability constants for protein or 
enzyme binding to a wide range of metal ions are available. Predictive procedures 
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Figure 5.13 Correlation of the stability constants of divalent metal ions with the 
first binding constant for the same ions with the low molecular mass ligand 
imidazole. (A) Carbonic anhydrase (B) Carboxypeptidase. Correlation coefficients: 
0.960 and 0.977 for CA and CP, respectively; intercepts: 3.72 and 2.91 for CA and 
CP, respectively. 
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The significance of these kinds of correlations is that they also provide a 
method to discover new metal ion binding to proteins. This was verified by the 
.4+ 	 . strong binding of Ti to transfernn. Ti.4+  is expected to bind to transfernn even more 
strongly than Fe 3+, however, in practice, this may be influenced by other hydrolytic 
equilibria. The discovery of the Ti 4 - transferrin complex may provide new insights 
into the mechanism of the anticancer action of titanium. Transferrin could serve to 
deliver Ti4 to cancer cells and release it inside cells. Further biological 
investigations of titanium transferrin are needed. 
The intercepts for the correlations of the strength of metal binding to 
transferrin with R0 (Figure 5.3) are negative (-3.5 and -4.8 for hydroxide and 1,2-
dihydroxybenzene, respectively). They may provide information on the 
preorganization of metal binding sites in transferrin. Previously, for metal ion 
binding to low molecular mass ligands: 
M(H20)m + L = M(H20)mn(Ln) + n(H20) 	Equ. 5.3 
the intercepts of plots of log K i (Dolydentate) versus log K i (monodentate), where 
K i (polydentate) is the metal binding constants for an n-dentate chelating ligand (e.g. 
oxalate, and citrate) and K i (monodentate) is for a monodentate ligand (e.g. Off, 
NH3) have been shown to be related by the following equation [31,35]: 
log K 1 (Dolydentate) = log K1(Off) + (n-1)log 55.5 Equ. 5.4 
The term log 55.5 represents the entropy of translation of 1 mol H20 
generated at a concentration of 1 molal. Thus plots of log K 1 for bidentate chelating 
ligands such as oxalate should have intercepts of log 55.5 (1.74), and for tridentate 
chelating ligands such as citrate the intercept should be 2log 55.5 (3.49), for 
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hexadentate chelating ligands such as EDTA the intercept should be 5log 55.5 (8.70) 
[31]. This is shown in Figure 5.14. It has been noted that lower intercepts can be 
associated with unfavorable entropy effects involving flexible ligands, i.e. chelating 
agents with long arms that are immobilized on binding. For example, the correlation 
of log K 1 (DFB), where DFB is desferrioxamine-B which has 9 atoms between each 
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Figure 5.14 Correlation of the binding constants of metal ions for hydroxide 
with those for bidentate, e.g. oxalate (filled circle), tridentate, e.g. citrate (open 
circle), and hexadentate, e.g. EDTA (filled diamond). Data from ref. [19]. 
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The linear correlation between the strength of metal binding to transferrin and 
hydroxide gives an intercept of -3.5, which is much lower than expected for a 
tetradentate ligand (3log 55.5) from 2 Tyr, lAsp and iHis suggesting that 
unfavorable entropy effects are involved in metal binding to the protein. This is 
consistent with the large conformational change, which is known to accompany 
metal binding involving closure of the metal-binding cleft [20]. The possibility 
therefore arises that correlations between metal binding constants for proteins and 
those for low molecular mass ligands can be used to provide information about the 
preorganization of metal binding sites. Negative intercepts may be indicative of low 
preorganization and high loss of entropy on binding and positive intercepts indicative 
of high preorganization, and perhaps denticity of the protein. This interpretation of 
the intercept in terms of entropy effects is also supported by the correlations between 
the stability constant of metal binding to carbonic anhydrase (CA) and 
carboxypeptidase (CP) [33,34] with imidazole (Figure 5.13). For these plots, the 
intercepts are 2.9 and 3.7 for CA and CP, respectively. These values are close to 2log 
55.5 (3.4), which for low-molecular-mass-ligands would arise from binding to a 
tridentate chelating ligand. Indeed both CA and CP are tridentate proteins with Zn 2 
binding to 3 His imidazole Ns, and 2 His imidazole Ns and one Glu carboxylate, 
respectively, Figure 5.12 [37,38]. The positive intercept is consistent with the 
preorganization of the ligands in the Zn 2 metal binding sites of CA and CP. Unlike 
transferrin, which has a highly flexible metal binding site and changes its 
conformation on the binding of metal ions, CA and CP are more rigid and metal 
binding does not induce conformational changes. In fact, X-ray crystallographic 
studies on native and apo forms of carbonic anhydrase showed that they are virtually 
identical [39]. The organization of the Zn-binding ligands is thought to be critical to 
the activation of Zn 2 in these enzymes, the "entatic state" concept of Vallee and 
Williams [40]. Such correlations may therefore be useful for obtaining information 
about the preorganization of metal binding sites in solution, and this approach may 
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be useful in studies of designed metal sites in recombinant proteins [41]. This 
approach does not take into account entropy effects associated with the 
reorganisation of H20 either within or around the metal binding sites in the protein 
(enzyme) or the attaching metal complex. Perhaps the entropy effects associated with 
H20 accidentally cancel out. 
5.6 Conclusion 
The strength of binding of transferrin to a wide range of metal ions correlates 
well with the strength of metal binding to R0 ligands and therefore with metal ion 
acidity. There is a good agreement between the calculated (log K 1 14.6±0.2) and 
predicted (log K 1 15.6±1.6) stability constant from the log K(OH) correlation for Sc-
transferrin, which suggests that unknown stability constants for metal-transferrin (or 
other proteins) could be predictable. Furthermore, the correlation provided a basis 
for the discovery of a new metal ion (Ti 4 ) binding to transferrmn. The intercepts on 
log-log (linear free energy) plots for comparison of the binding of small ligands to 
the same metal ions correlate with preorganization of the ligands in proteins. For the 
hTF/Off correlation, the intercept is negative: metal binding requires a large 
conformational change in the protein with consequent loss of freedom of movement, 
and high loss of entropy, whereas for carboxypeptidase/imidazole and carbonic 
anhydrase/ imidazole correlations, the intercepts are positive with values appropriate 
for a tridentate chelating agent (ca. 2log 55.5), indicative of preorganised metal sites, 
and favorable entropy effects. Further studies of correlations of this type may be 
useful in the design of metal sites in engineered proteins and in rationalizing metal 
binding to proteins and in the discovery of new metal ion binding to proteins in 
general. 
176 
Chapter 5 Rationalization Metal-hTF binding constants & Ti-hTF 
5.7 References 
W. R. Harris, Struct. Bonding 1998, 92: 121 
C. A. Smith, E. W. Ainscough, H. M. Baker, A. M. Brodie, and B. N. Baker, I 
Am. Chem. Soc. 1994, 116: 7889 
G. F. Baxter, Pharm. 1 1989, 243: 805 
H. Li, P. J. Sadler, and H. Sun, I Biol. Chem. 1996, 271: 9483 
R. D. Shannon, Acta Crystallogr. 1976, 32A: 751 
B. K. Keppler, C. Friesen, H. Vongerichten, E. Vogel in Metal Complexes in 
Cancer Chemotherapy (Ed.: B. K. Keppler), VCH, Weinheim, Germany 1993, 
pp.297 
a) P. Kopf-Maier, and H. Kopf in Metal Compounds in Cancer Therapy (Ed.: S. P. 
Fricker), Chapman & Hall, London 1994, pp. 109 
b) C. Christodoulou, D. Ferry, D. Fyfe, A. Young, J. Doran, G. Sass, A. 
Eliopoulos, T. Sheehan, and D. J. Kerr, Proc. 88th  Ann. Meeting Am. Assoc. Cancer 
Res. (San Diego, CA) 1997, 38: 222 
C. V. Christodoulou, A. G. Eliopoulos, L. S. Young, L. Hodgkins, D. R. Ferry, 
and D. J. Kerr, I Brit. Cancer 1988, 77: 2088 
P. Köpf-Maier, and H. Kopf, Struct. Bonding 1988, 70: 105 
K. Ishiwata, T. Ido, M. Monma, M. Murakami, H. Fukuda, M. Kameyama, K. 
Yamada, S. Endo, S. Yoshioka, T. Sato, and T. Matsuzawa, Appl. Radiat. Isot. 1991, 
42: 707 
M. Goubeaud, G. Schreiner, and R. K. Thauer, Eur. I Biochem. 1997, 243: 110 
C. K. Luk, Biochemistry 1971, 10: 2838 
N. D. Chasteen, L. K. White, and R. F. Campbell, Biochemistry 1977, 16: 363 
N. Cols, N. Romero-Isart, M. Capdevila, B. Oliva, P. Gonzàlez-Duarte, R. 
Gonzãlez-Duarte, and S. Atrian, I Inorg. Biochem. 1997, 61: 157 
P.K. Bali, and W.R. Harris, Arch. Biochem. Biophys. 1990, 281: 251 
177 
Chapter 5 Rationalization Metal-hTF binding constants & Ti-hTF 
W. R. Harris, and V. L. Pecoraro, Biochemistry 1983, 22: 292 
W. R. Harris, Y. Chen, and K. Wein, Inorg. Chem. 1994, 33: 4991 
W. R. Harris, and J. Sheidon, Inorg. Chem. 1990, 29: 119 
G. Pettit, and L. D. Pettit, JUPAC Stability Constants Database 1993, JUPAC 
and Academic Software, Otley, United Kingdom 
E. N. Baker, Adv. Inorg. Chem. 1994, 41: 389 
21.a) W. R. Harris, Inorg. Chem. 1986, 25: 2041 
W. R. Harris, Biochemistry 1983, 22: 3920 
W. R. Harris, J. Inorg. Biochem. 1986, 27: 41 
W. R. Harris, and Y. Chen, I Inorg. Biochem. 1994, 54: 1 
J. Hirose, H. Fujiwara, T. Magarifuchi, Y. Iguti, H. Iwamoto, S. Kominami, and 
K. Hiromi, Biochim. Biophys. Acta 1996, 1296: 103 
A. Ford-Hutchinson, and D. Perkins, Eur. I Biochem. 1971, 21: 55 
J. M. Aramini, and H. J. Vogel, I Am. Chem. Soc. 1994,116: 1988 
G. Kubal, A. B. Mason, S. U. Pate!, P. J. Sadler, and R. C. Woodworth, 
Biochemistry 1993, 32: 3387 
D. C. Harris, and P. Aisen in Iron Carriers and Iron Proteins (Ed: T. M. Loehr,) 
VCH Pub. Inc., Weinheim 1989, pp. 239 
J. F. Harrod, and K. R. Taylor, Inorg. Chem. 1975, 14: 1541 
I. Bertini, C. Luchinat, L. Messori, A. Scozzafava, G. Pellacani, and M. Sola, 
Inorg. Chem. 1986,25: 1782 
J. M. Aramini, P. H. Krygsman, and H. J. Vogel, Biochemistry 1994, 33: 3304 
J. M. Aramini, and H. J. Vogel, I Am. Chem. Soc. 1994, 116: 1988 
R. D. Hancock, and A. E. Martell, Chem. Rev. 1986, 89: 1875 
R. D. Hancock, and A. E. Martell, Adv. Inorg. Chem. 1995, 42: 89 
S. Lindskog, and P. 0. Nyman, Biochem. Biophys. Acta 1964, 85: 462 
J. E. Coleman, and B. L. Vallee, I Biol. Chem. 1961, 236: 2244 
A. W. Adamson, I Am. Chem. Soc. 1954, 76: 1578 
178 
Chapter 5 Rationalization Metal-hTF binding constants & Ti-hTF 
A. Evers, R. D. Hancock, A. E. Martell, and R. J. Motekaitis, Inorg. Chem. 1989, 
28: 2189 
A. E. Eriksson, T. A Jones, and A. Liljas, Proteins. Struc. Func. Genet. 1988, 4: 
274 
D. C. Rees, M. Lewis, and W. N. Lipscomb, I Mo!. Biol. 1983,168: 367 
K. Hákansson, M. Carsson, L. A. Svensson, and A. Liljas, I Mol. Biol. 1992, 
227: 1192 
B. L. Vallee, and R. J. P. Williams, Proc. Natl. Acad. Sci. USA 1968, 59: 498 
D. S. Gregory, A. C. R.Martin, J. C. Cheetham, and A. R. Rees, Protein Engn. 
1993, 6: 29 
179 
Chapter 6 Bismuth Metallothionein 
Chapter 6 
Interactions of Bismuth Complexes with 
Metallothionein(II) 
6.1 Abstract 
Bismuth complexes are widely used as anti-ulcer drugs and can significantly 
reduce the side-effects of platinum anticancer drugs. Bismuth is known to induce the 
synthesis of metallothionein (MT)'in the kidney, but there are few chemical studies 
on the interactions of bismuth complexes with metallothionein. In this Chapter it is 
shown that Bi 3 binds strongly to metallothionein with a stoichiometry Bi: MT = 7: 1 
(Bi7MT) and can readily displace Zn 2 and Cd2 . Bismuth is still bound to the protein 
even in strongly acidic solutions (pH 1). Reactions of bismuth citrate with MT are 
faster than those of [Bi(EDTA)] -, and both exhibit biphasic kinetics. 'H NMR data 
show that Zn2 is displaced faster than Cd 2 , and that both Zn 2 and Cd2 in the 3-
domain (three metal cluster) of MT are displaced by Bi 3 much faster than from the 
a-domain (four metal cluster). The extended X-ray absorption fine structure 
(EXAFS) spectrum of Bi 7MT is very similar to that for the glutathione and N-acetyl-
L-cysteine complexes [Bi(GS)3] and [Bi(NAC)3] with an inner coordination sphere 
of three sulfur atoms and average Bi-S distances of 2.55 A. Some sites appear to 
'The abbreviations used in this Chapter are: 
1­146t, citric acid; EDTA, ethylenediaminetetraacetate; EXAFS, extended X-ray 
absorption fine structure; GSH, glutathione; MT, metallothionein; NAC, N-acetyl-L-
cysteine; PH*,  pH meter reading in D20 solution; RBC, ranitidine bismuth citrate; 
XANES, X-ray absorption near edge structure; XAS, X-ray absorption spectroscopy. 
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contain additional strong oxygen and weaker sulfur coordination. The Bi 3 sites in 
Bi7MT are therefore highly distorted in comparison with those of Zn 2 and Cd2 . 
6.2 Introduction 
Metallothioneins (MTs) constitute a family of low-molecular-mass cysteine-
rich, metal-binding proteins. Since the initial discovery of this small cadmium 
binding protein in equine renal cortex 40 years ago [1], very closely related proteins 
have been reported in a wide range of organisms, from mammals to fish, plants, 
micro-organisms and metal-resistant bacteria [2-8]. Recently, the discovery of a 
growth inhibitory factor (GIF) from human brain tissue and nerve and its 
characterization as a metallothionein (MT-Ill) has stimulated new interests in 
studying this small protein [9,10]. 
Mammalian metallothioneins (molecular mass ca. 7 kDa and 61 amino acids) 
contain a single polypeptide chain with seven bound metal ions (either Zn 2 or Cd2 ). 
Numerous studies [11-14] show that metallothionein contains two structurally-
independent cc (C-terminal) and P (N-terminal) domains. The seven metal ions are 
present in clusters of four and three metals bound to bridging and terminal cysteine 
thiolate ligands, with metal-to-thiolate ratios of M 4S 11 and M3 S9 for the a and 
domains, respectively [15]. All twenty cysteine residues participate in metal 
binding, and each of the seven Zn 2 or Cd2 ions is tetrahedrally coordinated to four 
cysteine thiolate sulfur atoms [16,17]. 
MT biosynthesis is induced by a wide range of factors, including metal ions, 
oxidative stress, glucocorticoid hormones and cytokines, leading to their implication 
in many diverse cellular processes. However, the primary function of MTs under 
normal physiological conditions is in regulating the intracellular concentration of the 
essential metal ions of zinc and copper [18,19], including its ability to donate metal 
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ions to apo-Zn2 enzymes [20,21], and in protecting cells and organisms against the 
harmful influences of toxic elements, such as, Cd 2 , Hg2 [22], probably Au [23,24] 
and Pt2 [25,26]. Metallothioneins also appear to play a role in radical scavenging, 
stress responses, and the pharmacology of metallodrugs and alkylating agents 
[19,27,28]. 
Bismuth is known to induce the synthesis of renal metallothionein [29]. 
Recent studies have demonstrated that Bi, as a potent MT inducer, might play an 
important role in clinical cancer chemotherapy and radiotherapy. Since it has been 
shown that pretreatment with bismuth complexes (bismuth subnitrate) can prevent 
adverse side-effects of anticancer drugs (cis-platin) and 'y-rays without compromising 
their antitumor activity [30-33]. The protection can probably be attributed to the fact 
that bismuth only induces MT in the tissues in which anticancer drug and irradiation 
cause toxicity but not in tumor tissues. However, there are few chemical studies of 
the reaction of Bi 3 with metallothionein [34,35]. Such interactions could also play a 
crucial role in the pharmacology of widely-used bismuth antiulcer drugs including 
colloidal bismuth subcitrate (De-Nol ®) and ranitidine bismuth citrate (Pylorid ® and 
Tritec®) [36-38]. 
In this Chapter, the kinetic reactions of either EDTA or citrate complexes of 
Bi3 with rabbit liver metallothionein-11 were monitored by UV, NMR, and the 
structure of Bi-MT was studied by X-ray absorption spectroscopy (XAS). 
6.3 Experimental Procedures 
6.3.1 Materials 
Rabbit liver Zn7MT(II) (catalog no. M9542) and Zn 2Cd5MT(II) (catalog no. 
M5392) were purchased from Sigma, and bismuth citrate [Bi(Hcit)] and ranitidine 
bismuth citrate (RBC, batch no.0018 E93K0441) were supplied by GlaxoWelicome 
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plc. Bismuth citrate was dissolved in the minimum amount of Ca. 10% ammonium 
hydroxide solution until it became a clear solution (pH Ca. 7), and [Bi(EDTA)] -, 
prepared according to the literature method [39], gave a satisfactory elemental 
analysis. Solutions of [Bi(EDTA)] - were prepared by dissolving known amounts of 
solid [Bi(EDTA)] - in H20 (or D20) and adjusting the pH to Ca. 7. 
6.3.2 Kinetics of Reactions of B:3+  Complexes with Zn 7MT(II) 
All the reactions were performed in 20 mM Tris-HC1 buffer containing 10 
mM NaCl at pH 7.4. Fresh solutions of metallothionein and bismuth complexes were 
purged for 10 min with argon or nitrogen to minimise the oxidation of the 
metallothionein. Concentrations of MT(II) were determined from the absorbance at 
220 nm for Zn7MT(II) in 0.01 M HC1 using E= 47,300 M'cm' [40]. To study 
reactions with Bi 3 complexes, 0.5 ml of Zn7MT(II) solution was placed into a 1 cm 
cuvefte and sealed with parafilm. After temperature equilibration for Ca. 10 min in 
the cuvette, 40 mol equiv of Bi(III) complexes, ([Bi(cit)] - or [Bi(EDTA)] -), were 
added and the course of the reaction was monitored by UV spectrophotometry using 
a computer controlled Perkin-Elmer Lambda 16 spectrometer equipped with a PTP- 1 
temperature programmer. The absorbance recorded after 2 or 3 days was assumed to 
represent the equilibrium situation. The kinetic data were analyzed by a nonlinear 
least-squares fitting based on an exponential function using the program 
Kaleidagraph (Synergy Software). Two kinetic steps were resolved which obeyed 
first-order kinetics. 
6.3.3 Stoichiometry of Bismuth Metallothionein 
Appropriate volumes of a 3.75 mM [Bi(EDTA)] - solution were added to 1.0 
ml aliquots of 15 jiM Zn7MT(II) (in 20 mM Tris-HC1, 10 mM NaCl, pH 7.4) to 
produce different molar ratios of [Bi(EDTA)] - to protein and the samples were left 
for about 1-2 days at 298 K to equilibrate. The absorbance at 350 nm (Bi-S ligand-to- 
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metal-charge-transfer band) was recorded, and the stoichiometry of Bi-MT was 
obtained from the titration curve. The total sulfur content (due to cysteine and 
methionine), Bi, Cd and Zn contents were also measured using ICP-AES (Thermo 
Jarrell Ash, IRIS) at 180.731 nm (S), 223.061 nm (Bi), 213.856 nm (Zn) and 226.502 
nm (Cd). This was carried out with help from Dr. David White. The Bi-MT sample 
for ICP-AES was prepared as follows: after addition of 40 mol equiv of [Bi(EDTA)] - 
to Zn2Cd5MT(II) solution (pH 7.6, 50 mM phosphate buffer) and equilibration for 48 
h at 298 K, excess of Bi 3 and displaced Zn2 and Cd2 were removed by 
ultrafiltration (Centricon 3, Amicon). The final solution was diluted with 2% HNO3 
and the metal and sulfur contents were measured without any digestion of the sample 
[41]. 
6.3.4 'H-NMR Studies of Reactions of Bi3 with Zn 2Cd5MT(II) and 
Zn 7MT(II) 
'H-NMR spectra of 0.5 mM rabbit liver Zn2Cd5MT(II) or Zn 7MT(II) (50 mM 
phosphate buffer, pH*  7.6) were recorded on a Bruker DMX500 spectrometer 
operating at 500.13 MHz at 298 K. Typical pulsing conditions for 'H were: 7 p.s 
pulsewidth, 16 k data points, 3 s recycle delay, 16 to 64 transients. A 2D TOCSY 
spectrum (mixing time 65 ms) was acquired using 2 k data points in the 12 
dimension, acquisition time 0.13 s, 48 scans and 320 increments in the fi dimension, 
in a total time of 14 h. All solutions were purged with nitrogen for at least 5 mm. 
After recording an initial proton NMR spectrum, a 40-fold excess over protein of 
either [Bi(EDTA)] - or RBC was added to the Zn2Cd5MT(II) or Zn 7MT(II) solution, 
and an NMR spectrum was recorded immediately (within ca. 3 min of mixing). 
Further spectra were recorded at frequent intervals over the next 9 h. Protein 
solutions were then allowed to react overnight and small molecules were removed by 
ultrafiltration (Centricon 3) and washing 4 times with 50 mM deuterated phosphate 
buffer, each about 1.5 h, and then a 2D TOCSY spectrum (mixing time 65 ms) was 
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recorded. The peaks for [Zn(EDTA)] 2 and [Cd(EDTA)] 2 were integrated relative to 
the internal reference dioxane. The 2D TOCSY experiments were set-up with help 
from Dr. Hongzhe Sun. 
6.3.5 X-ray Absorption Spectroscopy: Data Collection and Sample 
Preparation 
X-ray spectra were recorded by Dr. Ian Harvey and Mr. K. C. Cheung at the 
Bi L111 edge on EXAFS station 7.1 at the Daresbury Laboratory Synchrotron 
Radiation Source. The operating energy was 2 GeV and average current was 
approximately 200 mA. Powder samples were finely ground and mounted either as 
thin films or diluted appropriately with boron nitride. Solution samples were 
contained in sample cells with mylar windows and a 2 mm path-length. In addition to 
the model compounds used for calibrating phase-shifts, two model complexes 
[Bi(GS)3] and [13i(NAC)3] were also studied by XAS for comparison. Data for the 
glutathione and N-acetyl-L-cysteine complexes were collected at ambient 
temperature in transmission mode using Ar/He filled ionisation chambers (up to 3 
scans per sample). Data for the Bi 7MT samples were collected at 100 K in 
fluorescence mode using a scintillation detector (5-8 scans). The monochromator was 
detuned to 70% to reject harmonics. X-ray damage was checked by comparison of 
the data sets during collection and by the absence of colour changes or edge shifts: 
there was no evidence of radiation damage to any samples. Samples were prepared as 
follows: for [Bi(GS)3] and [Bi(NAC)3], 3 mol equiv of GSH or NAC were added to 
50 mM [Bi(cit)] - followed by adjustment of the pH to ca. 7.0. Powder samples were 
prepared by freeze-drying the solution samples. For Bi 7MT, 5 mg Zn2Cd5MT(II) was 
dissolved in ca. 1 ml 20 mM Tris-HC1 buffer (pH 7.6) deoxygenated with N2 gas, and 
40 mol equiv of [Bi(cit)] - was added and equilibrated overnight. Some yellow 
participate appeared in this yellow solution, and was separated by centrifugation, 
washed three times with water, and finally lyophilised giving a slightly brown solid 
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(hereafter called 'brown MT precipitate'). The excess of [Bi(cit)] - was removed from 
the yellow solution by ultrafiltration three times using water as eluant (Centricon 3), 
and the final yellow solution was freeze-dried to give a yellow solid (hereafter called 
Bi7-MT). 
6.3.6 X-ray Absorption Spectroscopy: Data Analysis 
This was carried out by Dr. Ian Harvey. Background subtraction was 
achieved using the motif-based SPLINE program [42], modified for use with 
EXCURV. Data analysis was accomplished using EXCURV98 [43] via the single 
scattering curved-wave method for EXAFS calculations. Edge positions were 
calibrated against a Au foil at the L 11 edge, taking the first derivative maximum as 
13,734 eV. Phase shifts were derived from ab initio calculations within EXCURV98, 
and were extensively checked against the crystallographically characterised model 
compounds [Bi(HEDTA)], [{ D-(-)-pencillaminato-O,S ,N } Bid] [44], 
Na2 [Bi2(citrate) 2] . 7H20 [45], [Bi(SC6F5 )3(OPPh3)2] CH202 and 
[Bi(SC6F 5)3{S=C(NHMe)2}3] (a gift from Dr. N. C. Norman, University of Bristol) 
[46]. Agreement between EXAFS and crystallographic parameters was better than ± 
0.01 A for sulfur (± 0.02 A for 3-4 A), ± 0.02 A for oxygen with sulfur present (± 
0.01 A if no heavy scatterers present), and ± 10% for coordination numbers. The 
EXAFS data were weighted by k 3 to compensate for the diminishing amplitude at 
high k. The data range used for analysis varied marginally between samples. 
6.4 Results 
6.4.1 Kinetics of Reactions of Bismuth Complexes with Zn 7MT(II) 
Reaction of bismuth complexes with rabbit liver Zn 7MT(II) produced a new 
UV absorbance band centred at 350 nm, which has been observed previously when 
bismuth complexes react with glutathione, Figure 6.1. This band is thus assigned as 
a Bi-S ligand-to-metal charge-transfer band. This band was used to monitor the 
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nm 
Figure 6.1 UV spectrum of 15 mM [Bi(EDTA)f after reaction with excess of 
GSH in 0.1 M Tris-HC1 buffer, pH 7.4. 
progress of reactions of bismuth complexes with metallothionein under pseudo 
first-order conditions (40-fold molar excess of Bi 3 over MT). Figure 6.2 shows 
absorption spectra recorded for the reaction of excess [Bi(EDTA)] - with Zn7MT(II) at 
different times at 298 K. The overall reaction was relatively slow, requiring over 10 
hours for completion. The reaction of [Bi(cit)] with Zn 7MT(II) gave rise to similar 
spectral changes, although it was much faster. Figure 6.3 and Figure 6.4 show the 
time courses of the absorbance changes. It can be seen from Figure 6.4 that for the 
reaction of [Bi(cit)] with Zn 7MT(II), about one third of the total absorbance change 
II 
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Figure 6.2 Displacement of Zn 2 from Zn 7MT(II) by Bi3 . Dependence of 
absorption spectrum on time for a solution containing Zn 7MT(II) (25 jxM) and 40 
mol equiv [Bi(EDTA)] - in 20 mM Tris-HC1, 10 mM NaCl buffer solution at pH 7.4, 
298 K. The broad band centred at 350 nm is indicative of formation of Bi 3 -S 
(thiolate) bonds. Reaction times from bottom to top: 0, 2, 10, 30, 60, 90, 120 and 150 
minutes. 
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Figure 6.3 Determination of pseudo first-order rate constants for reaction of 
[Bi(EDTA)] with Zn 7MT(II). Dependence of absorbance at 350 nm on time for the 
reactions of [Bi(EDTA)] - (40 mol equiv) with Zn7MT(II) (25 pM) in 20 mM Tris-
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Figure 6.4 Determination of pseudo first-order rate constants for reaction of 
[Bi(cit)] - with Zn 7MT(II). Dependence of absorbance at 350 nm on time for the 
reactions of 40 mol equiv of [Bi(cit)] with Zn 7MT(II), in 20 mM Tris-HC1, 10 mM 
NaCl, pH 7.4, 298 K. The exponential fit is also included. 
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occurred within the first 5 mm. However, the total increase in absorbance for both 
reactions was similar after 1 or 2 days, indicating that equilibrium probably involved 
the formation of a similar final B i-MT product. 
Kinetic data were analyzed using the nonlinear least squares best fits based on 
an exponential function. The reaction of [Bi(EDTA)] - and [Bi(cit)] - appeared to be 
biphasic; the rate constants are listed in Table 6.1. The dependence of the rate on 
[Bi] was investigated for [Bi(cit)] - . The first step appeared to be dependent of [Bi], 
Table 6.1. The second step appeared to be independent of [Bi] and the rate was 
similar for [Bi(EDTA)] - and [Bi(cit)] - . 
Table 6.1 Pseudo first-order rate constants for reactions of Zn 7MT(II) and 
Zn2Cd5MT(II) with [Bi(EDTA)] and [Bi(cit)]. The conditions for UV reactions 
were 25 tM Zn7MT(II) in 20 mM Tris-HC1 buffer containing 10 mM NaCl, pH 7.4 
at 298 K, and for NMR 0.5 mM proteins in 50 mM phosphate buffer pH*  7.6, 298 K. 
Bi complex Conc. 
(MM) 
Protein k1 x103 
(s) a 
k2 X104 
(s ) a 
Method 
[Bi(EDTA)] - 1.02 Zn7MT(II) 0.95±0.2 0.5±0.4 UV 
20 Zn7MT(II) 7.2 0.59 NMR 
20 Zn2Cd5MT(II) 5.8 1.0 NMR 
[Bi(cit)] - 5.08 Zn7MT(II) 5.3±0.4 0.57±0.7 UV 
2.54 Zn7MT(II) 4.6±0.2 1.2±0.3 UV 
1.02 Zn7MT(II) 4.0±0.5 1.1±0.4 UV 
0.51 Zn7MT(II) 3.2±0.5 1.0±0.2 UV 
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6.4.2 Stoichiometry of Binding of Bi3 to Metallothionein 
The extent of Bi 3 binding to Zn7MT was investigated in two ways: by 
determination of the change in absorption at 350 nm, and by determination of the Bi: 
S ratio in the product via ICP-AES. Figure 6.5 shows the change in the extinction 
coefficient at 350 rim (As) with variation of the [Bi(EDTA)] - : Zn7MT molar ratio. 
The value of Ac increases linearly, and plateaus at a ratio of ca. 7.0, reaching a final 
value of ca. 15,000 M cm-1 . By ICP-AES, the stoichiometry of purified Bi-MT (see 
Experimental section) was determined to be Bi: S1.0: 3.0 (±0.1), and the mol ratio 
of Bi: Zn> 170: 1. Since there are 21 S atoms in MT (20 Cys + 1 Met) the mol ratio 
of Bi to MT is 7:1. 
. 
. 
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[Bi(EDTA)]/[Zn 7MT] 
Figure 6.5 Stoichiometry of Bi 3 binding to Zn7MT. UV titration curve (350 run) 
for addition of [Bi(EDTA)] - to Zn7MT(II) (15 tM) in 20 mM Tris-HC1 containing 10 
mM NaCl, pH 7.4. The overall absorbance changes suggest the formation of Bi7MT. 
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6.4.3 Effect of pH on Bi 7MT 
A solution containing Bi 7MT was generated by reacting Zn 7MT (25 .IM) with 
40 mol equiv of [Bi(EDTA)] - in 20 mM Tris-HC1 buffer, 10 mM NaCl, pH 7.4 for 
about 1 day at 298 K, followed by ultrafiltration to remove excess [Bi(EDTA)] and 
other low molecular mass molecules. The variation of the absorbance of Bi 7MT(II) at 
350 nm with pH is shown in Figure 6.6. With decreasing pH, the absorbance 
decreased only slightly, suggesting that Bi 3 remained bound to the protein even at 
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Figure 6.6 Stability of Bi 7MT in acidic solutions. Dependence of the absorbance of 
Bi7MT at 350 nm (due to Bi-S bonds) on pH. 
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6.4.4 Gel Filtration Profile of Bi 7MT 
Solutions of Bi 7MT (prepared from Zn7MT) and Zn7MT were 
chromatographed on Superdex G-200 in 20 mM Tris-HC1, pH 7.4, at room 
temperature, and the protein was monitored at 280 run. It was shown that Bi 7MT 
migrates approximately like Zn 7MT, and exhibits a similar retention time to Zn 7MT, 
Figure 6.7. 
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Figure 6.7 Gel filtration chromatography of B1 7MT and Zn7MT. 
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6.4.5 'HNMR Studies 
Reactions of [Bi(EDTA)] - with Zn7MT and Zn2Cd5MT(II) were followed by 
'H NMR spectroscopy. Since [Zn(EDTA)] 2 and [Cd(EDTA)] 2 formed via 
displacement of Zn2 and Cd2 from the protein by Bi 3 have characteristic 'H NMR 
shifts [47], it was possible to monitor the kinetics of displacement of these metal ions 
individually from the protein. The 500 MHz 'H NMR spectra of rabbit liver 
Zn2Cd5MT(II) at different times after addition of 40 mol equiv of [Bi(EDTA)] are 
shown in Figure 6.8. The intense resonances at ca. 3.1 ppm can be assigned largely 
to the P protons of Cys and Lys residues, and the two singlets at 2.10 and 2.16 ppm 
to the N-acetyl-CH3 and cCH 3 of the terminal N-acetyl-methionine residue, 
respectively [48]. The resonances at 0.8- 1.7 ppm can be assigned to the methyl 
groups of Ala, lie and Lys residues on the basis of their chemical shifts and coupling 
constants [48]. The peaks which appear at 2.92, 2.76 and 2.65 ppm after addition of 
[Bi(EDTA)] - can be assigned to the ethylenic protons of EDTA complexed to 
[Zn(EDTA)] 2 , [Cd(EDTA)] 2 and [Ca(EDTA)] 2 , respectively [47]. Cd-satellites (due 
to 'Cd and 113 Cd, total natural abundance 25%) can be clearly observed for 
[Cd(EDTA)] 2 peaks. The relative integrated areas of the peaks at 2.92 and 2.76 ppm 
(for [Zn(EDTA)] 2 and [Cd(EDTA)] 2 , respectively), increased with time as shown in 
Figure 6.9. Most of the Zn2 was already present as an EDTA complex by the time 
the first spectrum was recorded (ca. 3 min after addition of [Bi(EDTAf) whereas the 
peaks for [Cd(EDTA)] 2 continued to increase in intensity for a period of about 6 h. 
There were no further changes to the spectrum after 15 h, at which point the relative 
integrated peak ratio [Zn(EDTA)] 2 [Cd(EDTA)] 2 at 2.92 and 2.76 ppm, was 2.0: 
5.3, which suggested that all Zn2 and Cd2 had been displaced from the protein by 
Bi3t Gradual changes were also observed for the metallothionein resonances during 
the course of the reaction. There was an overall broadening of all resonances, the 
peak at 1.16 ppm which can be assigned to the 3 protons of A1a23 (CH3) [12] 
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rr T,i 	[Ca(EDTA)]2 	+IBI(EDTA)T 
[Zn(EDTA)] 2 
Zn 2 Cd 5 MT(II) 
... ... 
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Figure 6.8 Displacement of Zn 2 and Cd2 from Zn2Cd\1T(TD by Bi. 
Dependence of the 500 MHz 'H NMR spectrum of 0.5 mM Zn2Cd5MT(H) (50mM 
phosphate buffer, pH*  7.6, 298 K) on time after addition of 40 mol equiv of 
[Bi(EDTA)]. The appearance of peaks for [Zn(EDTA)] 2 and [Cd(EDTA)] 2 is 
evident: the NCH-) peaks appear as singlets and the CH 2CO2 peaks as quartets (With 
"Cd satellites for [Cd(EDTA)J 2 ). A small amount of Ca 2 (ca. 05 Ca/-?VI is 
also released by the protein and becomes bound to EDTA. 
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intense peak at Ca. 3.10 ppm decreased in intensity, and broadening of the two 
singlets at 2.10 and 2.16 ppm and peaks from 0.8- 1.7 ppm was notable. 
It can be seen clearly from Figure 6.9 that Zn2 was displaced from 
Zn2Cd5MT(II) by Bi3 (added as [Bi(EDTA)] - ) very rapidly (within 3 mm), while 
Cd2 was displaced relatively slowly (> 4 h). By the time the first spectrum was 
recorded, the [Cd(EDTA)] 2 peak at 2.76 ppm had reached 115 of its final intensity 
(attained after overnight equilibration). After a further 5 min the peak had doubled in 
intensity. The rate constants for Cd 2 displacement were determined using nonlinear 
least squares best fits, Figure 6.9. This was a biphasic process with pseudo-first 
order rate constants of 5.8x10 3 s' and 1.0x10 4 s 1 (half lives of 2 min and 1.9 h, 
respectively), whereas the rate of Zn 2 displacement was too fast to determine 
accurately by NMR spectroscopy. 
0.5 
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Figure 6.9 Kinetics of displacement of Zn 2 and Cd2 by Bi3 . Dependence of 
relative areas of 'H NMR peaks for zinc and cadmium EDTA on time for the reaction 
of 0.5 mM Zn2Cd5MT(II) with 40 mol equiv of [Bi(EDTA)] - at 298 K, in 50 mM 
phosphate buffer, PH*  7.6. Exponential fits gives rate constants of k1 = 5.8x10 3 s 1 
and k2 = 1.0x10"' s 1 for the two phases of Cd 2 displacement. 
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The reaction of [Bi(EDTA)] - with Zn 7MT(II) was also investigated by 'H 
NMR spectroscopy. The integrated area of the peak for [Zn(EDTA)] 2 at 2.92 ppm 
relative to the internal reference is shown in Figure 6.10. About 3/7 of the Zn 2 was 
displaced within 3 min of mixing, and the rate could not be determined by NMR 
spectroscopy. The remaining Zn 2 was displaced by Bi 3 in a biphasic process. Using 
nonlinear least squares best fits (Figure 6.10), rate constants of 7.2x10 3 s' and ca. 
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Figure 6.10 Kinetics of displacement of Zn 2 by Bi3 . Dependence of the relative 
areas of 'H NMR peaks for [Zn(EDTA)] 2 on time for the reaction of 40 mol equiv of 
[Bi(EDTA)] - with 0.5 mM Zn7MT(II). Exponential fits give rate constants of k 1 = 
7.2x10 3 s and k2 = 0.59x10 s 1 for the two slower phases of Zn 2 displacement. 
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Studies of the reaction of the antiulcer drug ranitidine bismuth citrate (RBC) 
with metallothionein using UV and NMR spectroscopy were hampered due to the 
strong UV absorption from ranitidine and intense 'H NMR signals of ranitidine and 
citrate. However, yellow solutions were obtained when ranitidine bismuth citrate was 
added to metallothionein under conditions similar to those used for [Bi(EDTA)] - and 
[Bi(cit)]. The product obtained after ultra-filtration to remove excess ranitidine 
bismuth citrate and other small molecules was adjudged to be almost identical to 
Bi7MT obtained from the reaction of [Bi(EDTA)] - with metallothionein since it had a 
similar 'H NMR spectra. 
The 21) 'H TOCSY NMR spectrum (mixing time 65 ms) of purified Bi 7MT is 
shown in Figure 6.11 together with that for Zn 7MT for comparison. A notable 
change is the absence of several cross peaks assignable to the Cys 13  CH2 protons 
[14,49,50] in the region 2.7 - 3.3 ppm for Bi 7MT (boxed in Figure 6.11). 
6.4.6 X-ray Spectroscopy' 
XANES and EXAFS measurements were made on solution and solid 
samples containing Bi: glutathione and Bi: N-acetyl-L-cysteine in molar ratios of 1:3, 
and on solid Bi-MT samples obtained by reacting excess [Bi(cit)] - with 0.7 mM 
Zn2Cd5MT(II). 
XANES spectra at the Bi L 111 edge are broad and featureless due to the large 
core-hole lifetime, Figure 6.12. However, there is a significant difference in the Bi 
L111 edge positions between sulfur-containing and light-atom complexes of the order 
of 10 eV (13425 eV for [Bi(SC6F 5)3(OPPh3 )21 -CH2C12 and 
[Bi(SC6F 5)3{SC(NHMe)2 } 3], 13436 eV for [Bi(HEDTA)], 13434 eV for 
2 Collaboration with Dr. Ian Harvey who analyzed the data 
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Figure 6.11 2D TOCSY 'H NMR spectra (mixing time 65 ms). (A) 0.5 mM rabbit 
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Na[Bi(citrate)]•711 20. The edge positions for [Bi(GSH)3], [Bi(NAC)3] and both Bi-
MT samples indicate that all these samples have sulfur-based ligation for Bi. 
The EXAFS data for [Bi(GSH)3] and [Bi(NAC)3] (both in solid and solution) 
are essentially identical. Analysis of the data (Table 6.2 and Figure 6.13) gave rise to 
coordination numbers of 3.0±0.3, with sulfur as the only coordinating atom, with an 
average Bi-S bond length of 2.56 A. 
Energy (eV) 
Figure 6.12 XANES spectra of B17MT and model complexes of [Bi(GSH) 31 and 
[Bi(NAC)3]. 
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The EXAFS spectra of the two Bi-MT samples (Bi 7-MT and brown MT 
precipitate) were quite distinct from each other. By comparing the EXAFS of Bi 7MT 
with those of [Bi(GS)3] and [Bi(NAC) 3 ] (Figures 6.13a and b, respectively), it can 
be seen that the coordination number of Bi in Bi 7MT is similar to that [Bi(GS) 3] and 
[Bi(NAC)3 ]. The Fourier transform for Bi 7-MT is dominated by a single shell best 
simulated with 3.0±0.1 S at 2.55±0.01 A, a similar distance and coordination number 
as those determined for the model complexes. Fits were attempted with other sulfur 
coordination numbers, but on refinement the coordination number always returned to 
3. The Fourier transform suggests that additional weakly scattering shells are present, 
including a small amount of oxygen (0.5±0.3) at 2.18±0.02 A. The coordination 
number for this shell is poorly defined, but it is certainly less than unity. There is also 
reasonable evidence that the small peak in the Fourier transform at Ca. 3 A is due to 
additional sulfur scattering (1.9 S) at 3.09±0.1 A. The refined coordination number of 
1.9 for this additional shell has a large uncertainty (±2) and is highly correlated with 
its own Debye-Waller factor. Therefore, this parameter must be treated with caution. 
This type of split sulfur ligation has a number of precedents, including the model 
compound [Bi(SC 6F5 )3 {SC(NHMe) 2 } 3 ] used in this study (3 S at 2.72 A, 3 S at 2.95 
A). X-ray fluorescence measurements on Bi 7MT gave Bi : Zn> 17:1 (the very low 
level of Zn limited the measurement), in agreement with the ICP-AES measurement. 
The brown MT precipitate sample gave much weaker EXAFS amplitudes 
compared to the all the other samples. Fitting the data with a single shell of sulfurs 
resulted in large residuals in the Fit Index and the model was clearly incomplete in 
both the EXAFS and Fourier transform. Extensive analysis resulted in two different 
plausible models of equal quality. Both models suggest that the weaker EXAFS is 
due to destructive interference of two (or more) shells, rather than lower coordination 
numbers. Model 1 (Table 6.2) consists of mixed oxygen (3.1 at 2.46 A) and sulfur 
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Figure 6.13 (A) EXAFS spectra, and (B) Fourier transforms of the EXAFS 
spectra. (a) {Bi(GS)3] solution, (b) Bi 7MT, and (c) brown MT precipitate, model 2. 
Dotted line, calculated; solid line, experimental. 
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Table 6.2 EXAFS data. Bi3 coordination number (N), Bi-ligand distances (R), 
Debye-Waller factors (2&), fit index (PT) and R-factor (R). 
Sample N R(A) 2a2 (A2) FT R(%) 
[Bi(GSH)3 1 solution 3.1 	S 2.565 0.009 3.1 19.3 
[Bi(GSH)3 ] powder 2.7 S 2.553 0.012 7.1 28.6 
[Bi(NAC) 3] solution 2.8 S 2.55 1 0.007 4.5 22.7 
[Bi(NAC)3] powder 3.2S 2.57 1 0.010 3.8 22.6 
Bi7MT 3.0 S 2.553 0.009 6.2 27.3 
1.9±2.OS 0.50 3.092 0.039 5.6 24.0 
2.180 0.001 
Brown MT ppt 
Model 1 2.9 	S 2.514 0.017 3.3 20.3 
2.10 2.464 0.004 
Model 2 2.9S 2.576 0.014 
3.2 S 2.877 0.045 3.3 19.1 
Rexafs 	
N 
V Ui (1 exP - theor I) x 100% 
Attempts to model bismuth as a back-scatterer was unsuccessful. Although the 
models have equal Fit Indices, model 2 has a marginally lower R-factor (19.1 % 
versus 20.3 %). Additionally the difference in the Debye-Waller factors for the 
oxygen (0.004 A 2  ) and sulfur (0.017 A2) in model 1 seems implausibly large. The 
refined coordination number for oxygen in model 1 is very highly correlated to a 
number of other parameters due the interference of the two scattering waves. Because 
of these potential problems with model 1 and the similarity of model 2 to known 
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model systems, model 2 is suggested as a more reliable one. Brown MT precipitate 
may represent a adduct of polymerization of Bi-MT. 
6.5 Discussion 
Metallothionein appears to play an important role in human health and 
disease as well as in the mechanism of action of therapeutic agents. Its synthesis is 
induced in biological systems by a variety of metal ions including Zn 2 , Cd2 , Cu 
and Bi3 , and this induction may provide protection from toxicity by allowing 
sequestration of the metal. Metallothionein may also play a role in cellular resistance 
to Pt anticancer drugs. Administration of bismuth compounds can induce the 
synthesis of metallothionein in the kidney but not in the tumour tissue. This reduces 
the renal toxicity of cis-DDP without compromising its chemotherapeutic activity 
[30,33]. Therefore it has been suggested that bismuth compounds are ideal for 
clinical application as adjuncts in chemotherapy with cisplatin. Moreover, MT has 
been shown to be able to suppress the occurrence of acute gastric mucosal lesions 
[51], a disease consisting of acute hemorrhagic erosion and acute gastric ulcer. 
Bismuth compounds have been used in medicine for centuries, mainly for the 
treatment of peptic ulcers and gastric disorders. Therefore, MT may also play an 
important role in the pharmacological activity of bismuth antiulcer drugs. 
Metal ions have been reported to bind to MT with a variety of 
stoichoimetries, ranging from 7, 10, to 12 and even up to 20 metal ions per protein 
molecule and with different geometries (from tetrahedral, square-planar, to linear). 
These include mono-valent metal ions such as Au [23] and Cu [52,53], divalent 
metal ions such as Zn2 , Cd2 , CO2 and Hg2 , trivalent metal ions such as In 3 and 
3+ 	 3+ 	 3 Sb [35], and TcO [54,55]. In the present studies the stoichiometry of Bi ..  binding 
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to MT was determined as 7:1 using both UV titration and ICP-AES to measure the 
metal and sulfur contents. This result is in agreement with previous brief reports 
[34,35] on bismuth metallothionein. X-ray and NMR studies of ZnCd7MTs have 
shown that the metals are distributed in two clusters as M4S 11 (a) and M3 S9 (f3) with 
the metals coordinated tetrahedrally [16]. Surprisingly, in the present work, EXAFS 
data suggest that Bi 3+  coordinates strongly to only three cysteine sulfurs with an 
average Bi-S bond length of 2.55 A. This bond length is almost identical to that 
found in X-ray structures of low M Bi(III) thiolate complexes (Bi-S 2.5 to 2.6 A) 
[46,56]. The fit for the EXAFS data for Bi 7MT suggests the presence of additional 
sulphur scattering at Ca. 3.1 A. To retain the metal clusters, a much distorted 
tetrahedral geometry is required with three Bi-S bond distances of 2.55 A and a 
longer Bi-S contact of Ca. 3.1 A. Although the 3.1 A distance is well-defined, the 
associated coordination number is not, and the required coordination number for 
distorted tetrahedral geometry is well within the error range. In the crystal structure 
of [Bi(5C6F 5)3 ], Bi3+  coordinates to three sulfurs with Bi-S bond lengths of 2.53 to 
2.58 A, and an additional long Bi-S bond of 3.32 A [46]. Molecular modelling of 
H97MT [57] suggests that the geometry of Hg 2 is distorted away from tetrahedral 
due to extensive interactions with solvent water. The recent EXAFS studies on 
H97MT have shown that the nearest coordination number for Hg 2 is 2, with Hg-S 
bond lengths of 2.33 A and two-less-well-defined long bonds of ca. 3.4 A [58]. It has 
been thought that the binding site cage of MT is too small to accommodate the 
volume of tetrahedral HgS 4 units. However, Cd2 , which has a similar ionic radius 
(0.92 A) and the same charge, coordinates tetrahedrally to sulfurs of Cys residues. 
The coordination geometry is therefore largely dependent on the metal ion, e.g. Ag, 
diagonal (CN, 2); Cu, trigonal (CN, 3) [59] and Tc03 , square pyramidal (CN, 5) 
[55]. Previously reported structural data are summarized in Table 6.3. 
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Table 6.3 Summary of structural parameters for various metallothioneins (for 
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The presence of additional short Bi-O bonds (2.18 A) for at least some of the 
Bi3+ i ions n Bi 7MT suggests that some Bi.3-i-  ions also have bound water, or more 
likely hydroxide or oxide, or possibly oxygen donors from amino acid side chains 
such as Ser, Thr, Asp or Glu. Alkoxide donors from Ser or Thr are attractive because 
Bi-OR (alkoxide) bonds are known to be short and strong in several bismuth citrate 
adducts [38]. However, no Ser or Thr side chains are particularly close to the metal 
clusters in zinc and cadmium metallothioneins with known structures, although 
Ser32 and Ser35 are less than 7 A away from the M4 S, 1 cluster in the a domain and 
Ser2, Serl8 and Ser28 are less than 7 A from the M 3 S9 cluster in the 13  domain [11- 
13]. Alkoxide coordination to Bi.3+ 
 
often gives rise to lone-pair electron effects and 
distorted coordination spheres for Bi.3+ 
 
[38]. At biological pH, ZnCdMT(II) (x+y=7) 
is negatively charged (-2), whereas Bi 7MT(II) would have an overall positive charge 
(+5). Thus the additional oxygen ligands may serve to neutralise the excess charge. 
Previously it has been shown [60] that Bi 3 binds to the Cys residue of 
glutathione and induces large low-field shifts of the 'H NMR resonances of 13 CH2 
protons (ca. 1.4 ppm). Free and Bi-bound glutathione are in exchange at an 
intermediate rate on the NMR time-scale at biological pH (Ca. 1500 s'). The NMR 
data (Figure 6.11) were also consistent with S-only binding, in agreement with the 
EXAFS data. The overall broadening of the 'H NMR spectrum of Bi 7MT and the 
disappearance of the 2D TOCSY cross-peak for the P CH2 of Cys residues (Figure 
6.11) suggests a facile exchange of Bi 3 between different sites even though binding 
is thermodynamically very strong. Other cross peaks, notably those for Lys and Thr, 
residues which are widespread throughout the protein, remain unchanged in 
comparison with Zn7MT, indicating that Bi7MT probably has a folded conformation 
although the overall 3D structure may be different. Gel filtration chromatography 
studies show that Bi 7MT migrates in a similar manner to Zn 7MT suggesting that their 
molecular masses and shapes are similar. However, when Bi 7MT was left in a 
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solution for a longer period (several days) or when a high concentration of protein 
(Zn7MT or Zn2Cd5 MT) was used to produce Bi 7MT, a yellow precipitate appeared, 
indicating that a possible polymerization reaction had occurred. The disappearance of 
the 13 CH3 'H NMR resonance of A1a23 (1.16 ppm) suggests that the structure of 
Bi7MT in this region may be more flexible, and involved in dynamic exchange 
between different conformations. Previous molecular modelling studies have shown 
that Cys26 in the 13  domain is more solvent accessible and can be displaced from 
Zn2 binding by the thiolate sulfur of glutathione [61]. 
Bi-S bonds in MT(II) appear to be remarkably stable even down to pH values 
near 1.0, in contrast to Zn 2 and Cd2 which are 50% dissociated at pH 4.6 and 3.05, 
respectively [53], but similar in strength to Cu-MT (pH 1 ,2 , 0.44) [53]. The affinity of 
Bi3 for MT(II) is therefore higher than that of Zn 2 and Cd2 . 
The kinetics of reactions between bismuth complexes and MT(II) were 
elucidated in two ways: by observing the absorbance changes at 350 nm due to the 
formation of Bi-S bonds and the appearance of new 'H NMR peaks resulting from 
the formation of either zinc or cadmium EDTA complexes after displacement of 
EDTA from Bi 3 . 'H NMR also allowed the kinetics of Zn 2 and Cd2 displacement 
by Bi3  to be monitored separately. Biphasic processes were observed for both 
[Bi(cit)] - and [Bi(EDTA)] - . In the fast step, the displacement of Zn 2 from Zn7MT by 
[Bi(cit)] occurred four times faster than that by [Bi(EDTA)] -, while the second step 
was very similar for both of these bismuth complexes. This is probably due to 
differences in structure: bismuth citrate contains dimeric units [Bi 2(cjt) 2 ]2 [45] in 
which the Bi 3  ion has apparent vacant coordination sites (perhaps occupied by the 
6s2 lone pair of electrons) and therefore may be able to attack the Cys sulfur of MT 
more readily than [Bi(EDTA)] - in which the EDTA ligand is wrapped around Bi 3 
[39]. By comparing the kinetics of reaction of [Bi(EDTA)] - with Zn7MT and with 
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Zn2Cd5 MT (with Zn2  in the 13-domain), it was shown that metal ions in 13-domain of 
MT can be replaced preferentially, and cooperatively and rapidly (within minutes) by 
Bi3 , and there is little difference between the reactivity of Zn 3 and Zn2Cd [3 domains. 
The first step may involve displacement of metal ions in the [3 domain by Bi3 and 
one metal ion in the a domain, as judged from NMR data, and the second step may 
involve displacement of the other metal ions in the a domain. There have been 
several previous studies of metal and ligand displacement from Zn 7MT and Cd7MT 
[25,26], and multi-phase processes have always been observed. Biphasic kinetics 
have usually been explained on the basis of formation and breakdown of 
intermediates [25,26]. However only a single kinetic step for metal displacement has 
been observed for reaction of EDTA with Cd 7MT in the 13  domain and also one Cd2 
in the a domain can be extracted by EDTA more readily than the other Cd 2 ions 
[62]. In this work, NMR data indicated the rapid removal of a small amount of Ca 2 
from the protein (0.5 Ca2+  per MT II) during reaction with [Bi(EDTA)]. This is 
assumed to be surface- bound Ca 2  which has little effect on the cluster structures. Its 
presence has been observed previously [47]. 
The high stability of bismuth metallothionein suggests that it could play a 
significant role in the mechanism of action of bismuth-based drugs both in bacteria 
and in human beings. It may be an important species for bismuth transport from the 
liver to the kidney, and be involved in bismuth storage in the kidney. In addition, the 
neurotoxicity of bismuth drugs (encephalopathy) could be also related to the binding 
of Bi3 to the brain-specific metallothionein(III), since the distribution of Bi 3 in 
mouse brain is very similar to that of Cu and Ag [63]. 
6.6 Conclusion 
Bi3  originating from bismuth citrate antiulcer compounds and from Bi 
EDTA, binds very strongly to MT(II) and readily displaces Zn 2 and Cd2t Despite its 
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higher charge, Bi 3 also forms a 7:1 complex (Bi 7MT), the same stoichiometry for 
binding as zinc and cadmium. EXAFS data show that on average each Bi 3 is 
coordinated strongly to only 3 cysteine sulfurs (at 2.55 A) in contrast to Zn 2 and 
Cd2  which have clusters based on M(Cys)4 centres. The presence of a less well-
defined longer Bi-S contacts of 3.1 A for some Bi 3 ions suggests that Bi 7MT does 
contain clusters although Bi-Bi contacts were not detectable. For at least some of the 
Bi3 ions in Bi 7MT, there is additional oxygen coordination as strong Bi-O bonds of 
2.2 A. This could arise from Bi-alkoxide linkage to Ser or Tbr side-chains, or perhaps 
from oxide coordination. Remarkably, Bi 3 is still bound to MT even at low pH 
values (e.g. pH 1), again in contrast to Zn 2 and Cd2 . Displacement of Zn2 and Cd2 
from the P domain (M3 S9) by Bi3 was much faster than from the a domain. These 
differences between the structure and reactivity of bismuth metallothionein compared 
to zinc metallothionein are likely to have implications for its biological properties. 
Since bismuth citrate complexes are widely used as antiulcer drugs, and pretreatment 
with bismuth compounds can protect against some of the toxic side-effects of the 
anticancer drug cisplatin, further studies of bismuth metallothionein are warranted. 
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First Specific Ti 1"Protein Complex: 
ntial Relevance to Anticancer Activity of 
the Sun, Hongyan Li, Richard A. Weir, and 
J. Sadler" 
Biological interest in titanium complexes arises from current 
clinical trials of two anticancer agents [Ti"(bzac) 2(OEt)2] 
(Hbzac = 1,3-diphenyl-1,3-propanedione) and [Ti"Cp2Cl2] ,[1, 2] 
and the potential radiopharmaceutical use of compounds 
containing "Ti isotopes.[ 3] Moreover, since enormous amounts 
of titanium occur in a wide variety of materials, especially 
Ti02 , there are abundant opportunities for Ti ions to enter 
into biochemical pathways in living systems. However, very 
little is known about the biological chemistry of Ti com-
pounds. There appear to be no reports of specific binding of Ti 
ions to prdieins, and the mode of action of Ti anticancer 
complexes is poorly understood. We chose to study the 
binding of Ti" ions to the blood plasma protein transferrin 
since this protein has been implicated in the transport and 
delivery of metal ions such as Gal" (as 67Ga) and Ru" to 
cancer cells. 14 ' 1  We show here that Ti ll forms a strong 
complex with human serum transferrin (hTF) by binding to 
the specific Fe" binding sites in this protein. This appears to 
be the first characterization of a specific Ti - protein complex, 
one which may play a role in the mechanism of action of the 
titanium anticancer drugs. 
Our initial experiments focussed on the reaction of 
titanium(Iv) citrate 161 with human serum apotransferrinJ 71 
When titanium(iv) citrate was added to an aqueous solution 
of apo-transferrin (apo-hTF), three new bands gradually 
appeared in the UV difference spectrum and increased in 
intensity over a period of 12 h, Figure 1. The wavelengths of 
the two sharp bands at 241 and 295 nm are typical of 
[*1 Prof. Dr. P. J. Sadler, Dr. H. Sun, H. Li, R. Weir 
Department of Chemistry, University of Edinburgh 
West Mains Road, Edinburgh EH9 3JJ (UK) 
Fax: (+44)131-650-6452 
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Figure 1. a) UV difference spectra of apo-hTF (13 ,1  in 10mM Hepes, 
5mM HCO, pH 7.4, 310K) after addition of 2 molequiv titanium(iv) 
citrate. Reaction times (from bottom to top): 1, 5, 10, 20, 40, 150, and 
720 mm. b) Titration curve for addition of titanium(iv) citrate to apo-hTF 
(conditions as above). Each solution was left > 12 h to reach equilibrium. 
/.e is the absorbance at 241 nm divided by the transferrin concentration. 
phenolate groups generated by the binding of metal ions to 
Tyr residues (Tyr 95 and Tyr 188 in the N-lobe, Tyr426 and 
Tyr517 in the C-lobe) in the specific iron binding sites. 181 The 
third, broader band at 315 nm (AE =47OO±3OOM-1 cm') is 
likely to be a ligand-to-metal charge-transfer (LMCT) band. 
However, we could find no reports of such LMCIF bands for 
titanium(Iv) phenolate complexes in the literature. To confirm 
this assignment, titanium(Iv) citrate was titrated into a 
solution of the model ligand ethylenebis(o-hydroxyphenyl-
glycine) (EHPG, pH 7.4, 10mM Hepes buffer), a ligand used 
previously for mimicking Fe" binding. ['] The UV difference 
spectra were almost identical to those from reaction of 
titanium(Iv) citrate with transferrin and 1H NMR shifts of the 
aromatic protons of EHPG induced by titanium(iv) citrate are 
consistent with the binding of Till ions to phenolate groups on 
the ligand. 
Analysis of the titration curve for reaction of apo-hTF with 
titanium(iv) citrate (Figure 1 b) suggests that two Ti ll ions 
bind strongly to transferrin (i.e. one in each lobe). A similar 
stoichiometry of Ti:hTF = 1.9( ± 0.1):1 was obtained from the 
measurement of the titanium content of purified titanium 
transferrin by inductively coupled plasma atomic emission 
spectroscopy (ICP-AES). The value of the extinction coef-
ficient for the first step of Ti" binding to transferrin 
(occupation of one lobe), &, is 17000±400M -1 cm-1 at 
241 nm, which is the same as the value determined for TjIV 
binding to ethylenebis(o-hydroxyphenylglycine) (& 
17 000 M 1 cm), suggesting that two tyrosines are involved 
in binding Ti" in both the N- and C-lobes (linear increase in 
AE with occupation of sites, see Figure 1 b). The resulting 
yellow Ti2 - hTF solution was stable at ambient temperature. 
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Figure 2. °C NMR spectra (125 MHz) 
of apo-hTE Top: 1.6mM, 10mM 
H 13CO, 100mM KCI, 70% H20/30% 
D20, pH 7.5. Bottom: Same solution 
treated with 2 molequiv TjIV  (10mM 
aqueous solution of (TiCp 2Cl2 1 solubi-
lized by addition of 1.2molequiv so-
dium citrate). A similar signal for bound 
was also seen on reaction of hTF 
with titanium(,v) citrate. This peak is 
weaker than that of, for example Bi 2 -
hTF,' 4 ' suggesting a difference in the 
extent of lobe closure and anion ex-
change rate. Labels I and 2 refer to 




mine by UV spectrosco-
py whether the anticanc-
er drug [TiCp2C12] can 
transfer Ti ions to hTF 
were hampered by the 
absorption of the drug 
itself. Therefore 'H and 
13C NMR spectroscopy 
were used to establish 
this interaction. We rea-
soned that in blood plas-
ma [TiCp2Cl2} may be 
present as a citrate ad-
duct in view of the high 
concentration of plasma 
citrate (ca. 100 .LM). 
Therefore reactions were 
carried out with the drug 
solubilized by approxi-
mately 1 molequiv cit-
rate. The exact nature 
of this complex was not 
established and we refer 
to it as (TiCp2 ) 2 . It is 
clear from 1 H NMR 
spectra that the Cp li-
gands remain bound and 
citrate probably displa-
ces the Cl- ligands by 
analogy to recently re- 
ported amino acid com-
plexes. 1101 In the ' 3C NMR spectrum a new signal assigned to 
bound 13C0 appeared at 6 = 166.1 (Figure 2), almost 
identical to signals observed on reaction of hTF with 
titanium(Iv) citrate in the presence of H 13C0. The chemical 
shift of this bound anion is close to that observed previously 
for other metallotransferrins (6 = 165.4 for Al", 6 = 166.5 for 
Gal", 6 = 166/166.2 for TV",[", 12]  6 = 166.8/167.2 for Sc111 ,l'3) 
and 6 = 165.8 for Bill [ ) .[' 4] 
Even though 1 H NMR spectra of hTF are complicated by 
the overlap of a large number of resonances, it was clear that 
Ti" binding caused characteristic changes in certain regions, 
for example new peaks appeared in the N-acetyl region (6= 
2.066 and 2.055 due to glycan chains), and in the high-field 
region (6 = 0.284, 0.050, - 0.073, Figure 3). Resonances due to 
bound Cp (6 6.2-7.0) disappeared and new peaks at 
approximately 6 = 6.0 can be assigned to displaced Cp ligands. 
The apparently strong binding of Till ions to transferrin is 
consistent with predictions based on metal ion acidity: the 
most acidic metal ions bind the most strongly. 1151 In view of the 
PKa values of Ti" and Fe" ions (<1 and 2.7, respectively), 1161 
Ti" might be expected to bind to transferrin even more 
strongly than Fe" (although in practice this may be influenced 
by other hydrolytic equilibria). We found that Fe" ions can 
displace TjIV  ions from transferrin but only slowly. Upon 
addition of 2 mot equiv [Fe"(nta) 2] (nta = nitrilotriacetate) to 
Ti2 — hTF (pH 7.4) a band appeared at approximately 465 nm, 
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Figure 3. a) High-field region of the 'H NMR spectrum (500 MHz) of 
apo-hTF and changes induced by added b) titanium(Iv) citrate, and 
c) {TiCp2 } 2 (2 molequiv, pH*  7.4, 0.1m KC1, 10mM bicarbonate). The 
signals in this region are largely from methyl groups situated over aromatic 
rings in the protein. The spectra are complicated by the broadness of the 
signals from this 80 kDa protein and by peak overlap, but it is clear that Ti" 
binds similarly in both cases with displacement of the citrate and C  
ligands. 
to proceed in two steps, the first lasting about 20 min and the 
second lasting over 5 h. 
Since hTF in blood plasma is only about 30% saturated 
with Fe" ions,117 Ti" ions entering the blood, for example 
from anticancer complexes, could readily be taken up by this 
protein. Transferrin could serve to deliver Till to cancer cells 
and release it inside cells (at low pH), as is well-documented 
for Gal" and Ru" ions. [4,51  Biological investigations of 
titanium transferrin would therefore appear to be warranted. 
Experimental Section 
Apo-hTF was purchased from Sigma (Catalog No. T0519) and was washed 
three times with 0.1m KCI using Centricon30 ultrafilters (Amicon) to 
remove low molecular mass impurities. Protein concentrations were 
determined by means of the extinction coefficent c,,=93000M 1 cm 1 .1 18 
Ethylenebis(o-hydroxyphenylglycine) (Sigma), Ti ... C13 (Sigma), sodium 
citrate (Sigma), titanocene dichloride (Aldrich), NaHCO 3 (Sigma), and 
NaH 13CO3 (MSD isotopes, >99% enriched) were used without further 
purification. 
Measurements of pH were made using a Corning 145 pH meter equipped 
with an Aldrich microcombinatjon electrode calibrated with Aldrich buffer,  
solutions of pH 4, 7, and 10. Meter readings for D 20 solutions are 
designated as pH*. 
A 200mM fresh purple solution of [Ti"(cit), n] (cit = citrate) was prepared 
under N2 by adding sodium citrate (1 mL of a 250mM solution) to a known 
amount of Ti"C1 3 , and the pH was adjusted to approximately 6.0 by 
addition of solid NaHCO3.191  After bubbling with 02, a colorless solution 
of titanium(iv) citrate was obtained, which was then diluted to roughly 
3.3mM for UV experiments. UV spectra were recorded on a computer-
controlled Perkin Elmer lambda 16 spectrometer; the temperature of the 
cell (1 cm) was maintained at 310 K. 
A 10mM yellow titanocene solution was prepared by dissolving a known 
amount of [TiCp2Cl2] in a sodium citrate solution (Ti:cit = 1:1.2), and the 
pH was adjusted to 4.5 (1M NaOH). 
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'H and 'C NMR spectra were recorded on a Bruker DMX 500 NMR 
spectrometer at 500 and 125 MHz, respectively. The experimental con-
ditions were similar to those reported previously.[ 141 The 'H NMR reference 
was endogenous formate (6 = 8.465 at pH*>  7.0 relative to trimethylsilyl 
propionate (TSP)), which was always present in transferrin samples as a 
minor impurity. The 13C NMR reference was added dioxane (6 = 67.4 
relative to TSP). 
The titanium content of transferrin was measured using inductively coupled 
plasma atomic emission spectroscopy (ICP-AES; Thermo Jarrell Ash IRIS, 
aO 323.40 nm). The T"12-hTF samples for ICP-AES were prepared as 
follows: titanium(iv) citrate (2.2 molequiv) was added to apo-hTF (in 
1?mM Hepes buffer, pH 7.4, 10mM bicarbonate) and left to equilibrate for 
over 24 h at 310 K. The protein was then purified by ultrafiltration 
(entricon30, Amicon), washing four times with 0.1m KCI and twice with 
water. An aliquot of the final solution was diluted with concentrated HNO 3 
(a. 6m) and the titanium content was measured without any digestion of 
tle sample. 20I The transferrin concentration in this sample was determined 
by titrating with Fe" ions (added as [Fe(NTA) 21) by measuring the 
absorbance at 465 nm (e=495OM'cm' for diferric transferrin).( 211 
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Platinum(n) Complexes with Constructive and 
Destructive Interaction of Diphosphane and 
Binaphthol Ligands** 
Nicole M. Brunkan, Peter S. White, and 
Michel R. Gagne* 
(S,S)-2,3-Bis(diphenylphosphanyl)butane ((SS)-Chiraphos) 
and its achiral analogue 1,2-bis(diphenylphosphanyl)ethane 
(dppe) belong to a class of chelating diphosphanes that form 
five-membered rings with late transition metals. These 
diphosphanes usually adopt a 6- or A-skew conformation 
(Scheme 1).[11  With the achiral dppe, the two conformers are 
 
Ph 	 Ph 
I p — Ph Ph Ph 	 ' 	Pt 









Scheme 1. a) skew conformations of dppe in platinum complexes. b) (S,S)-
Chiraphos and its preferred 6 conformation in the complex. 
equally favorable; however, backbone modification of chiral 
diphosphanes makes one conformer more stable than the 
other. [2) For example, the trans-methyl substituents. of (S,S)-
Chiraphos favor the 6 conformer (pseudoequatorial versus 
[*] Prof. M. R. Gagné, N. M. Brunkan, P. S. White 
Department of Chemistry, CB#3290 
University of North Carolina 
Chapel Hill, NC 27599-3290 (USA) 
Fax: (+ 1)919-962-6341 
E-mail: mgagne@unc.edu  
[**] This work was supported in part by the National Science Foundation 
under the auspices of a CAREER development award to MRG 
(CHE-9624852) and an equipment grant to the University of North 
Carolina for the purchase of a CCD diffractometer (CHE-9709977). 
We also acknowledge the Petroleum Research Fund, administered by 
the ACS, for partial support. NMB is a UNC Board of Governors 
Graduate Fellow. We thank Prof. H. Holden Thorp (UNC-Chapel 
Hill) for generous access to his UV/Vis spectrometer. 
Angew. Chem. mt. Ed. 1998,37, No. 11 	0 WILEY-VCH Verlag GmbH, D-69451 Weinheim, 1998 	1433-7851/98/3711-1579 $ 17.50+50/0 	 1579 
BS 19802 
	 FEBS Letters 422 (1998) 315-320 
[1 H, 13 C] NMR determination of the order of lobe loading of human 
transferrin with iron: comparison with other metal ions 
Hongzhe Sun', Mark C. Coxa, Hongyan Lie- , Anne B. Mason b,  Robert C. Woodworth b, 
Peter J. Sadler' , * 
Department of Chemistry, University of Edinburgh, King's Buildings, West Mains Road, Edinburgh EH9 3JJ, UK 
bDeparlmen t of Biochemistry, University of Vermont College of Me'!cine, Burlington, VT 05405, USA 
Received 22 October 1997; revised version received 26 December 1997 
stract Human serum transferrin (hTF) is a single-chain 
lobal glycoprotein (80 kDa) which transports Fe 3 and a 
riety of other metal ions in blood. Only diferric transferrin, not 
e apo-protein, binds strongly to transferrin receptors and is 
ken up by cells via receptor-mediated endocytosis. We show 
re that 2D I'H,' 3 C1 NIVIR studies of recombinant c-I 13 CtMet-
F allow the order of lobe loading with various metal ions, 
eluding Fe3 , to be determined. In particular, the resonance for 
et-464, a residue in the hydrophobic patch of helix 5, is very 
nsitive to iron binding in the C-lobe. The selectivity of lobe 
ading with Fe34' is compared to loading with Fe 21' (which binds 
Fe3 ), Al3 , Ga3 and Bi31'. Similar changes in shifts of the 
et residues are observed for these metal ions, suggesting that 
ey induce similar conformational changes in the protein. 
© 1998 Federation of European Biochemical Societies. 
?y words: Iron; Metalloprotein; Metal ion; 
uclear magnetic resonance spectroscopy; Transferrin 
Introduction 
Serum transferrin is a single-chain 80 kDa glycoprotein 
und in the blood, consisting of two similar lobes each of 
kDa connected by a short peptide. X-ray structures of 
snsferrins and lactoferrins [1-7] show that each lobe con-
ins an approximately octahedral Fe" 4' binding site consisting 
two tyrosinate oxygen atoms, one His nitrogen, one Asp 
rboxylate and two oxygen atoms from a bidentate carbo-
ite anion (the synergistic anion). Metal ions cannot bind 
rongly without concomitant binding of a synergistic anion. 
sides carbonate, other anions such as oxalate or malonate 
n also act as synergistic anions. While iron is the natural 
bstrate of transferrin, many other metal ions can bind to the 
)fl site, and this has led to the idea that transferrin acts as a 
-livery system' for both harmful and beneficial metal ions in 
e body. 
An important feature which has emerged from X-ray stud-
of transferrin and lactoferrin is that iron induces a con-
rmational change from a lobe-open (apo) to lobe-closed 
olo) form. Only diferric transferrin and not the apo-form 
:orresponding author. Fax: (44) (131) 650 6452. 
mail: p.j.sadler@ed.ac.uk  
,breviations: DSC, differential scanning calorimetry; EDTA, ethyl-
ediaminetetraacetate; EPR, electron paramagnetic resonance; 
MQC, heteronuclear multiple-quantum coherence; hTF, human 
-urn transferrin; hTF/2N, N-lobe of hTF; NTA, nitrilotriacetate; 
1*, pH meter reading in D 20 
binds strongly to the receptor protein on the surface of the cell 
and is taken up. Small angle X-ray scattering studies have 
shown that loading of transferrin with F e3+, 1n3+  Cu2+ or 
Al3 '4' causes a decrease in the radius of gyration of the protein 
consistent with lobe closure [8]. 0a3+  also probably induces 
lobe closure since gallium transferrin is recognised by the 
transferrin receptor [9]. This process may be relevant to the 
anticancer activity of Ga(NO,), and to the delivery of the 
radioactive isotope 67Ga to cells for diagnostic imaging. In 
blood plasma, transferrin is only about 30% saturated with 
iron, with occupies the N-lobe [10]. There is much interest in 
the functional differences between the two binding sites and 
numerous experiments in which metal ions are thought to 
load either the N- or C-lobes have been reported [11]. 
There appear to be few methods which currently allow a 
direct determination of the order of lobe loading of transferrin 
with metal ions. Methods such as EPR [12], DSC [13,14] and 
heteronuclear NMR spectroscopy [15-22] can often distin-
guish two stages of loading, but comparison with isolated 
individual lobes is necessary before the steps can be assigned 
to specific lobes. A direct determination of which lobe is 
loaded using gel electrophoresis is possible for some metal 
ions, but the procedure involves the use of 6 M urea which 
allows examination only of metals which bind tightly [23,24]. 
In the present work we show that the order of lobe loading 
can be determined directly under conditions of physiological 
relevance via 2D ['H,' 3C] NMR studies of recombinant (non-
glycosylated) hTF labelled with c-["C]Met. This method is 
successful even for paramagnetic Fe3+.  The ['H,"C] NMR 
resonances are used to compare the conformational changes 
induced by binding of Fe' with those induced by A1 34', Ga3 '4' 
and Bi"4'. 
2. Materials and methods 
2.1. Materials 
Recombinant hTF was expressed in baby hamster kidney cells using 
a pNUT plasmid with e-L-["C]methionine in the growth medium and 
purified as previously described [25,26]. Iron was removed from the 
proteins by treatment with NTA and EDTA (both I mM) in 0.5 M 
sodium acetate at p1-I 4.9, and followed by concentration in a Cen-
tricon 30 microconcentrator (Arnicon). Potassium chloride (ACS 
regent), [A] 2 (SO4 )3] (A.R.), ferrous ammonium sulphate 
([Fe(NH4 )2 (SO4 )21, AR.) and sodium bicarbonate (ACS regent) 
were purchased from Aldrich. Stock solutions of Fe 3+  and Ga34' 
were prepared from atomic absorption standards (1000 ppm, in 5% 
HNO,, Johnson Matthey) by adding of 2 mol equiv of H,NTA (Al-
drich) followed by pH adjustment to 6.0-7.0, freeze-drying, and redis-
solution in D 2 0. A [Bi(NTA)1 stock solution was prepared by dissolv-
ing [Bi(NTA)] [271 in D,O. Fresh Fe 24' solutions were prepared by 
dissolving known amounts of ferrous ammonium sulphate in D,O. 
14-5793/98/$19.00 © 1998 Federation of European Biochemical Societies. All rights reserved. 
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2.2. Sample preparations 
NMR samples of c-['C]Met-hTF (Ca. 0.3 mM) were prepared in 
0.1 M KCI in D20, and pH* values were adjusted to 7.4±0.1 using 
NaOD or DCI. Sodium bicarbonate in D20 (0.25 M) was added to 
transferrin solutions to give a concentration of 10 mM. Addition of 
metal complexes was made to protein samples containing bicarbonate 
to give metal: protein ratios of up to 2.5:1, and the pH*  was read-
justed to 7.4 ± 0.1(8.8 ± 0.1 for All) after each addition; the samples 
were left 30 min for equilibration. 
2.3. NMR spectroscopy 
['ft' 3C] HMQC [28] spectra were acquired on Varian Unity 600 
and Varian Unity-Plus 500 NMR spectrometers at 600 and 500 MHz, 
respectively, at 310 K. The sequence was optimised for 'J('H-
3̀ C) = 140 Hz, and 8-16 transients were acquired using 2 K points 
in f2 dimension ('H), 32-64 increments of t, ' 3 C frequency width of 
3 kHz (swl), and relaxation delay of 1.6s giving a total Ca. 30 min for 
the acquisition of each spectrum. The GARP-1 sequence [29] was used 
to decouple ' 3 C. After zero filling to 4 K  I K points, unshifted-
Gaussian functions were used for processing. The residual water sig-
nal was suppressed by a combination of presaturation and pulsed-field 
gradients. Peaks were referenced to sodium 3-(trimethylsi!yl)propio-
nate-2,2,3,3-d 4 (TSP) via the e-CH3 peak of L-methionine (external, 
15.14 ppm) for 'SC, and via formate (8.465 ppm, a minor impurity 
always present in the protein) for 'H. 
3. Results 
Recombinant non-glycosylated human transferrin with 
>95% c- 13 CH3 enrichment at all nine Met residues (Fig. 1) 
was prepared according to published procedures [30]. 2D 
['H, 13 C] NMR spectra of the labelled protein at low concen- 
tration (ca. 300 .tM) were obtainable within a short time (ca. 
0.5 h) using inverse detection techniques. Cross-peaks for 
eight Met residues were readily observed, and that for the 
ninth appeared when the temperature was raised from 310 
to 318 K, or when bicarbonate was added. Reasonable assign-
ments of these cross-peaks, as deduced previously from 2D 
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Fig. I. Distribution of the nine Met residues in human serum trans-
ferrin, based on the X-ray crystal structure of Fec-hTF [I]. The N-
lobe with an open interdomain cleft is on the left-hand side. The 
Met side-chains are shown in bold, and the residue numbers are in-
dicated. 
NMR data for hTF and hTF/2N [30], are shown in Fig. 2. 
The chemical shifts were constant over the range pH*  6.8-8.8. 
3.1. Detection of Fe3 binding to transferrin and order of 
lobe loading 
Fe3 , as [Fe(NTA)2], was added to hTF at pH*  7.4 to give 
Fe:hTF mol ratios of 0.5:1 and 2.0:1 (0.5 mol equiv steps). 
The addition of the first mol equiv of Fe 3 led to the dramatic 
disappearance of the cross-peak for Met-464 and was accom-
panied by the appearance of a new broad peak shifted by ca. 
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Fig. 2. 2D ['H,C] HMQC spectra of e-[' 3 C]Met-apo-hTF, and after addition of 10 mM bicarbonate at pH 7.4, and 1.0 and 2.0 mol equiv 
of Fe 3+  as an NTA complex. The assignments for Met resonances are based on [30]. The specific shifts of cross-peaks for the C-lobe residue 
Met-464 and Met-499 on binding the first equiv of Fe 3+  and N-lobe residues Met-309 and Met-313 on binding the second equiv are notable. 
The cross-peak for Met464 is broadened, see Fig. 4. The solid boxes indicate initial peaks and dotted boxes show new peaks. 
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Fig. 3. 2D [ 1 H, 13 C] HMQC spectra of e - [ 13 ClMet-apo-hTF in the presence of 10 mM bicarbonate, after addition of 1.0 mol equiv of ferrous 
ammonium sulphate (pH* 7.4), 1.0 mol equiv. of [Ga(NTA)2], 0.5 mol equiv of A13 or 0.5 mol equiv Bi3 . The solid boxes indicate initial 
peaks and dotted boxes show new peaks. 
high field in the 1 H dimension (Fig. 2). The cross-peak for 
Met-499 also disappeared and a new peak appeared which is 
shifted slightly to low field (Fig. 2). When the second mol 
equiv of Fe 3+  was added, there was no further change to these 
peaks, but shifts were observed for the cross-peaks of N-lobe 
residues Met-26, Met-109, Met-309 and Met-313. In addition, 
a shift of the peak for Met-382, which is in the C-lobe, was 
observed. The chemical shift changes are listed in Table 1, and 
coordination shifts are calculated on the assumption that the 
peaks for the iron-loaded protein are close to those for the 
apo-protein. Although the peak for Met-464 is markedly 
broadened by Fe 31 binding, a notable sharpening of the 
cross-peak for Met-109 was observed. 
The reaction of apo-hTF with Fe 2 (added as a solution of 
ferrous ammonium sulphate) was also studied under similar 
conditions. In this case, after addition of I mol equiv of Fe 2+  
(in the presence of 10 mM bicarbonate and after equilibration 
for ca. 30 mm), cross-peaks for both N- and C-lobe Met 
residues decreased in intensity and new peaks appeared with 
the same chemical shifts as those observed for Fe(III)2-hTF 
(Fig. 3 and Table I). The disappearance of peaks for apo-hTF 
and the appearance of these new peaks for Fe2-hTF was com-
plete after addition of 2 mol equiv of Fe 2+.  Similar spectra 
were obtained after leaving the same mixture overnight (>12 
h) at 310 K showing that equilibrium had indeed been 
reached. An additional experiment was also carried out in 
which 0.8 mol equiv of Fe 2+  (ferrous ammonium sulphate) 
was added to a solution of apo-hTF (80 .tM, 10 mM 
HCO, pH* 7.4)) without added KCI. The 2D [ 1 H, 13 C] spec-
tra recorded after average reaction times of ca. I h and 6 It (2 h 
accumulations) were both similar to that shown in Fig. 3 for 
reaction in the presence of KCI. 
Table 1 
'H and 13 C NMR chemical shifts of apo-hTF, iron(III)-induced coordination shifts (Lr8F e2_,TF_öpO_hTF) for the Met-(c)-' 3 CH3 residues of 
hTF at 310 K, their locations, and distances between Met-- 13 CH 3 and Fe3 
Residue (lobe) 	Location 	 e- 13CH3 distance from Fe 3 (A) 	& ( 1 11/13C) (ppm) 
	A8 ('l-l/13 C)" (ppm) 
N-1obe 	C-lobe' 
Met-26 (N) buried 23.1 1.98/16.02 0.03/0.13 
Met-109 (N) partially buried 16.5 1.99/14.61 0.01/-0.l0 
Met-256 (N) completely exposed 30.0 2.13/15.54 0.00/0.00 
Met-309 (N) mostly buried 17.1 2.27/17.52 -0.05/0.28 
Met-313 (N) partially exposed 21.4 2.29/15.22 0.05/0.24 
Met-382 (C) partially exposed 22.1 21.5 2.07/15.23 0.03/-0.20 
Met-389 (C) completely buried 12.2 2.01/15.481 
0.20/1.90" Met-464 (C) Trp460 hydrophobic patch of helix 5 16.1 1.38/16.30 
Met-499 (C) mostly exposed 21.8 1.86/15.40 0.04/0.11 
'Data from model of hTF/2N [36] based on the X-ray structure of N-lobe of diferric rabbit serum transferrin [7]. 
bData  from the X-ray structure of Fec-hTF [I]. 
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Fig. 4. Slices through 2D ['H,' 3 C1 HMQC spectra of e-l' 3 C]Met -
apo-hTF, and after addition of one mol equiv of Bi ll, two mol 
equiv of AI3 , two mol equiv of Ga3+, or one mol equiv of Fe 3+  
(as Fe(NTA)2 ), showing the similar shifts of Met-464 on occupation 
of the C-lobe site. The H linewidth of Met-464 is ca. 30 Hz for 
apo-hTF, Bi,-hTF, Al 2 -hTF and Ga 2 -hTF, and ca. 80 Hz for Fec-
hTF. 
3.2. Uptake Gc? , A P + and Ri3 + by transferrin 
The binding of these metal ions to apo-hTF was also 
studied by 2D ['H, 13 C] NMR under similar conditions. On 
addition of [Ga(NTA)2], the behaviour of the cross-peaks was 
similar to that observed for Fe 2+,  with addition of I mol 
equiv of GaS+ causing a decrease in intensity of the initial 
peaks for apo-hTF and appearance of a new set of peaks 
H. Sun et aL/FEBS Letters 422 (1998) 315-32 
for both N- and C-lobe Met residues (Fig. 3). However, ther 
was less broadening of peaks for Met-464 than in the case o 
the reaction with Fe2F  (or Fe3 ). Addition of the second mc 
equiv of Ga 3 led to a further increase in intensity of th 
peaks for Ga 2 hTF and almost complete disappearance o 
peaks for apo-hTF. The chemical shifts changes observed 
were identical to those observed for binding of Fe 3+. 
No changes to the 2D [ 1 H,'3 C] NMR spectrum were oh 
served on reaction of apo-hTF with A1 3 (added as Al2(SO4 )3 
at pH* 7.4 in the presence of 10 mM bicarbonate. Howevet 
on increasing the pH*  to 8.8, peaks for the N-lobe resonance 
Met-109, Met-309, Met-313 and interlobe Met-382 decrease 
in intensity and new cross-peaks appeared (Fig. 3). On addi 
tion of the second equiv of A1 3 , peaks for Met-464, Met-38 
and Met-499 were perturbed. The new cross-peak for Met-46 
appeared at 1.17/18.20 ppm, a similar shift change to tha 
observed for Fe 3+ binding to the protein. The shift change 
for the other Met peaks in the spectrum were also similar t 
those observed with Fe 3+. 
Addition of 0.5 mol equiv of Bi3 (as [Bi(NTA)]) led to 
decrease in intensity of peaks for C-lobe residues and appear 
ance of new peaks characteristic of Bi-hTF (Fig. 3). Again th 
large shift of the peak for Met-464 to 1.17/18.20 ppm wa 
notable, with no changes in shift for the N-lobe peaks. Thes 
changes were complete in the presence of 1 mol equiv of Bi34 
Addition of a second mol equiv of Bi 3+ caused a decreas 
intensity of peaks for N-lobe residues and appearance c 
new peaks with shifts similar to those of Fe 2hTF, but peak 
for apo-hTF still remained in the spectrum. Interestingl) 
when 1 mol equiv of Fe' (as Fe(NTA)2) was added to Bi t 
hTF, Fe 3+ did not occupy the vacant N-lobe, but instea 
displaced Bi 3 from the C-lobe, as judged from the 21 
NMR spectra. 
4. Discussion 
Transferrin is a major transport protein in blood, and bind 
not only to the natural metal ion Fe 3+, but also to other metz 
ions of toxic (e.g. A1 3 [9]), therapeutic (e.g. Bi 3 [31]) an 
diagnostic (e.g. SlGaS+  [91) interest. The protein possesses tw 
similar metal binding sites in the N- and C-lobes which diffe 
slightly in their affinities, but the factors which direct metz 
ions to specific lobes of hTF are poorly understood. Th 
strength of metal binding to hTF correlates with metal io 
acidity: the most acidic metal ions (Fe 3 , Bi3 ) binding th 
Table 2 
Order of lobe loading of serum apo-transferrin with various metal ions using different techniques 
Metal 	Loading complex 	Technique 	 pH or pH* 	Anion 	 Lobe preference 
N- 	 C_ 
At Al III  2 (SO4 )3 'H, ['H,' 3 C1 NMR 8.8 HCO 	 + 
Sc Sc"(NTA)2 'H NMR 7.4 HCO + 
Fe Fe ... (NTA)2 l'H, 13 C1 NMR 7.4 HCO + 
electrophoresis 6-8.5 HCO 
calorimetry + 
F&'(NH4 )2 (SO4 )2 l'H,' 3C1 NMR 7.4 HCO 	 + + 
electrophoresis 7.4-8.5 HCO + 
Ga Ga' 11 (NTA)2 ['H, 13 C] NMR 7.4 HCO 	 + + 
'H, ['H,' 3 C] NMR 7.2 oxalate + 
TI Tl"C13 205T1 NMR 7.3-7.8 HCO + 
Ri Bi ... (NTA) 'H, ['H, 13 C) NMR 7.4 HCO + 
The results of the present studies as well as data from previous reports, for which the references are given in [II] and [12], are included. 
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most strongly [32]. Only when hTF is loaded with metal ions 
in both lobes does it bind strongly to the receptor and so the 
conformational changes which accompany metal binding are 
of direct relevance to its recognition by cells. The 2D ['H,' 3 C] 
NMR method reported here allows the direct determination 
of the order of loading of the lobes of intact hTF with metal 
ions, and, moreover, for the first time using NMR, it is pos-
sible to compare directly structural changes induced by Fell 
in comparison to other metal ions. 
Using recombinant hTF labelled specifically with E-
[ 13 qMet, it is possible to detect peaks for eight (and some-
times all) of the nine Met residues in hTF at micromolar 
concentrations, and although the protein is expensive to pro-
duce, it can be demetallated and recycled for studies under 
different conditions. The recombinant hTF is non-glycosyl-
ated, but there is no evidence that glycosylation affects metal 
uptake [26]. The SCH3 peaks are convenient for NMR studies 
since they are singlets, and moreover the Met residues are well 
spread throughout the protein and occupy several types of 
environment (Table 1 and Fig. 1). Since the (carbon atoms 
of the) SCH3  groups are all over 12 A from Fe 3+'  it is a 
reasonable assumption that the SCH 3 cross-peaks are little 
affected by the paramagnetism of Fell if the effects are pre-
dominantly dipolar (high-spin S= 5/2 [12], dipolar shifts M 1/ 
P, dipolar broadening oc 11r6 , where r is the distance between 
Fell and nucleus of interest [33,341). 
Previously we have described the use of 'H NMR to deter-
mine the order of lobe loading of hTF with A1 3 and Ga3 
[35-37]. This required studies on the isolated N-lobe alone 
and the use of specific resonances as fingerprints. Although 
His 1 H NMR resonances were useful for fingerprinting, they 
were difficult to follow on account of their sensitivities to pH 
near pH 7. This is not the case with c-[' 3 C]Met resonances, 
and, moreover, the resonance for Met-464 is a specific and 
sensitive indicator for C-lobe binding. It is also possible to 
determine successfully the order of loading using, e.g. hetero-
nuclear NMR, DSC and EPR [12,13], but again comparison 
with isolated N-lobe is necessary. Although apo-hTF can 
sometimes be separated from mono- (Fec or FeN) and di-
metal transferrin by electrophoresis, the method requires 
harsh conditions (6 M urea) and is successful only for very 
tightly bound metal ions [23,24,38]. 
Importantly the present study has allowed determination of 
the order of lobe loading of hTF with Fe 3+  (as an NTA 
complex in the presence of HC0 as synergistic anion), 
and, in agreement with previous reports, the C-lobe is occu-
pied preferentially. Met-464 is situated in the hydrophobic 
patch (V454-W460-M464, the analogue of L122-W128-1132 
in the N-lobe) of helix 5, which backs onto the metal binding 
sites and H-bonds to the synergistic anion [1,7]. This result 
indicates that the cross peak for Met-464 is a sensitive indi-
cator of metal binding to the C-lobe. We found that reaction 
of one mol equiv of Fe 2  with apo-hTF led to the occupation 
of both lobes with iron, in contrast to previous reports in 
which it was concluded that this method of loading with 
iron leads to selective loading of the N-lobe [23,24]. Although 
Cl— ions have been reported to affect the distribution of iron 
between the two lobes [39], this did not appear to be the case 
under the conditions used here. 
Since the shifts and broadening of ['H,' 3 C] NMR resonan-
ces upon loading apo-hTF with 2 mol equiv of Fe 2+  were the 
same as that with Fe 3+'  it can be concluded that Fe 2+  is  
oxidised as it is taken up, and this was confirmed by the 
appearance of the characteristic t yros inate to Fe3+ charge-
transfer band at 465 nm [12]. The detailed mechanism of 
this process appears to be unknown, but probably involves 
02 as oxidant. 
The results obtained here for the order of lobe loading with 
Ga3+, Bill and Al3+ agree with previous reports. The behav-
iour of Bill resembles that of Fell (as NTA complexes) with 
preferential binding to the C-lobe, whereas Ga 3 shows little 
preference for either lobe. Under the conditions of our experi-
ments, A1 3  does not load either the N-lobe or the C-lobe at 
pH* 7.4, but at pH* 8.8, preferentially loads the N-lobe, in 
contrast to Fell and Bi 3 at pH*  7 (Table 2). The difference 
may be related both to the presence of NTA as a bound 
ligand on the loading Fell and Bill complexes, and to the 
change in charge of the protein (and especially the charge in 
the interdomain cleft) at high pH. 
Although the shift changes for Met resonances induced by 
Fe 3+  are similar to those induced by G a3+, A13+ and Bill, 
implying that these metals all induce similar conformational 
changes on binding, Fell markedly broadens the cross-peak 
for Met-464 (Fig. 4). The contribution of paramagnetic effects 
to peak broadening remains to be determined, but may be 
very small at such a large distance (>ca. 12 A) from Fe 3+ 
if dipolar in origin. It is therefore possible that iron causes a 
reduction in mobility of this group, or a change in its dynamic 
exchange behaviour, which is different from that induced by 
the other metals studied. Further work is required to inves-
tigate this. 
5. Conclusion 
2D ['H, 13 C] NMR provides a rapid method of determining 
the order of lobe loading of transferrins with metal ions via 
the use of E-[' 3 C]Met-labelled recombinant transferrin. Under 
the conditions we have used (10 mM bicarbonate, 0.1 M KCI 
at pH* 7.4), NTA complexes of Fe 3+  and Bi ll preferentially 
load the C-lobe, whereas G a3+ shows little preference, and, in 
the absence of NTA, All does not bind at pH 7.4 but 
preferentially loads the N-lobe at pH*  8.8. Reaction of hTF 
with Fe' gave rise to both N- and C-lobe loading (with Fe ll) 
under the conditions used, in contrast to previous reports 
[24,38]. The Met residues of hTF are well distributed through-
out the protein, and the changes in shift of their ['H,' 3C] 
NMR resonances can be used as finger-prints of conforma-
tional changes induced by various metal ions. A significant 
result from this work is that Fe 3+ ,  Ga3+, A13+ and Bill all 
induce similar conformational changes as judged from the 
changes in shifts of resonances. 
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N-lobe versus C-lobe complexation of bismuth by human transferrin 
Hongzhe SUN*,  Hongyan Ll, Anne B. MASONt, Robert C. W000WORTHt and Peter J. SADLER*l 
Department of Chemistry, University of Edinburgh. Edinburgh EH9 3JJ. U.K., and toepadment of Biochemistry, University of Vermont College of Medicine. Burlington, 
VT 05405, U.S.A. 
Interactions of recombinant N-lobe of human serum transferrin 
(hTF/2N) with Bill, a metal ion widely used in medicine, have 
been investigated by both UV and NMR spectroscopy. The 
bicarbonate-independent stability constant for Bill binding (K) 
to hTF/2N was determined to be log K* 18.9 ±0.2 in 5 m 
bicarbonate/10 mM Hepes buffer at 310 K, pH 7.4. The presence 
of Fell in the C-lobe of intact hTF perturbed Bill binding to the 
N-lobe, whereas binding of Bill to the C-lobe was unaffected by 
the presence of Fell in the N-lobe. Reactions of Bill (as bismuth 
nitrilotriacetate or ranitidine bismuth citrate) with hTF/2N in 
solutions containing 10 m bicarbonate induced specific changes 
to high-field 'H-NMR peaks. The 'H co-ordination shifts induced 
by Bill were similar to those induced by Fell and Ga 34 , suggesting 
that Bill binding causes similar structural changes to those 
induced by hTF/2N. 13C-NMR data showed that carbonate 
binds to hTF/2N concomitantly with Bill. 
Key words: metal binding, NMR spectroscopy, protein con-
formation, stability constant, serum protein. 
INTRODUCTION 
Transferrin belongs to a class of 80 kDa monomeric glycopro-
teins, which are functional in iron transport and detoxification in 
vertebrates [1,2]. It has two structurally similar lobes, each of 
approx. 40 kDa, linked by a short peptide and each lobe contains 
an interdomain high-affinity metal-binding site [3,4]. The X-ray 
crystal structures of rabbit serum transferrin [5,6], the related 
protein diferric lactoferrin [7,8] and monoferric human trans-
ferrin [9] show that Fe 3+  in each lobe has approx. octahedral co-
ordination, consisting of two oxygens from two tyrosine side-
chains, one nitrogen from histidine, one oxygen from aspartate 
and two oxygens from a bidentate synergistic anion, carbonate. 
An important feature that has emerged from X-ray studies of 
transferrin and lactoferrin is that iron induces a conformational 
change from a lobe-open (apo-form) to a lobe-closed (holo-
form). Only the holo-form (metal loaded in both lobes), and not 
the apo-form, binds strongly to the cell receptor and is taken up. 
Many other metal ions can bind in the Fell site [10]. Recently we 
found that Bill, a large metal ion of ionic radius 1.03 A 
(0.103 nm), which is widely used in medicine in anti-bacterial 
and anti-ulcer drugs [11,12], binds to human serum transferrin 
(hTF) strongly with bicarbonate-independent stability constants 
(K*) of log K' 1 and log K, = 19.4 and 18.6 respectively (in 
10 m Hepes buffer/5 mM bicarbonate at 310K, pH 7.4) [13]. 
We were subsequently able to correlate strength of binding of a 
wide range of metal ions to transferrin with metal acidity (log 
KOH) [ 14,15]. This binding ability is of potential importance for 
the transport and delivery of bismuth-containing drugs and 
control of bismuth levels in the body, since the distribution of 
bismuth in blood plasma and other biofluids is still not well 
understood. 
Previously we have shown that there is preferential binding of 
Bi34 to the C-lobe of hTF with bicarbonate as the synergistic  
anion [13]. There is currently much interest in the functional 
difference between the two lobes of transferrin. In blood, 
transferrin is only about 30% saturated with Fell, and this is 
thought to occupy the N-lobe [16]. To investigate possible inter-
lobe interactions, we have now determined the stability constant 
for Bill binding to the recombinant N-lobe of hTF (hTF/2N) 
and compared it with that for Bill binding to intact hTF, 
with Fell occupying either the N- or the C-lobe. We have 




Apo-hTF was purchased from Sigma (catalogue no: T0519). 
hTF/2N was expressed in the methylotrophic yeast, Pichia 
pastoris, by placing the hTF/2N cDNA under the control of the 
methanol-inducible alcohol oxidase promoter, and purified as 
described previously [17]. The Fell was removed by additions of 
metal-removal buffer [1 mM nitrilotri acetate (NTA)/l mM 
EDTA/0.5 M sodium acetate (pH 4.9)) [18], followed by ultra-
filtration three times (I h each time) in a Centricon 10 (Amicon, 
Stonehouse, Gloucestershire, U.K.). Finally, the protein was 
washed four times with 0.1 M KCI to remove low-molecular-
mass impurities via ultrafiltration (Centricon 10). For apo-hTF, 
a similar procedure was used to remove low-molecular-mass 
impurities (Centricon 30). Monoferric transferrins (selective 
loading of Fell in either the N- or C-lobe of transferrin) were 
prepared as described previously [19]. Use of the reported 
procedure for selective Fell loading of the N-lobe [using 
Fe(NH 4) 2(SO4),] appears to provide > 80% selective N-lobe 
loading [20], although in NMR experiments we have found that 
Abbreviations used: hTF, human serum transferrin; hTF/2N, recombinant N-lobe of hTF; FeN,c-hTF,  monoferric Iransferrin with Fe 
31 in the N- or C-
lobe; K*,  bicarbonate-independent stability binding constant; NTA, nitrilotriacetate; pH, pH meter reading for 2H 20 solution; RBC, ranitidine bismuth 
citrate. 
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the selectivity is slightly lower [21]. Crystalline Bi-NTA was 
synthesized using a procedure in the literature [22] and had a 
satisfactory elemental analysis. Ranitidine bismuth citrate (RBC) 
was supplied by Glaxo Wellcome (Stevenage, Herts., U.K.). 
NaHCO3, KCI, H 3NTA and Hepes were purchased from Aldrich 
(Milwaukee, WI, U.S.A) and NaH' 3CO3 (99% enriched- 13C) 
was from MSD Isotopes (Montreal, Canada). 
Preparation of NMR samples 
To allow 1 H-2H exchange, apo-hTF/2N was dissolved in 0.1 M 
KCI in 2H 20, and after adjustment of the pH*  (pH meter reading 
for 'H 20 solution) to 7.8, this was left for 4 h at ambient 
temperature. After freeze-drying, the sample was redissolved in 
2H 20 containing 10 mM NaHCO 3 . The pH* was then readjusted 
to 7.80±0.05, when necessary, using Na0 2H and 2HCI (0.2 M). 
The pH* values of NMR solutions were recorded before and 
after NMR measurements. 
Samples for electronic absorption spectroscopy 
These were prepared by diluting aliquots of stock apo-hTF/2N 
or monoferric transferrin solutions to approx. 10' M with 
10 mM Hepes buffer, pH 7.4. The concentrations were deter-
mined spectrophotometrically on the basis of c280 38600 and 
103000 M' cm' for hTF/2N and monoferric transferrins re-
spectively [17,23]. Immediately before addition of Bi 3 , an aliquot 
of a concentrated solution of NaHCO 3 (0.25 M) was added to 
give 5 mM HCO3- . The spectrum of the apo-hTF/2N solution 
(containing 5 mM bicarbonate) was recorded after equilibration 
at 310 K for 10 mm. Aliquots of the stock solution of bismuth 
(usually 5-20#1 of Bi-NTA solution) were then added to the 
apo-hTF/2N cuvette and spectra were recorded after at least 
0.5 h equilibration at 310K. A similar procedure was used for 
titration of monoferric transferrins with Bi-NTA. 
RESULTS 
Electronic absorption spectroscopy 
The complexation of metal ions to the phenolate groups of 
the tyrosine residues in the specific metal-binding sites of apo-
transferrin led to the production of two new absorption bands at 
241 and 295 nm [2]. These new bands are readily apparent in 
difference UV spectra of metal-containing transferrin and apo-
hTF. 
The recombinant N-lobe of transferrin (hTF/2N) was titrated 
with Bi-NTA (x = 1,10), and the absorbance at 241 nm was 
monitored. TL UV difference spectra and titration curves are 
shown in Figures 1 and 2 respectively. For the NTA: Bi = I: 
curve, Ac increases linearly with an increase in the ratio of 
Hi: hTF/2N, and from the initial slope of the curve the molar 
absorption coefficient of Bi-hTF/2N was obtained as 
22000 M- '-cm- '. Owing to NTA competition, the titration curve 
for NTA:Bi = 10:1 levelled off, and Bi 3 was loaded only 
partially into the metal-binding site of hTF/2N. This curve was 
used to calculate the stability constant of Bi-hTF/2N. 
The stability constant determination was on the basis of the 
competition reaction of NTA and hTF/2N with Bi 3 , and 
the following equations were used: 
Bi-NTA + hTF/2N = Bi-hTF/2N + NTA 
Ka = [Bi-hTF/2N][NTA]/[Bi-NTA][hTF/2N] 	 (1) 
Bi 3 +hTF/2N = Bi-hTF/2N 
K = [Bi-hTF/2NJ/[Bi3][hTF/2N] = KBjNTA  K 	 (2) 
Ka was obtained from the Hill plot: 
I / Y = I + I /K . [NTA]/[Bi-NTA] 	 (3) 
where Y = [Bi-hTF/2N]/[hTF/2N] 01 , and the concentration of 
Bi-hTF/2N was calculated by assuming that full loading of 
NMR spectroscopy 
'H-NMR spectra were recorded on Bruker DMX 500 or Varian 
Unity 600 spectrometers at 500 and 600 MHz respectively. 
Spectra were acquired using 0.7 ml of solution in 5-mm tubes 
(0.9mM hTF/2N) at 310K, and 400-1200 transients, 6 1us (50°) 
pulses, recycle time of 2 s, 16 K data points and water suppression 
via pre-saturation. The chemical shift reference compound was 
dioxane via endogenous formate (8.465 ppm., pH* > 7), which 
was always present in our samples as a minor impurity. Res-
olution enhancement of the spectra was achieved by processing 
the free induction decays with a combination of unshifted sine-
bell and exponential functions (line broadening of 1.5-5 Hz) on 
a Silicon Graphics computer using Varian VNMR software 
(VNMR, 4.3) and Xwin NMR (2.0). Two-dimensional TOCSY 
and NOESY spectra (mixing times 60 and 50 ms respectively) of 
hTF/2N at pH* 7.25 were acquired using 2 K data points in the 
12 dimension, acquisition time 0.12 s, 48 scans and 256 increments 
in the fl dimension, in a total time of 14 h. Unshifted Gaussian 
functions were used in both dimensions for processing two-
dimensional spectra. 
The 'H-decoupled 13C spectrum was recorded at 310 K on the 
Bruker DMX 500 MHz NMR spectrometer equipped with a 
5-mm broad-band probe at a resonance frequency 125 MHz. 
Typically 20000-40000 transients were collected using a pulse-
width of 8 4us (50°), a relaxation delay of 2 s and 16 K data 
points. The spectra were processed using an exponential function 







Figure 1 WI difference spectra for Bi binding to hTF/2N 
Bi.NTA (0.2, 0.4. 0.6, 0.6, 1.0 and 1.4 molar equivalents) was added to 1.09 x 10 M 
recombinant hTF/2N in 10 m Hopes butter containing 5 mM bicarbonate, at 310 K. pH 7.4. 
The two absorption bands at 241 and 295 nm are indicative of Bi 3 binding to the specific 
binding site of hTF/2N. 
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Figure 2 Titration curves for BI binding to recombinant hTF/2N 
Bi-NTA (where x = land 10) was added to 1.09 xl 
_5  M recombinant hTF/2N in 10 mM 
Hepes tufter containing 5 mM bicarbonate at pH 7.4, ie equals the absorbance at 241 nm 
divided by the transterrin concentration. The insert is based on the titration at Bi-NTA 10 with 
hTF/2N, and allows determination at log /( = 1.40: R = 0.997. 
hTF/2N with Bill gives a molar absorption coefficient of 
22000 M' cm''. By plotting I / Y versus [NTA]/[Bi-NTA] (Fig-
ure 2 insert), log K was obtained from the slope as 1.40±0.2. 
The reported (log) stability constant of Bi-NTA is 17.75 [24], 
therefore the stability constant of Bi-hTF/2N is log K = 
19.15±0.2 (in 10 m Hepes and 5 m bicarbonate at 310 K, 
pH 7.4). The bicarbonate-independent binding constant (log K*) 
can be calculated to be 18.9±0.2 using the procedure reported 
previously [25]. 
The effect of bound Fell on the uptake of Bill into either the 
N- or C-lobe of intact hTF was studied. Apotransferrin was 
selectively loaded with Fell in the C- or N- lobe and then titrated 
with Bill. The results are shown in Figure 3. When Bill (as Bi-
NTA) binds to the vacant C-terminal site of monoferric trans-
ferrin with Fell in the N-lobe (Fe,-hTF), the initial slope of the 
curve (,c 21740 M' cm -') is close to that observed for apo-
transferrin (& 21900 M'cm'') [13]. In contrast, binding of 
Bill to the vacant N-terminal site of monoferric transferrin with 
Fell in the C lobe (Fe-hTF) gave a much lower molar absorption 
coefficient of 12600 M'cm'. For hTF/2N, the titration curve 
is almost identical with that of N-terminal monoferric transferrin 
(Fe,,-hTF) with a molar absorption coefficient of 
22000 M' cm''. 
Ligand competition 
Competition between hTF/2N and citrate for Bill binding was 
investigated. Large excesses of citrate removed Bill from the 
binding site. The & value appeared to decrease almost linearly 
with increase of citrate concentration (Figure 4). From the linear 
range, it was calculated that an approx. 125-fold molar excess of 
Figure 3 Titration curves for Bill binding to monoferric transferrins 
Bi-NTA was added to 1.09 x 10 5  M nionoterric transterrins IFe N-hTF (s); Fe.hTF (A)l in 
10 mM Hepes butter containing 5 mM bicarbonate at pH 7.4. L56 equals the absorbance at 
241 nm divided by the transferrin concentration: r is the ratio at [Bi] to IhTFI. The titration curve 
for hTF/2N (0) is included for comparison. 
citrate (1.36 mM) is required to remove Bill from hTF/2N 
completely. However, for the intact protein Bi 2-hTF, such an 
excess of citrate appeared to remove only about half of the 
bound Bi ll from the protein. 
' 3C-NMR analysis 
These experiments were carried out to investigate whether the 
binding of Bill to hTF/2N also involves concomitant binding of 
(bi)carbonate as a synergistic anion. Proton-decoupled ' 3C-NMR 
spectra of a solution containing hTF/2N and 10 mM 13C-
enriched bicarbonate (> 99% in 13C) in the absence or presence 
of Bill are shown in Figure 5. In the absence of Bill, the sharp 
signal at 161.1 p.p.m. can be assigned to free bicarbonate, and 
the broad envelope at 168-182 ppm. to backbone and side 
chain carbonyl groups of the protein. After addition of 1.0 molar 
equivalent of Bill (as Bi-NTA), a new peak at 165.7 ppm. is 
observed, which can be assigned to bound (bi)carbonate 
[13,26,27]. 
'H-NMR analysis 
These experiments were carried out to investigate bismuth-
induced structural changes in hTF/2N. Additions of Bill were 
made (0.6 and 1.0 molar equivalent of [Bi-NTA]) to hTF/2N in 
the presence of 10 mM bicarbonate. Specific resonances in both 
high- and low-field regions of the spectrum progressively dis-
appeared and new resonances appeared, indicative of strong 
binding of Bi ll and slow exchange between apo-hTF/2N and Bi-
hTF/2N on the 'H-NMR chemical shift time scale. Peaks A, B 
B 
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Figure 4 Competition between hTF/2N and citrate for Bill  
Changes in molar absorption coefficient at 241 nm of Bi.hTF were monitored with increasing 
citrate concentrations at 310 K and pH 7.4. This experiment was carried out by first adding 
3.0 molar equivalents of Bi.NTA to hTF/2N to form Bi.hTF/2N, followed by titration with citrate. 
Each solution was allowed to equilibrate for 30 mix before recording the absorbance. The data 
for hTF were obtained under similar conditions. 
and C in the high-field region (Figure 6A) gradually decreased in 
intensity, and new peaks A', B' and C' appeared and increased 
in intensity on addition of 0.6 and 1.0 molar equivalent of Bill. 
Peaks A (-0.602 ppm.) and B (-0.339 ppm.) have previously 
been assigned as lie' 32 y-CH, and Leu' 22 6-CH 3 respectively, on 
the basis of ring-current calculations and with the aid of mutation 
of Trp128 [28,29]. Two-dimensional TOCSY and NOESY 
spectra of apo-hTF/2N and Bi 05-hTF/2N were also recorded 
(results not shown). Analysis of most of the resonances was 
impossible due to the large number of overlapping cross-peaks. 
However, the two-dimensional spectra are well resolved in the 
high-field region. Peaks A (y-CH 2 of lie' 32) and B (8-CH 3 of 
Leu' 22) had associated cross-peaks at 0.100, 0.400, 0.830 and 
1.378 ppm., and 0.413, 0.543, 1.143 and 1.457 ppm. resp-
ectively, which are consistent with intramolecular nuclear Over-
hauser effects for isoleucine and leucine spin systems. Similar 
patterns of cross-peaks for A and A', B and B', and C and C' in 
the NOESY spectrum of this aliphatic region strongly suggested 
that A' is the bound form of A, and B' and C' are the bound 
forms of B and C respectively. With 1.0 molar equivalent of Bill  
present, the new resonances increased their intensities further, 
while the resonances for hTF/2N disappeared almost completely. 
Notable shifts induced by Bill binding are those for peak A, 
0.100 ppm. to high-field, peak B, 0.059 ppm. to low-field, and 
peak C, 0.126 to low-field (Table 1 and Figure 7). 
In the histidine C2H region (Figure 8), a notable change is the 
appearance of peaks at 7.613 and 7.626 ppm. (J'). Peaks D, 0, 
H, and I decreased in intensity, and new peaks K', H', and I' also 
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Figure 5 Carbonate binding to bismuth N-lobe transferrin 
13C('H).NMR spectra (125 MHz) 01(A) hTF/2N (1.8 mM, 80% H 20, 20% 2H 20, pH 7.6) in U 
presence of 10 mM NaH 13 CO3, and (B) with addition 011.0 molar equivalent of Bi.NTA. 
appeared after addition of Bill. Peaks H' and I' appeared 
undergo low-field shifts of 0.085 and 0.076 p.p.m. respectively o 
addition of 1.0 molar equivalent of Bill, although again, ur 
ambiguous correlations between peaks cannot be made. A shar 
resonance at 5.995 ppm., which is sensitive to oxalate an 
insensitive to bicarbonate, decreased in intensity and appeared 
shift to 6.004 ppm. (broad peak) when 1.0 molar equivalent c 
Bill was added (results not shown). 
Changes were also observed in the region 1.9-2.3 p.p.m 
which contains resonances for Met-CH 3 and carbohydrat 
(results not shown). Resonances at 2.096, 2.074 and 2.059 ppm 
have not been observed previously for hTF/2N samples, and ar 
thus assigned to the two carbohydrate residues that are attache 
to the protein in the yeast expression system [17]. The presenc 
of carbohydrate was also confirmed by the presence of intens 
resonances from 3.0 to 4.5 p.p.m. (results not shown). Peaks 
2.218, 2.165, 2.143 and 1.967 p.p.m. have been assigned pre 
viously [30] to S-CH 3 of Met"', Met"", Met 256 and Met`/Met'  
respectively. Upon addition of 0.6 molar equivalent of Bill,  th 
broad resonances assigned to Met'°°/Met 2° decreased in intensit 
and a broad shoulder appeared at 1.982 p.p.m.. On addition c 
1.0 molar equivalent of Bill, the latter peak increased in intensit 
further, and that for Met"'/Met" disappeared. Similarly, th 
Met323 resonance also disappeared, whereas peaks for Met"' an 
those for carbohydrate remained unchanged. 
hTF/2N was also titrated with the new bismuth anti-ulce 
agent, RBC. This gave rise to NMR spectra identical with thos 
obtained with Bi-NTA in the presence of 10 mM bicarbonate 
pH of 7.8 (results not shown), apart from peaks that were du 
to added ligands. 
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Figure 6 The high-held region of 'H-NMR spectra of hTF/2N and its B1 3 and Fe  3+  complexes 
Resolution-enhanced 500 MHz 'H-NMR spectra are shown of hTF/2N and its Bill and Fe  31  complexes in 10 m bicarbonate at pt-r at 7.8, 310 K: (A) with addition of 0 (bottom), 0.6 (middle) 
and 1.0 (top) molar equivalents of Bi-NTA; and (B) with addition 010 (bottom), 0.5 (middle) and 0.9 (top) molar equivalents of [Fe(NTA) 2]. 
Table 1 Chemical shifts (J) for 'H-NMR resonances of hTF/2N and Its 
metal complexes 
Connectivilies were obtained from double-quantum-tittered COSY, TOCSY and NOESY, and 
assignments are on the basis of previous work [1828]. For peaks' labels, see Figure 6. Ox, 
oxalate; CO3 . carbonate. 
Leu' 	 tle' 
Protein 	B 	BI 	B2 	A 	C 
hTF/2N -0.333 	0.418 	0.542 -0.605 -0.173 
ox-hTF/2N -0.343 0.412 0.548 -0.617 -0.166 
Ga-ox-hTF/2N -0.308 	0.299 	0.567 -0.897 -0.044 
8 (Ga) 0.035 -0.113 0.019 -0.28 0.122 
hTF/2N -0.335 -0.601 -0.178 
CO,-hTF/2N -0.335 -0.589 -0.173 
Ga-0O3-hTF/2N -0.413 - 0.846 -0.014 
(Ga) -0.078 -0.257 0.159 
CO,-hTF/2Nf -0.333 -0.635 -0.110 
Al-CO3-hTF/2N - 0.401 - 0.839 - 0.042 
8 (At) -0.068 -0.204 0.068 
CO,-hTF/2N -0.339 -0.603 -0.178 
Fe-0O3-hTF/2N - 0.378 - 0.825 - 0.081 
A8 (Fe) -0.039 -0.222 0.097 
CO3-hTF/2N -0.339 	0.413 	0.543 -0.603 -0.170 
Bi-CO3-hTF12N - 0.280 0.359 0.561 - 0.703 - 0.044 
&8 (Bi) 0.059 	- 0.054 	0.018 - 0.100 0.126 
Co-ordination shill; tpH 	at 8.8: 	pH' 7.80; for these data, hTF/2N was expressed in 
the methytotrophic yeast P. pastUris and contained two carbohydrate residues that are not 
present in the N-lobe of the intact serum protein [17]. 
In order to compare 'H chemical shifts induced by Bill with 
those induced by Fell, a titration of hTF/2N with Fell [added 
as Fe(NTA) 2] in the presence of 10 mM bicarbonate at pH*  7,8 
Ile-132 	Leu-122 	Peak C 
G at Ga 
(ox) I 	Fe BI 
Ga 	BI hAl 
(ox) iIl 
UFe 
BI Ga Al 
Figure 7 Stack plot illustrating the changes In shifts of the high-field 
resonances after metal binding 
See text for details. 
was also carried out. Although 'H-NMR spectra were broadened 
upon addition of Fell, owing to the paramagnetic effects 
of bound high-spin Fell, new peaks in the high-field (Figure 
6B) and methionine regions were still observable. The chemical 
shifts induced by Fell appeared to be almost identical with 
those induced by Bill in these regions, indicative of a similar 
binding mode and similar structural changes. Notable co-
ordination shifts induced by Fell complexation are those of 
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Figure 8 Effect of Bi lland bicarbonate on the aromatic region (His region) 
of the 500 MHz 'H-NMR spectra of transferrin N-lobe 
hTF/2N (bottom) addition of 10 ruM bicarbonate to hTF/2N (tower middle) and subsequent 
additions of 0.6 (upper middle) and 1.0 aol (top) equivalents 01 Bi-NTA. 
0.039 p.p.m. to high field, and peak C, 0.097 p.p.m. to low field 
(Table I and Figure 7). In the histidine C2H region, peaks at I 
(8.052 p.p.m.), H (7.920 p.p.m.) and D (7.682 ppm.) became 
significantly broadened on addition of 0.5 molar equivalent of 
Fell, and disappeared almost completely after addition of slightly 
less than 1.0 molar equivalent of Fell (to avoid excess of non-
protein-bound Fell). 
DISCUSSION 
Bill [ionic radius 1.03 A (0.103 nm)] is a much larger ion than 
Fell [radius 0.65 A (0.065 nm), high-spin state], but binds to 
human transferrin almost as strongly as Fel l, a feature which can 
be correlated with its high acidity (low pK of bound H 20) [24]. 
In the present work we have determined the binding constant 
for Bill binding to hTF/2N, log K*  [25] of 18.9 ±0.2. Thus Bi ll  
binds to the N-lobe almost as strongly as to the intact protein 
(log K1 ° = 19.4, log K2* = 18.6 [13]). This appears to be the first  
determination of a binding constant for any metal ion for the 
isolated N-lobe. 
The larger stability constant for Bill binding to hTF can be 
associated with Bill uptake by the C-lobe, since this lobe has 
been shown by two-dimensional 1 H- and 13C-NMR studies of 
Met-e- 13C-labelled protein to take up Bill preferentially [21]. 
Other metal ions, such as Fell, Zn 2 and Sm3 , also show 
preferential binding to the C-lobe, although Ni 2l and All', under 
certain conditions, are taken up preferentially by the N-lobe of 
hTF [18,31]. The specificity of uptake can be influenced by the 
initial ligand complexed to the metal ion, the synergistic anion 
and the pH. Since the transferrin receptor binds much more 
strongly to transferrin loaded with two Fell ions, it is interesting 
to examine possible communication between the N- and C-lobes. 
In this work, we have investigated the effect of Fell loading of 
the N- or C-lobe on the binding of Bill to the other lobe. With 
Fell in the N-lobe of hTF (Fe,,-hTF), Bill binds to the C-lobe as 
strongly as it does in the apoprotein (N-lobe vacant), whereas the 
binding of Bill to the N-lobe of hTF with Fell in the C-lobe 
(Fe-hTF) is much weaker than binding to the isolated N-lobe. 
Calorimetric studies of the binding of Fell to ovotransferrin 
have shown that binding to one lobe is communicated to the 
other [32], and ' 3C-NMR studies have suggested that Ga 3 
binding to the N-lobe is communicated to the C-lobe [30]. 
Previous reports have shown that A1 3 , Zn2 , Nd3 and Sm 3 also 
have a higher affinity for the C-lobe compared with the N-lobe 
[33-35]. 
Since a large excess of citrate is required to remove significant 
amounts of Bill from transferrin (Figure 4), it seems likely that 
citrate would not be a major competitor for Bill in blood plasma 
(citrate concentration 100M [36]; hTF:citrate ratio approx. 
1:3). Comparison of the curves in Figure 4 suggests that citrate 
is much less effective in removing Bill from the C-lobe compared 
with the N-lobe. In blood, hTF is normally saturated to a level 
of only 30% with Fell, which occupies the N-lobe [16], 
although it has been suggested that this switch from C- to N-lobe 
preference may be related to the presence of receptor protein [37]. 
In general, the 'H-NMR spectrum of hTF/2N consists of a 
large number of broad overlapping resonances. However, reason-
able assignments have been proposed previously for several 
peaks in the high-field region, specifically for Leu' 22 and Ile' 32, 
which are above and below Trp' 28 in the hydrophobic patch of 
helix 5. This helix makes contact with the anion and metal-
binding site via its N-terminal end. Therefore these resonances 
are sensitive to metal binding (Figure 6A) and the shift changes 
may arise from small movements of the side chains of Leu 122 and 
lIe' 32 relative to that of Tip 121.  On titration of hTF/2N with Bill  
these peaks show NMR shifts characteristic of slow Bi ll exchange 
(on the NMR time scale), indicative of strong Bill binding. As 
can be seen from Figure 7, the shift changes for these resonances 
induced by Gal, A13 and Bill are all of the same sign and 
similar in magnitude, suggesting that all the metal ions induce 
a similar conformational change in this part of the protein. 
Interestingly, the sign of the shift change for Leu 122 (Figure 7) 
with Bill is opposite to that with Ga 3 , A1 3 and Fell, although 
similar to that seen for Ga 3 with oxalate as synergistic anion. 
Therefore this maybe a consequence of both the large size of Bill  
(ionic radius 1.03 A) compared with Ga 3 (0.62 A), A1 3 (0.54 A) 
or Fe 3+  (0.65 A), and the large size of oxalate compared with 
carbonate. We have shown previously [29] that oxalate binding 
causes shifts of the hTF/2N resonance at 5.995 p.p.m. No such 
shifts were observed in this work with bicarbonate as the 
synergistic anion, which may be indicative of a different binding 
mode or affinity for these two anions before addition of metal. 
The shift changes for the Met-S-e-CH 3 resonances of hTF/2N 
N-lobe versus C-lobe complexation of bismuth by transferrin 	111 
on Bill binding are similar to those observed previously [29] for 
Ga3 . The methionine residues are well dispersed in the protein's 
structure, and their behaviour is probably a good indication of 
the similar binding mode of these metal ions. In view of this it 
will be interesting to investigate the binding of Bill-transferrin to 
the transferrin receptor. Such work is in progress. 
Our studies show that Bill in the form of the anti-ulcer drug, 
RBC, is also readily transferred to hTf/2N, forming the same 
transferrin adducts as for Bi-NTA. Citrate is readily displaced 
from Bill by hTF/2N and could act as a transfer agent in blood 
plasma. Further experiments on blood plasma are required to 
establish whether this is the case. 
Conclusion 
We have made the first determination of a stability constant for 
metal binding to recombinant N-lobe of human transferrin. 
The metal ion used, Bill, is important because it forms the basis 
of widely used anti-ulcer drugs. Bill  binds strongly to hTF/2N 
(log K* = 18.9±0.2 in 5 mM bicarbonate/ 10 mM Hepes buffer 
at 310K, pH 7.4). The presence of bound synergistic anion 
(CO,' -) was confirmed by 13C- and 1 H-NMR studies, and 
suggested that the conformational changes induced by Bill  
binding are similar to those induced by Fe 3 ', At'* and Ga 3 . 
Studies on hTF suggested that occupation of the C-lobe by Fell  
perturbs Bill binding to the N-lobe, but Fell occupation of the 
N-lobe has little effect on Bill binding to the C-lobe. Future 
work will focus on an investigation of the biological activity of 
bismuth transferrin. 
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Bismuth complexes are widely used as anti-ulcer 
rugs and can significantly reduce the side effects of 
latinum anti-cancer drugs. Bismuth is known to induce 
re synthesis of metallothionein (MT) in the kidney, but 
rere are few chemical studies on the interactions of 
ismuth complexes with metallothionein. Here we show 
iat Bi3 ' binds strongly to metallothionein with a stoi-
iiometry bismuth:MT = 7:1 (Bi 7MT) and can readily 
isplace Zn2 + and Cd24 . Bismuth is still bound to the 
rotein even in strongly acidic solutions (pH 1). Reac-
ons of bismuth citrate with MT are faster than those of 
Ii(EDTA)1', and both exhibit biphasic kinetics. 'H 
MR data show that Zn 2 + is displaced faster than Cd2 , 
rid that both Zn2 and Cd2 ' in the fl-domain (three 
ietal cluster) of MT are displaced by Bi' + much faster 
ian from the a-domain (four metal cluster). The ex-
nded x-ray absorption fine structure spectrum of 
i7MT is very similar to that for the glutathione and 
..acetyl-L-cysteine complexes [Bi(GS) 3 ] and [Bi(NAC),] 
ith an inner coordination sphere of three sulfur atoms 
rid average Bi-S distances of 2.55 A Some sites appear 
contain additional short Bi-.O bonds of 2.2 A and 
Hager Bi-S bonds of 3.1 A. The Bi3l  sites in Bi 7MT are 
ierefore highly distorted in comparison with those of 
n2 and Cd24 . 
Metallothionein (MT) 1 is an intriguing, low molecular mass 
(-7 kDa), cysteine- and metal-rich protein. It was first isolated 
from equine renal cortex 40 years ago (1) and contains 61 
amino acids, of which 20 are cysteine residues. Since then, 
similar proteins have been isolated from the kidney, liver, and 
intestines of a variety of animal species (2), fungi (3, 4), plants 
(5), and metal-resistant bacteria (6-8). The two major isoforms 
of mammalian MT (MT(I) and MT(II)) differ only in minor 
sequence changes and overall charge. Recently, the discovery 
of a growth inhibitory factor (GIF) from human brain tissue 
and nerve and its characterization as a metallothionein 
(MT-III) has stimulated new interests in studying this small 
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I Physical Sciences Research Council, Biotechnology and Biological Sci-
ences Research Council, and the Committee of Vice-Chancellors and 
Principals (Overseas Research Student award to H. L.). The costs of 
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The abbreviations used are: MT, metallothionein; H 4 cit, citric acid; 
EXAFS, extended x-ray absorption fine structure; GSH, glutathione; 
NAC, N-acetyl-L-cysteine; pH*,  pH meter reading in D,O solution; 
XANES, x-ray absorption near edge structure; XAS, x-ray absorption 
spectroscopy; ICP-AES, inductively coupled plasma-atomic emission 
spectroscopy; TOCSY, total correlation spectroscopy; GIF, growth in-
hibitory factor.  
protein (9, 10). 
The functions of metallothionein are still not fully under-
stood. It appears to play a fundamental role in the metabolism 
of copper and zinc ions under various physiological conditions 
(11, 12), including its ability to donate metal ions to apo-Zn' 
enzymes (13, 14). Metallothionein may also be important for 
sequestering toxic Cd 21  ions, and probably also Hg2 (15), Au 
(16, 17), and Pt2 (18, 19), thereby preventing reactions with 
other cellular targets in mammals and other higher organisms 
(20). Metallothionein also appears to play a role in radical 
scavenging, stress response, and the pharmacology of metallo-
drugs and alkylating agents (12, 21, 22). 
The best characterized mammalian metallothioneins contain 
a single polypeptide chain with seven bound metal ions (either 
Zn' + or Cd2 ) The x-ray crystal structure of rat liver Zn 2 Cd5 -
MT(II) (23) and NIv[R solution structures of rabbit liver Cd 7 -
MT(II) (24), rat liver Cd 7 -MT(II) (25), and human liver Cd 7 -MT 
(26) show that metallothionein contains two structurally inde-
pendent a (C-terminal) and 0 (N-terminal) domains, which are 
linked in the protein via two amino acids. The seven metal ions 
are present in clusters of four and three metals bound to 
bridging and terminal cysteine thiolate ligands, with metal-to-
thiolate ratios of M4S,, and M,S9 for the a- and 13-domains, 
respectively (23). When both Zn' and Cd 2 are present, Cd 2 
binds preferentially to the a-domain, whereas Zn' is found 
preferentially in the /3-domain (23, 28). A Zn,Cd three-metal 
cluster (/3 domain) in MT has the same structure as a Cd, 
cluster (23). The a-domain binds Cd 2 ' ions cooperatively (29). 
All 20-cysteine residues participate in metal binding, and each 
of the seven Zn2 or Cd2 ions is tetrahedrally coordinated to 
four cysteine thiolate sulfur atoms (30, 31). 
Bismuth is known to induce the synthesis of renal metallo-
thionein (32), and it has been shown that pretreatment with 
bismuth complexes can prevent the toxic side effects of the 
anti-cancer drug cisplatin without compromising its anti-tumor 
activity (33-36). The protection probably involves platinum 
binding to Bi-induced metallothionein. However, there are few 
chemical studies of the reaction of Bi' + with metallothionein 
(37, 38). Such interactions could also play a crucial role in the 
pharmacology of widely used bismuth anti-ulcer drugs includ-
ing colloidal bismuth subcitrate (De-Nol ® ) and ranitidine bis-
muth citrate (Pylorid® and Tritec® ) (39-41). Here we report 
investigations of reactions of EDTA and citrate complexes of 
Bi' + with metallothionein studied by UV, NMR, and x-ray 
absorption spectroscopy (XAS). 
EXPERIMENTAL PROCEDURES 
Materials—Rabbit liver Zn7 MT(II) (catalog number M9542) and 
Zn2 Cd5 MT(II) (catalog number M5392) were purchased from Sigma, 
and bismuth citrate (Bi(Hcit)J and ranitidine bismuth citrate (batch 
number 0018 E93K0441) were supplied by GlaxoWellcome plc. Bismuth 
citrate was dissolved in the minimum amount of -10% ammonium 
hydroxide solution until it became a clear solution (pH —7), and 
LBi(EDTA)1 -, prepared according to the literature method (42), had a 
satisfactory elemental analysis. Solutions of [Bi(EDTA)] were pre- 
29094 	 This paper is available on line at http://www.jbc.org  
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pared by dissolving known amounts of solid [Bi(EDTA)1 in H 2 0 (or 
D20) and adjusting the pH to –7. 
Kinetics of Reactions of Bi3 Complexes with Zn 7MT(II)—All the 
reactions were performed in 20 mm Tris-HC1 buffer containing 10 mrs 
NaCI at pH 7.4. Fresh solutions of metallothionein and bismuth com-
plexes were purged for 10 min with argon or N, to prevent oxidation of 
the metallothionein. Concentrations of MT(II) were determined from 
the absorbance at 220 nm for Zn 7 MT(II) in 0.01 at HCI using ie = 
47,300 m' cm (43). To study reactions with Bi' complexes, 0.5 ml of 
Zn7 MT(II) solution was placed into a 1-cm cuvette and sealed with 
paraflim. After temperature equilibration for –10 min in the cuvette, 
40 mol eq of Bi(III) complexes ([Bi(cit)] or [Bi(EDTA)]) were added 
and the course of the reaction was monitored by UV spectrophotometry 
using a computer controlled Perkin-Elmer Lambda 16 spectrometer 
equipped with a PTP-1 temperature programmer. The absorbance re-
corded after 2 or 3 days was assumed to represent the equilibrium 
situation. The kinetic data were analyzed by a nonlinear least squares 
fitting based on an exponential function using the program Kaleida-
graph (Synergy Software). Two kinetic steps were resolved which 
obeyed first-order kinetics. 
Stoichiometry of Bismuth Metallothionein—Appropri ate volumes of a 
3.75 mm [Bi(EDTA)] solution were added to 1.0-ml aliquots of 15 pat 
Zn7 MT(II) (in 20 mm Tris-HC1, 10 mm NaCl, pH 7.4) to produce different 
molar ratios of [Bi(EDTA)I to protein and the samples were left for 
about 1-2 days at 298 K to equilibrate. The absorbance at 350 nm (Bi–S 
ligand-to-metal-charge-transfer band) was recorded, and the stoichiom-
etry of Bi-MT was obtained from the titration curve. The total sulfur 
content (due to cysteine and methionine), bismuth, cadmium, and zinc 
contents were also measured using the ICP-AES (Thermo Jarrell Ash, 
IRIS) at 180.731 nm (sulfur), 223.061 nm (bismuth), 213.856 nm (zinc) 
and 226.502 nm (cadmium). The Bi-MT sample for ICP-AES was pre-
pared as follows. After addition of 40 mol eq of [Bi(EDTA)} to 
Zn,Cd,MT(II) solution (pH 7.6, 50 mm phosphate buffer) and equilibra-
tion for 48 hat 298 K, excess of Bi', and displaced Zn2*  and Cd 21  were 
removed by ultrafiltration (Centricon 3, Amicon). The final solution was 
diluted with 2% HNO,, and the metal and sulfur contents were meas-
ured without any digestion of the sample (44). 
'H NMR Studies of Reactions of Bi 3 with Zn 2 Cd5MT(II) and 
Zn 7MT(I1)—'H NMR spectra of 0.5 mm rabbit liver Zn,Cd,MT(II) or 
Zn7 MT(II) (50 mm phosphate buffer, pH* 7.6) were recorded on a 
Bruker DMX500 spectrometer operating at 500.13 MHz at 298 K. 
Typical pulsing conditions for 'H were: 7-ps pulse width, 16,384 data 
points, 3-s recycle delay, 16-64 transients. A two-dimensional TOCSY 
spectrum (mixing time 65 ms) was acquired using 2048 data points in 
M dimension, acquisition time 0.13 s, 48 scans, and 320 increments in 
the ft dimension, in a total time of 14 h. All solutions were purged with 
nitrogen for at least 5 mm. After recording an initial proton NMR 
spectrum, a 40-fold excess over protein of either [Bi(EDTA)} or rani-
tidine bismuth citrate was added to the Zn,Cd,MT(II) or Zn 7 MT(II) 
solution, and an NMR spectrum was recorded immediately (with –3 
mm of mixing). Further spectra were recorded at frequent intervals 
over the next 9 h. Protein solutions were then allowed to react over-
night, and small molecules were removed by ultrafiltration (Centricon 
3) and washing four times with 50 mm deuterated phosphate buffer, 
each about 1.5 h, and then a two-dimensional TOCSY spectrum (mixing 
time 65 ms) was recorded. The peaks for [Zn(EDTA)]' and [Cd-
(EDTA)] 2 were integrated relative to the internal reference dioxane. 
X-ray Absorption Spectroscopy Data Collection and Sample Prepara-
tion—X-ray spectra were recorded at the bismuth L w edge on EXAFS 
station 7.1 at the Daresbury Laboratory Synchrotron Radiation Source. 
The operating energy was 2 GeV, and average current was approxi-
mately 200 mA. Powder samples were finely ground and mounted 
either as thin films or diluted appropriately with boron nitride. Solution 
samples were contained in sample cells with mylar windows and a 
2-mm path length. In addition to the model compounds used for cali-
brating phase shifts, two model complexes [Bi(GS),] and [Bi(NAC),] 
were also studied by XAS for comparison. Data for the glutathione and 
N-acetyl-L-cysteine complexes were collected at ambient temperature in 
transmission mode using argon/helium-filled ionization chambers (up 
to three scans per sample). Data for the Bi 7 MT samples were collected 
at 100 K in fluorescence mode using a scintillation detector (five to eight 
scans). The monochromator was detuned to 70% to reject harmonics. 
X-ray damage was checked by comparison of the data sets during 
collection and by the absence of color changes or edge shifts; there was 
no evidence of radiation damage to any samples. Samples were pre-
pared as follows. For [Bi(GS),] and [Bi(NAC),l, 3 mol eq of GSH or NAC 
were added to 50 mm [Bi(cit)] - followed by adjustment of the pH to 
–7.0. Powder samples were prepared by freeze-drying the solution 
300 	350 	400 	450 	500 
FIG. 1. Displacement of Zn' from Zn 7MT(fl) by Bi 3 . Depend-
ence of absorption spectrum on time for a solution containing Zn 7 M'4111) 
(25 gm) and 40 mol eq of [Bi(EDTA)] in 20 mm Tris-HC1, 10 mm I'aCl 
buffer solution at pH 7.4, 298 K. The broad band centred at 350 n4n is 
indicative of formation of Bi' –S (thiolate) bonds. Reaction times fjrom 
bottom to top: 0, 2, 10, 30, 60, 90, 120, and 150 mm. I 
samples. For Bi7MT, 5mg of Zn2 Cd5 MT(II) was dissolved in –1 ml 
mm Tris-HC1 buffer, pH 7.6, deoxygenated with N 2 , and 40 mol e 
[Bi(cit)] - was added and equilibrated overnight. Some yellow par 
pate appeared in this yellow solution and was separated by centrifi 
tion, washed three times with water, and finally freeze-dried givir 
slightly brown solid (hereafter called "brown MT precipitate"). 
excess of [Bi(cit)] was removed from the yellow solution by ultrafil 
tion three times using water as eluant (Centricon 3), and the f 
yellow solution was freeze-dried to give a yellow solid (hereafter ca 
B'7 -MT). 
X-ray Absorption Spectroscopy Data Analysis—Background subti 
tion was achieved using the motif-based SPLINE program (45, 
modified for use with EXCURV. Data analysis was accomplished us 
EXCURV98 (46) via the single scattering curved-wave method for] 
AFS calculations. Edge positions were calibrated against a Au foil at 
L1, edge, taking the first derivative maximum as 13,734 eV. Ph 
shifts were derived from ab initio calculations within EXCURV98 
were extensively checked against the crystallographically characteri 
model compounds [Bi(HEDTA)], [(D-( –)-pencillaminato-O, S,N}Bi 
(47), Na2 [Bi2(citrate),] 7H 2 0 (48), [Bi(SC,F,) 3 (OPPh3 )2 ]-CH2 C12  
[Bi(SC,F,),lS=C(NHMe),),i (49). Agreement between EXAFS and ci 
tallographic parameters was better than ±0.01 A for sulfur (±0.02 A 
3-4 A), ±0.02 A for oxygen with sulfur present (±0.01 A if no hat 
scatterers present), and ±10% for coordination numbers. The EXA 
data were weighted by k' to compensate for the diminishing ampliti 
at high k. The data range used for analysis varied marginally betwi 
samples. 
RESULTS 
Kinetics of Reactions of Bismuth Complexes with 
Zn 7MT(II)—Reaction of bismuth complexes with rabbit liver 
Zn7 MT(II) produced a new UV absorbance band centered at 
350 nm. This was used to monitor the progress of reactions of 
bismuth complexes with metallothionein under pseudo first-
order conditions (40-fold molar excess of Bi 3 over MT). Fig. 1 
shows absorption spectra recorded for the reaction of excess 
[Bi(EDTA)] - with Zn 7 MT(II) at different times at 298 K, and 
the time course for the absorbance changes is shown in Fig. 2. 
The overall reaction was relatively slow, requiring over 10 h for 
completion. The reaction of [Bi(cit)] - with Zn 7 MT(II) gave rise 
to similar spectral changes, although it was much faster. About 
one-third of the total absorbance change occurred within the 
first 5 mm. However, the total increase in absorbance for both 
reactions was similar after 1 or 2 days, indicating that equilib-
rium probably involved the formation of a similar final Bi-MT 
product. 
Kinetic data were analyzed using the nonlinear least squares 
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FIG. 2. Determination of pseudo first-order rate constants for 
ieaction of [Bi(EDTA)] with Zn 71VT(II). Dependence of absorbance 
350 nm on time for the reaction of [Bi(EDTA)] - (40 mol eq) with 
Zn7 MT(II) (25 in 20 mm Tris-HC1, 10 mi NaCl, pH 7.4, 298 K The 
curve is a nonlinear least squares fit using an exponential function. 
[Bi(EDTA)J - and [Bi(cit)] - appeared to be biphasic; the rate 
constants are listed in Table I. The dependence of the rate on 
FBi] was investigated for [Bi(cit)] -. The first step appeared to 
le dependent of FBi], Table I. The second step appeared to be 
independent of [Bi], and the rate was similar for [Bi(EDTA)] 
and [Bi(cit)] -. 
Stoichiometry of Binding of Bi 3 + to Metallothionein-The 
extent of bismuth binding to Zn 7 MT was investigated in two 
ivays: by determination of the change in absorption at 350 nm 
and by determination of the bismuth:sulfur ratio in the product 
via ICP-AES. Fig. 3 shows the change in the extinction coeffi-
cient at 350 nm (€) with variation of the [Bi(EDTA)] - :Zn 7 MT 
molar ratio. The value of z€ increases linearly, and plateaus at 
a ratio of -7.0, reaching a final value of -15,000 cm . By 
ECP-AES, the stoichiometry of purified Bi-MT (see "Experimen-
tal Procedures") was determined to be bismuth:sulfur = 1.0:3.0 
±0.1), and the mol ratio of bismuth:zinc > 170:1. Since there 
pre 21 sulfur atoms in MT (20 Cys + 1 Met), the mol ratio of 
bismuth to MT is 7:1. 
Effect of pH on Bi 7MT-A solution containing Bi7 MT was 
generated by reacting Zn 7 MT (25 p.M) with 40 mol eq of 
1Bi(EDTA)] in 20 mm Tris-HC1 buffer, 10 mivi NaCl, pH 7.4, for 
:about 1 day at 298 K, followed by ultrafiltration to remove 
excess [Bi(EDTA)] - and other low molecular mass molecules. 
With de&easing pH, the absorbance of Bi 7 MT(II) at 350 nm 
decreased only slightly, and by <20% at pH values as low as 
1.0, suggesting that Bi3 remains bound to the protein even in 
strongly acidic solutions. 
Gel Filtration Profile of Bi7MT-Bi 7 MT (prepared from 
Zn7MT) exhibited a similar retention time to Zn 7 MT when 
chromatographed on Superdex G-200. 
'H NMR Studies-Reactions of [Bi(EDTA)1 with Zn 7 MT 
and Zn2 Cd5 MT(JJ) were followed by 'H NMR spectroscopy. 
Since [Zn(EDTA)] 2  - and [Cd(EDTA)]2 - formed via displace-
ment of Zn2 and Cd2 from the protein have characteristic 'H 
NMR shifts (50), it was possible to monitor the kinetics of 
displacement of these metal ions individually from the protein. 
The 500 MHz 'H NMR spectra of rabbit liver Zn2 Cd,MT(II) at 
different times after addition of 40 mol eq of EBi(EDTA)] - are 
shown in Fig. 4. The intense resonances at -3.1 ppm can be 
assigned largely to 9 protons of Cys and Lys residues, and the 
two singlets at 2.10 and 2.16 ppm to the N-acetyl-CH 3 and 
I eCH3 , respectively, of the terminal N-acetylmethionine residue 
(51). The resonances at 0.8-1.7 ppm can be assigned to methyl 
groups of Ala, Ile, and Lys residues on the basis of their chem- 
ical shifts and coupling constants (51). The peaks that appear 
at 2.92, 2.76, and 2.65 ppm after addition of [Bi(EDTA)] can 
be assigned to the ethylenic protons of EDTA complexed to 
[Zn(EDTA)] 2 , [Cd(EDTA)] 2 , and ECa(EDTA)1 2 , respectively 
(50). Cadmium satellites (due to 111 Cd and " 3 Cd, total natural 
abundance 25%) can be clearly observed for [Cd(EDTA)] 2 
peaks. The relative integrated areas of the peaks at 2.92 and 
2.76 ppm (for [Zn(EDTA)] 2 and [Cd(EDTA)] 2 , respectively), 
increased with time as shown in Fig. 5. Most of the Zn 2 was 
already present as an EDTA complex by the time the first 
spectrum was recorded (-3 min after addition of [Bi(EDTA] ), 
whereas the peaks for [Cd(EDTA)] 2 continued to increase in 
intensity for a period of about 6 h. There were no further 
changes to the spectrum after 15 h, at which point the relative 
integrated peak ratio [Zn(EDTA)] 2 : [Cd(EDTA)] 2  at 2.92 and 
2.76 ppm, was 2.0:5.3, which suggested that all Zn 2 and Cd2 
had been displaced from the protein by Bi 3 Gradual changes 
were also observed for the metallothionein resonances during 
the course of the reaction. There was an overall broadening of 
the resonances, the peak at 1.16 ppm, which can be assigned to 
the (3 protons of Ala 23 (CH 3 ) (24) disappeared, the intense peak 
at -3.10 ppm decreased in intensity, and broadening of the two 
singlets at 2.10 and 2.16 ppm and peaks from 0.8-1.7 ppm was 
notable. 
It can be seen clearly from Fig. 5 that Zn 2 + was displaced 
from Zn2 Cd5 MT(II) by Bi3 + (added as [Bi(EDTA)] ) very rap-
idly (within 3 mm), while Cd2 + was displaced relatively slowly 
(>4 h). By the time the first spectrum was recorded, the [Cd-
(EDTA)] 2 peak at 2.76 ppm had reached one-fifth of its final 
intensity (attained after overnight equilibration). After a fur-
ther 5 min the peak had doubled in intensity. The rate con-
stants for Cd 2 + displacement were determined using nonlinear 
least squares best fits (Fig. 5). This was a biphasic process with 
pseudo first-order rate constants of 5.8 x iO s and 1.0 x 
10 s- I (half-lives of 2 min and 1.9 h, respectively), whereas 
the rate of Zn 2 + displacement was too fast to determine accu-
rately by NMR spectroscopy. 
The reaction of [Bi(EDTA)] - with Zn 7 MT(II) was also inves-
tigated by 'H NMR spectroscopy. About three-seventh of the 
Zn2 + was displaced within 3 min of mixing, and the rate could 
not be determined by NMR. The remaining Zn 2 + was displaced 
by Bi3 in a biphasic process. Using nonlinear least squares 
best fits, rate constants of 7.2 X iO s- 1 and -5.9 X 10 s - 1 
(half-lives of 1.6 min and 3.3 h, respectively) were determined. 
Studies of the reaction of the anti-ulcer compound ranitidine 
bismuth citrate with metallothionein using UV and NMR spec-
troscopy were hampered by the strong UV absorption from 
ranitidine and intense 'H NMR signals of ranitidine and cit-
rate. However, yellow solutions were obtained when ranitidine 
bismuth citrafe was added to metallothionein under conditions 
similar to those used for [Bi(EDTA)J - and [Bi(cit)] -. The prod-
uct obtained after ultrafiltration to remove excess ranitidine 
bismuth citrate and other small molecules was almost identical 
to Bi7 MT obtained from the reaction of [Bi(EDTA)] with met-
allothionein as judged by 'H NMR spectroscopy (data not 
shown). 
The two-dimensional 'H TOCSY NMR spectrum (mixing 
time 65 ms) of purified Bi 7 MT is shown in Fig. 6 together with 
that for Zn 7 MT for comparison. Notable is the absence of sev -
eral cross peaks assignable to Cys 13 CH,protons (26, 52, 53) in 
the region 2.7-3.3 ppm for BI 7 MT (boxed in Fig. 6). 
X-ray Spectroscopy-XANES and EXAFS measurements 
were made on solution and solid samples containing bismuth: 
glutathione and bismuthN-acetyl-L-cysteine in molar ratios of 
1:3 and on solid Bi-MT samples obtained by reacting excess 
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TABLE I 
Pseudo first-order rate constants for reactions of Zn7MT(II) and Zn 2 Cd5MT(II) with [Bi(EDTA)] and [Bi(cit)] 
The conditions for UV reactions were 25 pm Zn7 MT(II) in 20 mm Tris-HC1 buffer containing 10 mm NaCl, pH 7.4, at 298 K, and for NMR, 0.5 
mm proteins in 50 ms phosphate buffer, pH*  7.6, 298 K. 
Bi complex 	 Concentration Protein 	 k, X 103 k 2  X 10 Method 
mm s_I s-I 
[Bi(EDTA)] 	 1.02 Zn7MT(II) 	 0.95 ± 0.2 0.5 ± 0.4 lii? 
20 Zn7MT(1l) 7.2 0.59 NMR 
20 Zn2 Cd5MT(fl) 	 5.8 1.0 NMR 
[Bi(cit)] 	 5.08 Zn7 MT(II) 	 5.3 ± 0.4 0.57 ± 0.7 DV 
2.54 Zn7 MT(1) 4.6 ± 0.2 1.2 ± 0.3 DV 
1.02 Zn,MT(fl) 	 4.0 ± 0.5 1.1 ± 0.4 UV 
0.51 Zn7 MT(II) 3.2 ± 0.5 1.0 ± 0.2 DV 
Average ± S.D. for two to three experiments for UV measurements. 
FIG. 3. Stoichiometry of Di" binding to Zn 7 MT. DV titration 
curve (350 nm) for addition of EBi(EDTA)] to Zn 7 MT(II) (15 pm) in 20 
mm Tris-HCI containing 10 mm NaCI, pH 7.4. The overall absorbance 
changes suggest the formation of Bi 7MT (see text). 
XANES spectra at the Bi L 111 edge are broad and featureless 
due to the large core-hole lifetime (data not shown). However, 
there is a significant difference in the bismuth L 111 edge posi-
tions between sulfur-containing and light-atom complexes of 
the order of 10 eV (13,425 eV for [Bi(SC 6F5 )3(0PPh3 )2]CH2 Cl2 
and [Bi(SC 6F5 )3 {S=C(NHMe)2 ) 3 1, 13,436 eV for [Bi(HEDTA)], 
13,434 eV for Na[Bi(citrate)]•7H 2 0. The edge positions for 
[Bi(GSH)3], [3i(NAC)3 ], and both Bi-MT samples indicate that 
all these samples have sulfur-based ligation for bismuth. 
The EXAFS data for [Bi(GSH)3 ] and [Bi(NAC) 3 ] (both in solid 
and solution) are essentially identical. Analysis of the data 
(Table II and Fig. 7) gave rise to coordination numbers of 3.0 ± 
0.3, with sulfur as the only coordinating atom, with an average 
Bi-S bond length of 2.56 A. 
The EXAFS spectra of the two Bi-MT samples (B' 7 -MT and 
brown MT precipitate) were quite distinct from each other. By 
comparing the EXAFS of Bi 7 MT (Fig. 7ii) with those of 
[Bi(GS)3 ] (Fig. 7A, i) and [Bi(NAC)3 ] 1  it can be seen that the 
coordination number of bismuth in Bi 7 MT is similar to that of 
bismuth in [Bi(GS)3 ] and [Bi(NAC)3 ]. The Fourier transform 
for B' 7 -MT is dominated by a single shell best simulated with 
3.0 ± 0.1 sulfur at 2.55 ± 0.01 A, a similar distance and 
coordination number as those determined for the model com-
plexes. Fits were attempted with other sulfur coordination 
numbers, but on refinement the coordination number always 
returned to 3. The Fourier transform suggests that additional 
weakly scattering shells are present, including a small amount 
of oxygen (0.5 ± 0.3) at 2.18 ± 0.02 A. The coordination number 
for this shell is poorly defined, but it is certainly less than 
unity. There is also reasonable evidence that the small peak in 
the Fourier transform at -3 A is due to additional sulfur 
scattering (1.9 sulfurs) at 3.09 ± 0.1 A. The refined coordina-
tion number of 1.9 for this additional shell has a large uncer-
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FIG. 4. Displacement of Zn 2 and Cd2 from Zn2 Cd5 MT(H) by 
Bi3 . Dependence of the 500 MHz 'H NMR spectrum of 0.5 mm 
Zn2 Cd5MT(II) (50 mm phosphate buffer, pH*  7.6, 298 K) on time after 
addition of 40 mol eq of LBi(EDTA)J -. The appearance of peaks for 
[Zn(EDTA)] 2 and [Cd(EDTA)] 2 is evident; the NCH 2 peaks appear as 
singlets and the CH, CO2 - peaks as quartets (with "" 3 Cd satellites 
for [Cd(EDTA)1 2 ). A small amount of Ca 21 (-0.5 Ca2 fMTII) is also 
released by the protein and becomes bound to EDTA. 
factor. Therefore, this parameter must be treated with caution. 
This type of split sulfur ligation has a number of precedents, 
including the model compound [Bi(SC 6F5 )3 {S=C(NHMe)2 ) 3 ] 
used in this study (3 sulfurs at 2.72 A, 3 sulfurs at 2.95 A). 
X-ray fluorescence measurements on Bi 7 MT gave bismuth: 
zinc > 17:1 (the very low level of zinc limited the measure-
ment), in agreement with the ICP-AES measurement. 
The brown MT precipitate sample gave much weaker EXAFS 
amplitudes compared with all the other samples. Fitting the 
data with a single shell of sulfurs resulted in large residuals in 
the Fit Index and the model was clearly incomplete in both the 
EXAFS and Fourier transform. Extensive analysis resulted in 
two different plausible models of equal quality. Both models 
suggest that the weaker EXAFS is due to destructive interfer-
ence of two (or more) shells, rather than lower coordination 
numbers. Model 1 (Table II) consists of mixed oxygen (3.1 at: 
2.46 A) and sulfur (4.1 at 2.51 A) ligation. Model 2 is a split 
sulfur model (2.9 at 2.58 A, 3.2 at 2.88 A). Attempts to model  
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FIG. 5. Kinetics of displacement of Zn' and Cd' by Bi'. 
Dependence of relative areas of 1 11 NMR peaks for zinc and cadmium 
EDTA on time for the reaction of 0.5 mm Zn,Cd,MT(II) with 40 mol eq 
of [Bi(EDTA)1 at 298 K, in 50 mm phosphate buffer, PH*  7.6. Expo-
nential fitsigive rate constants of k, = 5.8 x 10 s' and k 2 = 1.0 X 
10- s' for the two phases of Cd' displacement. 
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FIG. 6. Two-dimensional TOCSY 'H NMR spectra (mixing time 
65 ms). A, 0.5 Inm rabbit liver Zn7 MT(II); B, Bi7 MT(II) in 50 mm 
I phosphate buffer, pH*  7.6. 
bismuth as a back-scatterer were unsuccessful. Although the 
models have equal fit indices, model 2 has a marginally lower 
R-factor (19.1% versus 20.3%). Additionally the difference in 
the Debye-Waller factors for the oxygen (0.004 A 2 ) and sulfur 
(0.017 A 2 ) in model 1 seems implausibly large. The refined 
coordination number for oxygen in model 1 is very highly cor-
related to a number of other parameters due the interference of 
the two scattering waves. Because of these potential problems 
with model 1 and the similarity of model 2 to known model 
systems, we suggest that model 2 is the more reliable. Brown 
MT precipitate may represent an intermediate (and less solu-
ble) stage on the path to B' 7 -MT. It is not clear if it is a fully or 
partially loaded structural intermediate. 
DISCUSSION 
Metallothionein appears to play an important role in human 
health and disease as well as in the mechanism of action of 
therapeutic agents. Its synthesis is induced in biological sys-
tems by a variety of metal ions including Zn 2 , Cd2 , Cu', and 
Bi3 , and this induction may provide protection from toxicity 
by allowing sequestration of the metal (2). Metallothionein may 
also play a role in cellular resistance to Pt anti-cancer drugs 
(18, 19). Administration of bismuth can induce the synthesis of 
metallothionein in kidney but not in tumor tissue. This reduces 
the renal toxicity of cisplatin without compromising its chemo-
therapeutic activity (33, 36). Therefore it has been suggested 
that bismuth compounds are ideal for clinical application as 
adjuncts in chemotherapy with cisplatin. Bismuth compounds 
have been used in medicine for centuries, mainly for the treat-
ment of peptic ulcers and gastric disorders. Therefore, MT may 
play an important role in the pharmacological activity of bis-
muth anti-ulcer drugs. 
Metal ions have been reported to bind to MT with a variety 
of stoichoimetries, ranging from 7, 10, to 12 and even up to 20 
metal ions per protein molecule and with different geometries 
(from tetrahedral, square-planar, to linear). These include 
monovalent metal ions such as Au (16) and Cu (54, 55), 
divalent metal ions such as Zn 2 , Cd2, CO21  , and Hg2 , tri-
valent metal ions such as In  and Sb 3 (38), and Tc0 3 (56, 
57). In the present studies we determined the stoichiometry of 
Bi3 + binding to MT as 7:1 using both UV titration and ICP-AES 
to measure the metal and sulfur contents. This result is in 
agreement with previous brief reports (37, 38) on bismuth 
metallothionein. X-ray and NMR studies of ZnCd 7 MTs have 
shown that the metals are distributed in two clusters as M 4 S 11 
(a) and M3 S9 (f3) with the metals coordinated tetrahedrally 
(30). Previously reported structural data are summarized in 
Table III. Surprisingly, our EXAFS data suggest that Bi 3 
(ionic radius 1.03 A) coordinates strongly to only three cysteine 
sulfurs with an average Bi—S bond length of 2.55 A. This bond 
length is almost identical to that found in x-ray structures of 
low Mr Bi(III) thiolate complexes (Bi—S 2.5 to 2.6A) (49, 58). 
The fit for the EXAFS data for Bi 7 MT suggests the presence of 
additional sulfur scattering at —3.1 A. To retain the metal 
clusters a much distorted tetrahedral geometry is required 
with three Bi—S bond distances of 2.55 A and a longer Bi—S 
contact of ca. 31A. Although the 3.1 A distance is well defined, 
the associated coordination number is not, and the required 
coordination number for distorted tetrahedral geometry is well 
within the error range. In the crystal structure of [Bi(SC 6 F5 )3], 
Bi3 + coordinates to three sulfurs with Bi—S bond lengths of 
2.53-2.58A, and an additional long Bi—S bond of 3.32 A (49). 
Molecular modeling of H97  MT (59) suggests that the geometry 
of Hg2 + is distorted away from tetrahedral due to extensive 
interactions with solvent water. The recent EXAFS studies on 
H97 MT have shown that the nearest coordination number for 
Hg2 is 2, with Hg—S bond lengths of 2.33 A and two less well 
defined long bonds of —3.4A(60). It has been thought that the 
binding site cage of MT is too small to accommodate the volume 
of tetrahedral HgS units. However, Cd 2 ', which has a similar 
ionic radius (0.92 A) and the same charge, coordinates tetra-
hedrally to sulfurs of Cys residues. The coordination geometry 
is therefore largely dependent on the metal ion, e.g. digo-
nal (CN, 2); Cu, trigonal (CN, 3) (61); and TcO 3 , square 
pyramidal (CN, 5) (57). 
The presence of additional short Bi—O bonds (2-18A) for at 
least some of the Bi3 I  ions in Bi7 MT suggests that some Bi 3 
ions also have bound water, or more likely hydroxide or oxide, 
or possibly oxygen donors from amino acid side chains such as 
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Sample N R 2,,2  Fl ft 
A A2 % 
[Bi(GSH)3 ] solution 3.1 sulfur 2.565 0.009 3.1 19.3 [Bi(GSH)3 ] powder 2.7 sulfur 2.553 0.012 7.1 28.6 [Bi(NAC)3 1 solution 2.8 sulfur 2.551 0.007 4.5 22.7 
[Bi(NAC)3 1 powder 3.2 sulfur 2.571 0.010 3.8 22.6 Bi7 MT 3.0 sulfur 2.553 0.009 6.2 27.3 
1.9 ± 2.0 sulfur 3.092 0.039 5.6 24.0 
0.5 oxygen 2.180 0.001 
Brown MT ppt 
Model 1 2.9 sulfur 2.514 0.017 3.3 20.3 
2.10 oxygen 2.464 0.004 
Model 2 2.9 sulfur 2.576 0.014 
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FIG. 7. EXAFS spectra (A) and Fourier transforms (B) of the 
EXAFS spectra. i, [Bi(GS)3 ] solution (top); ii, Bi7 MT (middle); iii, 
brown MT precipitate, model 2 (bottom). Dotted line, calculated; solid 
line, experimental. 
attractive to consider because Bi-OR (alkoxide) bonds are 
known to be short and strong in several bismuth citrate ad-
ducts (41). No Ser or Thr side chains are particularly close to 
the metal clusters in zinc and cadmium metallothioneins with 
known structures, although Ser 32 and Ser35 are less than 7 A 
away from the M 4S,, cluster in the a domain, and Ser', Ser' 5 , 
and Ser25 are less than 7 A from the M3 S9 cluster in the 6 
domain (23-25). Alkoxide coordination to Bi 3 + often gives rise 
to lone-pair effects and distorted coordination spheres for Bi 3 + 
(41). At biological pH, ZnCdMT(II) (x + y = 7) is negatively 
charged (-2), whereas Bi 7MT(II) would have an overall posi-
tive charge (+5). Thus the additional oxygen ligands may serve 
to neutralize the excess charge. 
Previously we have shown (62) that Bi 3 + binds to the Cys 
residue of glutathione and induces large low field shifts of the 
'H NMR resonances of 13 CH 2 protons (--1.4 ppm). Free an,d 
bismuth-bound glutathione exchange at an intermediate rate 
on the NMR time scale at biological pH (-4500 s'). The NMR 
data were also consistent with sulfur-only binding, in agree-
ment with the EXAFS data. The overall broadening of the 'H 
NMR spectrum of Bi 7 MT and the disappearance of the two-
dimensional TOCSY cross-peaks for /3 CH 2 of Cys residues (Fig. 
6) suggest a facile exchange of Bi 3 + between different sites, 
even though binding is thermodynamically very strong. Other 
cross-peaks, notably those for Lys and Thr, residues that are 
wide spread throughout the protein, remain unchanged in com-
parison with Zn7MT, indicating that Bi 7MT probably has a 
folded conformation although the overall three-dimensional 
structure may be different. Our gel filtration chromatography 
studies show that Bi 7 MT migrates in a similar manner to 
Zn7MT, suggesting that their molecular masses and shapes are 
similar, i.e. Bi3  has not induced MT polymerization. The dis-
appearance of the /3 CH, 'H NMR resonance of Ala 21 (1.16 ppm) 
suggests that the structure of Bi 7 MT in this region may be 
more flexible, and involved in dynamic exchange between dif-
ferent conformations. Previous molecular modeling studies 
have shown that Cys26 in the /3 domain is more solvent acces-
sible and can be displaced from Zn 2 + binding by the thiolate 
sulfur of glutathione (63). 
Bi-S bonds in MT(II) appear to be remarkably stable even 
down to pH values near 1.0, in contrast to Zn 2 and Cd2 , 
which are 50% dissociated at pH 4.6 and 3.05, respectively (55), 
but similar in strength to Cu'-MT (pH½ 0.44) (55). The affinity 
of Bi3 + for MT(II) is therefore higher than that of Zn 2 + and 
Cd2 
The kinetics of reactions between bismuth complexes and 
MT(II) were elucidated in two ways: by observing the absorb-
ance changes at 350 nm due to the formation of Bi-S bonds and 
the appearance of new 'H NMR peaks resulting from the for-
mation of either zinc or cadmium EDTA complexes after dis-
placement of EDTA from Bi 3 . 'H NMR also allowed the ki-
netics of Zn2 + and Cd2 + displacement by Bi 3 + to be monitored 
separately. Biphasic processes were observed for both [Bi(cit)] - 
and [Bi(EDTA)J -. In the fast step, the displacement of Zn 2 . 
from Zn7MT by [Bi(cit)] occurred four times faster than that 
by [Bi(EDTA)], while the second step was very similar for both 
of these bismuth complexes. This is probably due to differences 
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TABLE III 
Summary of structural parameters for various metallothioneins (for references, see text) 
Metal 	 Sample 	 Coordination number (N) 	 Distance 	 Geometry 	 Method 
Zn2 Zn2Cd5 MTH 4 sulfur 2.296 	2.476 Tetrahedral X-ray 
Cd2 4 sulfur 2.440 - 	2.621 Tetrahedral 
Zn2 Zn7 MTII 4 sulfur 2.35 ± 0.01 Tetrahedral EXAFS 
I 	Cd2 Cd7 MTII 4 sulfur 2.50 ± 0.02 Tetrahedral EXAFS 
Cu Cu12 MTII 3 sulfur 2.25 ± 0.02 Trigonal EXAFS 
Cu4 GIF(1-32) 2.9 sulfur 2.25 ± 0.02 Trigonal EXAFS 
Cu6 GIF(1-32) 3.1 sulfur 2.24 ± 0.02 Trigonal EXAFS owl 
A912 MTII 2 sulfur 2.45 ± 0.02 Diagonal EXAFS 
A917 MTH 2 sulfur 2.44 ± 0.02 Diagonal EXAFS 
TcO3 MTI 2 sulfur 2.31 ± 0.02 Square EXAFS 
2 nitrogen/oxygen 2.02 ± 0.02 Pyramidal 
Hg2 H97 MTII 2 sulfur 2.33 ± 0.02 Disordered EXAFS 
2 sulfur 3.4 Tetrahedral 
3 sulfur 2.42 ± 0.02 EXAFS 
Hg18 MTII 2 sulfur 2.42 ± 0.03 Trigonal? EXAFS 
0.6 chlorine 2.57 ± 0.03 
Bi3 Bi7 MTII 3 sulfur 2.55 ± 0.02 EXAYS 
2 sulfur 3.09 ± 0.02 
0.5 oxygen 2.18 ± 0.02 
Bi3 Brown 2.9 sulfur 2.58 EXAFS 
Bismuth 3.2 sulfur 2.88 
MTII 
un structure:bismuth citrate contains dimeric units [Bi2 (cit)2 ] 2  - 
1.48) in which the Bi3 + ion has apparent vacant coordination 
4ites (perhaps occupied by the 6 s 2 lone pair of electrons) and 
therefore may be able to attack Cys sulfur of MT more readily 
'ban [Bi(EDTA)] in which the EDTA ligand is wrapped 
round Bi3 " (42). By comparing the kinetics of reaction of 
Bi(EDTA)] - with Zn7 MT and with Zn2 Cd5 MT (with Zn2 + in 
he )3-domain), we have shown that metal ions in /3-domain of 
the MT can be replaced preferentially, and cooperatively and 
rapidly (within minutes) by Bi3 , and there is little difference 
etween the reactivity of Zn3 and Zn2 Cd /3-domains. The first 
Mep maybe involve displacement of metal ions in the 13-domain 
y Bi3 and one metal ion in the a domain, as judged from 
MR data, and the second step may involve displacement of 
he other metal ions in the a-domain. There have been several 
revious studies of metal and ligand displacement from Zn 7 MT 
nd Cd7MT (18, 19), and multiphase processes have always 
een observed. Biphasic kinetics have usually been explained 
n the basis of formation and breakdown of intermediates (18, 
19). However only a single kinetic step for metal displacement 
as been observed for reaction of EDTA with Cd 21  in the 
/3-domain of Cd7 MT, and also one Cd 21  in the a domain can be 
extracted by EDTA more readily than the other Cd 2 + ions (64). 
Our NMR data indicated the rapid removal of a small amount 
of Ca2 + from the protein (0.5 Ca2 + per MTII) during reaction 
with [Bi(EDTA)] -. We assume that this is surface bound Ca 2 + 
which has little effect on the cluster structures. Its presence 
has been observed previously (50). 
The high stability of bismuth metallothionein suggests that 
it could play a significant role in the mechanism of action of 
bismuth-based drugs both in bacteria and in man. It may be an 
important species for bismuth transport from the liver to the 
kidney and be involved in bismuth storage in the kidney. In 
addition, the neurotoxicity of bismuth drugs (encephalopathy) 
could be related to the binding of Bi3 + to the brain-specific 
metallothionein(III), since the distribution of Bi3 + in mouse 
brain is very similar to that of Cu and Ag (27). 
CONCLUSIONS 
We have established that Bi3l originating from bismuth 
citrate anti-ulcer compounds and from [Bi(EDTA)] - binds very 
strongly to MT(II) and readily displaces Zn2 + and Cd2 . De-
1 spite its higher charge, Bi3 also forms a 7:1 complex (Bi7 -MT),  
the same stoichiometry for binding as zinc and cadmium. EX-
AFS data show that on average each Bi3l  is coordinated 
strongly to only 3 cysteine sulfurs (at 2.55 A) in contrast to 
Zn2 and Cd2 , which have clusters based on M(Cys) 4 centers. 
The presence of less well defined longer Bi-S contacts of 3.1 A 
for some Bi3 + ions suggests that B'7 -MT does contain clusters, 
although Bi-Bi contacts were not detectable. For at least some 
of the Bi3 + ions in B'7-MT, there is additional oxygen coordi-
nation as short Bi-O bonds of 2.2 A. These could arise from 
bismuth-alkoxide linkages to Ser or Thr side chains or perhaps 
from oxide coordination. Remarkably, Bi3l is still bound to MT, 
even at low pH values(e.g. pH 1), again in contrast to Zn 2 and 
Cd2 . Displacement of Zn 2 + and Cd2 + from the /3-domain 
(M3S9 ) by Bi3 l was much faster than from the a-domain. These 
differences between the structure and reactivity of bismuth 
metallothionein compared with zinc metallothionein are likely 
to have implications for its biological properties. Since bismuth 
citrate complexes are widely used as anti-ulcer drugs, and 
pretreatment with bismuth compounds can protect against 
some of the toxic side effects of the anti-cancer drug cisplatin, 
further studies of bismuth metallothionein are warranted. 
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